var title_f24_18_24864="Portuguese man of war";
var content_f24_18_24864=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F67670&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F67670&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Portuguese man-of-war",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 245px; height: 426px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Note that the nematocysts on this species of jellyfish are on the tentacles, not on the bell.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Richard Weisman, PhD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_18_24864=[""].join("\n");
var outline_f24_18_24864=null;
var title_f24_18_24865="Patient information: Asperger syndrome (The Basics)";
var content_f24_18_24865=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?37/37/38481\">",
"         Patient information: Autism (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?40/46/41699\">",
"         Patient information: Autism spectrum disorders (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Asperger syndrome (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/asperger-syndrome-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H103508957\">",
"      <span class=\"h1\">",
"       What is Asperger syndrome?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Asperger syndrome is mild type of \"autism.\" Autism is a brain disorder that affects a person&rsquo;s behavior and makes it hard for the person to communicate and interact with others.",
"     </p>",
"     <p>",
"      Asperger syndrome affects each person in a different way. But most people with Asperger syndrome have a hard time relating to other people.",
"     </p>",
"     <p>",
"      Asperger syndrome starts in childhood. It is more common in boys than in girls.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H103508972\">",
"      <span class=\"h1\">",
"       What are the symptoms of Asperger syndrome?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The most common symptoms are unusual behaviors. For example, a child with Asperger syndrome might try to get another person's attention by pushing the other person. He or she might also play in the middle of a group of other children without noticing what the other children are doing or trying to join in their play.",
"     </p>",
"     <p>",
"      Here are some other things a child or adult with Asperger syndrome might do:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Stand too close to someone and talk non-stop about a single topic without noticing whether the other person is interested or even listening",
"       </li>",
"       <li>",
"        Not look into other people&rsquo;s eyes when talking to them. When speaking with someone else, the person with Asperger syndrome might instead stare at the other person&rsquo;s mouth or another part of his or her body.",
"       </li>",
"       <li>",
"        Have a facial expression that rarely changes",
"       </li>",
"       <li>",
"        Not use his or her hands or arms when talking",
"       </li>",
"       <li>",
"        Be disorganized and have problems finishing tasks, including school work",
"       </li>",
"       <li>",
"        Have trouble solving problems",
"       </li>",
"       <li>",
"        Be very sensitive to noises, odors, tastes, or visual information",
"       </li>",
"       <li>",
"        Have trouble knowing when someone is joking or teasing",
"       </li>",
"       <li>",
"        Have very specific, unusual interests, such as trains or vacuum cleaners",
"       </li>",
"       <li>",
"        Get very upset if a routine or plan changes",
"       </li>",
"       <li>",
"        Be clumsy",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H103508987\">",
"      <span class=\"h1\">",
"       Are there tests for Asperger syndrome?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes, there are a number of tests that different experts do to see if a person has Asperger syndrome. For children, these tests involve asking parents about how the child speaks and behaves. The doctor will also watch and talk with the child.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H103509002\">",
"      <span class=\"h1\">",
"       How is Asperger syndrome treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Treatments include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Therapy - Different types of therapy can teach children how to manage problems related to their disorder. For example, a child might have therapy to:",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"hyphen-block\">",
"       <li>",
"        Help control anxiety caused by loud noises or changes in his or her routine",
"       </li>",
"       <li>",
"        Learn how to recognize and respond to emotions",
"       </li>",
"       <li>",
"        Learn to understand tone of voice and body language",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Help with school - Children with Asperger syndrome might need extra help and support in school, especially with staying organized. They also often need help with reading and writing.",
"       </li>",
"       <li>",
"        Medicines &ndash; Doctors might prescribe medicines to treat conditions associated with Asperger syndrome. These conditions can include anxiety, depression, and problems paying attention. But medicines should only be used after therapy and education supports are in place.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H103509017\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?37/37/38481?source=see_link\">",
"       Patient information: Autism (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?40/46/41699?source=see_link\">",
"       Patient information: Autism spectrum disorders (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?24/18/24865?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 83673 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-190.111.122.2-BE0BA8F269-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_18_24865=[""].join("\n");
var outline_f24_18_24865=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H103508957\">",
"      What is Asperger syndrome?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H103508972\">",
"      What are the symptoms of Asperger syndrome?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H103508987\">",
"      Are there tests for Asperger syndrome?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H103509002\">",
"      How is Asperger syndrome treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H103509017\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?37/37/38481?source=related_link\">",
"      Patient information: Autism (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?40/46/41699?source=related_link\">",
"      Patient information: Autism spectrum disorders (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_18_24866="Alopecia areata 5";
var content_f24_18_24866=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F70996&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F70996&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Alopecia areata",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 380px; height: 272px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This child has smooth, well-demarcated, noninflammatory, asymptomatic patches of alopecia.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Goodheart, HP. Goodheart's Photoguide of Common Skin Disorders, 2nd ed, Lippincott Williams &amp; Wilkins, Philadelphia 2003. Copyright &copy; 2003 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_18_24866=[""].join("\n");
var outline_f24_18_24866=null;
var title_f24_18_24867="Tetrahydrozoline (nasal): Drug information";
var content_f24_18_24867=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Tetrahydrozoline (nasal): Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?3/55/3956?source=see_link\">",
"    see \"Tetrahydrozoline (nasal): Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block spa drugH1Div\" id=\"F15512122\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Special Alerts",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      FDA Issues Warning on Accidental Ingestion of Imidazoline Derivative Eye Drops and Nasal Sprays",
"     </span>",
"     <span class=\"collapsible-date\">",
"      October 2012",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       The U.S. Food and Drug Administration (FDA) has issued a warning that accidental ingestion by children of over-the-counter (OTC) imidazoline derivative eye drops and nasal sprays may result in serious harm. The eye drops and nasal sprays involved in cases of accidental ingestion contain the imidazoline derivatives tetrahydrozoline, oxymetazoline, or naphazoline. Serious adverse reactions (eg, coma, bradycardia, respiratory depression, sedation) requiring hospitalization were reported in children &le;5 years who had ingested even small amounts (eg, 1-2 mL). These products should be stored out of reach of children at all times; parents and caregivers should note that not all products are packaged in child-resistant packaging. If a child accidentally ingests these products, parents and caregivers should contact a poison control center at 1-800-222-1222 and seek emergency medical care immediately.",
"      </p>",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       For more information, please refer to:",
"       <a href=\"file://www.fda.gov/Drugs/DrugSafety/ucm325257.htm\" target=\"_blank\">",
"        file://www.fda.gov/Drugs/DrugSafety/ucm325257.htm",
"       </a>",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F9600033\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Tyzine&reg;;",
"     </li>",
"     <li>",
"      Tyzine&reg; Pediatric",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F9600163\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Adrenergic Agonist Agent;",
"     </li>",
"     <li>",
"      Decongestant;",
"     </li>",
"     <li>",
"      Imidazoline Derivative",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F9600130\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">",
"     <b>",
"      Nasal congestion:",
"     </b>",
"     Intranasal: Instill 2-4 drops or 3-4 sprays of 0.1% solution into each nostril every 3-4 hours as needed, no more frequently than every 3 hours",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F9600129\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Nasal congestion:",
"     </b>",
"     Intranasal:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children 2-6 years: Instill 2-3 drops of 0.05% solution into each nostril every 4-6 hours as needed, no more frequently than every 3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children &gt;6 years: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F9600131\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F9600150\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, intranasal, as hydrochloride [drops]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tyzine&reg;: 0.1% (30 mL) [contains benzalkonium chloride]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tyzine&reg; Pediatric: 0.05% (15 mL) [contains benzalkonium chloride]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, intranasal, as hydrochloride [spray]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tyzine&reg;: 0.1% (15 mL) [contains benzalkonium chloride]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F9600035\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F9600036\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Symptomatic relief of nasal congestion",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F15801080\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Other safety concerns:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Accidental ingestion: Serious adverse reactions (eg, coma, bradycardia, respiratory depression, sedation) requiring hospitalization have been reported in children &le;5 years of age who have accidentally ingested even small amounts (eg, 1-2 mL) of imidazoline-derivative (ie, tetrahydrozoline, oxymetazoline, or naphazoline) eye drops or nasal sprays. Store these products out of reach of children at all times. Contact poison control or seek medical attention if accidental ingestion occurs.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F9600039\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Transient stinging",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Sneezing",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Hypertension, palpitation, tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Tremor",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Blurred vision",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F9605851\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to tetrahydrozoline or any component of the formulation. The 0.5% solution is contraindicated in children &lt;2 years of age. The 0.1% solution is contraindicated in children &lt;6 years of age.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F9605852\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Somnolence: Profound sedation may occur in children following overdose. This may be accompanied by diaphoresis, hypotension, and/or shock. Do not exceed recommended dosages.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use with caution in patients with cardiovascular disease, including hypertension and coronary artery disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Endocrine disorders: Use with caution in patients with endocrine disorders, including diabetes and hyperthyroidism.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: For intranasal use only.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13300127\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F9600112\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the hypertensive effect of Tetrahydrozoline (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F9600037\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F9887149\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F9887150\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F9600152\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Tyzine Nasal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.05% (15 mL): $91.78",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.1% (15 mL): $68.88",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F9625213\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blood pressure, heart rate, symptom response",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F9600123\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stimulates alpha-adrenergic receptors in the arterioles of the nasal mucosa to produce vasoconstriction",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F9600124\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">",
"     Onset of action: Decongestant: 4-8 hours",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9935 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.243-2BB6473422-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_18_24867=[""].join("\n");
var outline_f24_18_24867=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15512122\">",
"      Special Alerts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9600033\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9600163\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9600130\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9600129\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9600131\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9600150\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9600035\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9600036\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15801080\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9600039\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9605851\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9605852\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13300127\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9600112\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9600037\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9887149\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9887150\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9600152\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9625213\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9600123\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9600124\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9935\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9935|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?3/55/3956?source=related_link\">",
"      Tetrahydrozoline (nasal): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?19/21/19795?source=related_link\">",
"      Tetrahydrozoline (ophthalmic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?5/62/6116?source=related_link\">",
"      Tetrahydrozoline (ophthalmic): Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_18_24868="Endometriosis implants";
var content_f24_18_24868=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F65789&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F65789&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 563px\">",
"   <div class=\"ttl\">",
"    The top, middle, and bottom series are representative of red, white, and black implants, respectively",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 543px; height: 430px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Revised American Society for Reproductive Medicine classification of endometriosis: 1996. Fertil Steril 1997; 67:817. Copyright &copy;1997 American Society for Reproductive Medicine.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_18_24868=[""].join("\n");
var outline_f24_18_24868=null;
var title_f24_18_24869="Parotid enlargement MRI";
var content_f24_18_24869=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F58074%7ERHEUM%2F80648&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F58074%7ERHEUM%2F80648&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    MRI of enlarged parotid glands in Sj&ouml;gren's syndrome",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 288px; height: 325px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    MRI of head in Sj&ouml;gren's syndrome showing symetrically enlarged parotid glands (arrows).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Creamer, MD, MRCP.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Parotid enlargement in Sj&ouml;gren's syndrome on MRI",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 353px; height: 288px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAEgAWEDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD558JXevQ2eu22gWrXdtcWEh1BPsonWO3XkyHIOzb1DjBB716F8LrSHRPiBa6F4v8ACV7qXiS/eH7HfR3KzNZxyRfLMsRDxS7VIfLZC7eQNpry6z8QarZaDfaNaXssOmXzpJdQR4AmKZ27j1IGT8ucZwcZArorD4reN7DwwfD1p4huk0ryvJEe1GdI8Y2LIV3quBgAMAB0qk7Gbjc5bXbKPTdb1CxhvIb6O2uJIVuoDmOcKxAdT3BxkfWqFLRUmglPwAuc8mkVSzADrU8wAX5QBjjFBLetitVqBFNuxYHBbGQOlVsVs+FryO11SNboK1pIQJVYZGPWqjq7Mmo2o3Rc06PT7N5ILzZOJkBDbeUrqvASR6bO9zG0T2rnGXUYB989KpHwP4h8TXN3qmk6dIdMiJMT4A3KOm0d6wtF1O70DVZoDEZFc7JoJVxznuOxrde69UcUo88dJXfU6P4jXun3uI7dYfPVssI4wufxA5q38LNCku7jctkA/aWVcqPpnvVnS9Dh17V1uJY1jO0Yjxx+fevZPCln/ZenokcIG04PHNaxhd8zMef3eRFax0WPT7jzZYIJJW27n8lcnb07ds1s6j4dtLiNb2ztbeKXHz4hXP8AKrkqlI5WBUqy5VycEN6Yx0981r6FaywhGlON4zzyDWpKicvYtBaKImtkjkY/M6oMt7k4rbi061knSW2gg8z+JxGoLDrgnHNQ+JLDZP54YH8cCsvTNcXT7nbIMkHoDmgWidmdleafBDbfaUtI3dxsyFBYDr1xkD2qnqOh211at5cEG/yyH3RBgR6GtKx1OC4iRw2Q33lU9KufZVz50UmB6EcMPf1qTSyZ8d+J/CItvEd3Ha2ZCMxKJFyB9K4fVEmsLxow0sbDqpBXFfV3xT0eLS9SttbsT5cQP75AMg574ry74nafoOpaNJqCXe3VNoYLjAasZ09NC6dTll72p4hI7SNl2LH3NMpaSuQ9M6/wLY6Ve6d4k/ty5ks7aO0iZbmKzFy8bG4iHyqWXGQSCdw4yOc4qPx3ZaXYxeHV0O6e8tZNNMhuJLQWzyN9pnBLKGbJGAucnhR6VzCSyJHIiSOqSAB1DEBgDkA+vIBoeWSRY1kkZljXagYkhRknA9Bkk/UmqurWI5XzXv8A1Yjq9pGnTanfR21uuWY8nsB61Rr1v4ZnQn0N/MgaTVIwzEjgAdqqnFSdmRXqOnG6Jfhn4RttX8Zm1d45LKyG5gVyHb0r6TtLS3t1CyKi44QAcD615X8B7GI6dq18hQGaZgB6CvV5YVFiYVYKcd+prtikkede7uQLf2dlM0xCK443daxbvV7OSZ9kTbn5LDgGt+x0O3MKyzxhkPVWq1N4csZbdvKtS4HXBHH0p6BZs87shDeXbSx5+U4Knr9a0vEVqy6QYERvMYZUxnHvWzJ4ZELiWzk8tCfmEg61U1Fp/JMEilUUfLs7mmRa254ZqkEa6ofNRVfGH34OaytN8QvoN5I+m3d0iBvnWMjaa1fiRFLZTSTJGCX++w6rXD2Ny1vpV1MIVJk+RZH6D1rGWjKUboreLtffxBrLT3DPtzjr0FfRul+EdBh+FU9xaQ20StamSO5iYh3fbnLV83+ForCfW4F1GRURm+Zj90fWum1jxz/Z1reaHpaYtFYoskb/ACkeoHpUQkleUupvUg21CC2POZGZnZnOWJ5NMpWOWJ9aSuU9FEix5RmzyO1R1etgrWb4GCDyfWqR4ptWIjK7aEooopFhRRRQAUUUUALSjHerWk3i6fqdpeNa292LeVZTb3KlopdpB2uAQSp6EZrvtS+J9pe2F1br8PvBNs08TRiaGwdXjyMblO/gjOQfWmknuyW32Op+AviSx1nxLoXhHVPBnhC6s2iuN95Npu+7fZFJKC0hbBOVA6dOK5yw1rS/iR408M6TrekeG/C2mtclJ7jRrMWrOGA4dmYjqoAPbcTzUH7O9zBafF/Q5rueKCFUu90krhFGbWUck8DmuQ8I2Gn6r4k06w1nUl0rT7iURy3rJvEIPRiMjjOBknAzntVJvQlrdHs2r2Y0Np9I8d/Cq00Xw+FlSHU9Mt5ZbiCQ7vJb7S0hWU7sfK5APBwAMVLpGnvpHwl8O6jpPw/0zxPqV5d3a3kk+nSXbRqhAUZjIwOo544471tfD3SPG/w91OO48T+J9LX4fKjG6km1BLu1u4WUnZDEcuXfPGFGcHr0NiwsfGeu/CTw6fhvLd2bDUNQeeG1vkszGjSExKQWGcDtzitU+pi27pninju5vdc1rS9PuvB+l+FLs/IkVtZyWnneYwUM4cnIBBwQPXr29a8LeB/Bfiq9+IGk21tFBHpxsdH0m+U5b7TiRDKzLw3mSpyccqQMCubTR/Ffhbx7ZeI/ivcu02mWE2oWQvdSWd7l4cCGJGQvt/fSocEYPzdeazvhrrV1p/wv+JGrxTAahDfaNdxucZMq3TvnB4PIzjB+lRfqzRps9R+A/jGx1GddNuop7MaRaGe73gqiIhVCuOpYswGDg9e/FeOfFUtH8TNfvPs0XkRavcQBY12jbHJtAwPYV6v4sXTdEePVdKljb/hP9f0+8ijBzttkaOeQ5JP/AC3fB+6cj04rxr4mXZb4l+NbF5RHDJrN2wbrhhK1aOTe5g6aS0Wh9A6DYw6v4Zh1GxW3iKqG3ADAGO9benxGSIAy/vCMZQZFfM/hDxpqGmabJpjXTrEDgKOR+NeueAPExfEV3JhyQAc8MPpW8ZqRxyi4uzPSLexYEzOxkVeCpXAP0pmo661ravBGoaTHyKDkj2rejAn8qJJlCuvYcU6y8KQx3CXLJ5kwb5VPIPvVXKUX0POpdO8R6zarctmGPdwj1i22iXdrqkomkYyPwQeR+FfQt1bw21m6OoaQjJ46V53cQRXGsxyQxsSD90mkncUqfKQaN4P1CBY5Vu9qP8wXHB+tdrpLS+V9muUAdOAexrYsFj+yBGHUYYelSC3QFQFyV+6e1LmNYwtsedfFFRJ4VvNyIPLBPI6V8o/ErWILs2kVou3bHh93JJr6l+LeqJb2F1auyPFJGfMbrjivinV5/PvpSG3KpwpPpWVaVo2Low5qnoUqSlpK5D0AooooAK0tK1GezWRIGdWcYytZ6kqcjrU9uzLIG37fUetVF2ZFRJxsz6O/ZrjludGvopMk+dkAcdhXtd/aS/ZgNnmSdsdq8Q+G3jjQNJ0K3Vb2KF41/ex9DnvXoVv8YPC7Wzu95GrqPl+bk/Wu6LSS1PLuru50iafqjRKxwyr0XNWdNvbi3uDDdwvEexbpWLofxO0PWJYra0lDzNy20j5RXam7sbqM5dH2jjPU07jVnsyLWrqIWkZngGG6Fen1rg/Ferw2elykRhY0BJbHJra8T6rFaQBfmVfQnpXmPifxJp1zotx9rZzeqp8lo/ug+9NaIU5XZ4d4u8Q/bry5MNwWikOMHNULuPydCt1Ry/mEttxxmsZllu9U8tF8yWWTaAv8RJr3fxXp2meFPBWnx31stxeuigL/AHTjmuePv3bNpxVNRSMbw78JtMtvh5c+JfFWqLbO0ZaCFWxt44z6k+leUx2mmPo95P8Aa5lv4pB5UPljY6E9c9jXb+M5/EPie1tNOsdKvDYWUIm2rGfT730xXBXN8txbW9rHbxW0acM4zlz6tU1OVaJGtJyl71zOop8i7HZdwbBxkdDTK5zsLtgQQ6jO81BdqEuHVegq1pIXe5ZSSO/pUWqLtvZPfmra925in+9aKlFFFQbBRRRQAUUUUALVvT9Mv9SaRdOsrq7aNdziCJpNo9TgHAqsvXmvoTQ28cWnwe8EP8LI7oxy3Vw2ptpqb5TeCUhBP1wnlhevy/3v4acVciUmtEfPFLmvSP2grd4fiVcy3KQpfXdnaXV2Ldt0XnvAhkMZ/ulskcn615tQ1Z2Ki7q5paAD/aUTBdxU5wK2/G0duBA8ceJmHzNjrUPgix8++aZ3CpGOhOM1H40kgOpeVbhtqDBycjNarSByN81fQ52iiisTsLkVpcpZi9MLC0Z/K8z+Et6V6f4a+H+j+JfCwlTUxZ6rCpfZtyHHYfpXlPny+QIPMfyd27Zu+XPriva/hBBDf6d5unSo2ox/JLC45A7Ee1b0VFuxx4lzjaSPNYLJtJ1ZJLvaVV9pBGR9a0PEN3NpWpxXmmXO5RhwAeBV/wAS6Fd6V4pubTVY3CXTFkYjrk9jWHr+hX1hYfaTh7ZjtBB5/EVTXKnYxi+aa5j3r4WfFOy1j7PZ6gRazjAcyNkN9DXu1n4j06zXM1xGYsAKxYcV+dAZkPykqfY1v/8ACTatNBBAby4bZwpMh4ojWTVpGkqEoO8HofoAmoWl+S0dwpZunuKbBp1s0hmKgOf4wMV8j+AvFHiG0ZVubi6eNPux7SSTXuum/EHWIIoIZ9BuZ2l6ShDhR61utVoY82vvHo9xKmnKWZhsAycnFeKfFD4y3WhCePS3hmibKBdwDqf54rnfih4z8RXy3ItLG4CxcFkUgJ/jXzlqFxcXV3JLeOzzscsT1rOpPkRpTg6r30Ow1D4i61q9rPbX1ypEx+8y/dHpXJS2M625uioMBbaHzwTVYRsVzg+1SmOQxqrsevCk9K53Jy3OpQUH7ppeHdFi1aWRZrtLVVUncyk59qztQs5LK4aKTnB4Yd619G1NtJVWW2DyK24F+Qfr7V0urazo3iJIpPsa2eoAAMyfdf2FUoRat1MnVnGTb1R50QR1q3plhLqF0sMO0E9S3QV2njSDT2OnpAkXnbcShBg4461g3NzFa3pawtzHsGFyf1o9nZ6j+sOUfdWpW1aztbGbyoZPOAGGfHAPtTL6DT47G2mtbhnnfIlTH3afFaXN2jyGCZ0P91cgGk0vQL3UpJUt42LR9eKGm9kEZJL3pbGXIuwgoTtPQ0iBnYKoJJ6AV0eo+HbjTRGmoxSpERkHHNdv8HPAUPia+ldWcSRHKhulCpNuw3iIqN0Q/DTwBreozxXlqjqF+YspwVFfQ+gWWs6WIftKfaLbIG4/ez71nC9i8L20kNpbPE0XEhUfeo0TxYmrIXjuWtpyxAjfgGuuMVFWRwuXM+Zml4ksJbh5UvE2FhmPPpXz345s72w1CRyZDYMCo8sZGa9p1nV7qLdFfxtMw5jkQ5/Cuasr22GqBdRRI7eXgrJ0U+pptXJvrc8H8KXEdj4ltri6gLQpKGPtzXZeK7+68SeJof7S88afEw8ny1yAvqc1p/FDwR/YVyuqWTRvYXLZV1PAJ7V1a/FTwnaeG7Gwu7ITSxIA4hTuB3JrJJR0bNZNzd0jUXxOlxDjw45n2QiKdwoAjAGOa+cPER0+LWJRZjzogxLYOAT7Guh8afES61nzrPRrdNI0l8hoIOsvux/oK4OsatVS0R0UKDjrIVuSSBgelNoorA7De8KRLdTT2pjVjKvBJwVx3FL4r0w2FxGRuKMuMn1rO0W7FlqUExyVVhux6V2fjSH7fpcd3bxERjkFjzj6VtFc0Djm3Csn0Z59RRRWJ2BRRRQAUUUUAdn4Nj8Atp0p8Y3PiaK/Ep2DTIYGi8vAxku2d2c9sdK3/CPiXwTZ+HWsr4+LtJu/3kd1Lo12AmrQszFUmRmAQhSF43DBYnOa8uoqlIzdJO92/vOj+IHiYeLfFFzqkdlHp9qUjgtbOIgrbwRoEjQHAzhVHaudAzwKSrFigku4lPQnmluy2+VXO+0u2srHRYGN0kM5BZg68iuCv5WmvJXd95LHkd66PxHeQ/ZhC2GmXhWA7VylaVX0RyYWL1mwooAya0NP0e/1BttnaTzH/YQkfnWSTex0ylGKu3YoBSQSOgq9omr32iX8d7pk7QToeCOh9iO4r1Hwl8D9T1jTnur66FntUnylTew+teZavo11pmo3FpOhDQuVJI61o4SjZmaq05+7c+gfDXxZ8K+LtKi0/wAeWH2fUokxHeRD5Sf5ivK/iTrNnLP/AGfpjlo43zuRsow7fjWbonhOTU9MkkgW5a9U5SFFzvH17Vv6P8MNS1C8hS6jWxQ8s0rBj+netrzkrHK3SU732Od8IeE59fv0tYyUMnR9pPHtXYr4OsLTXTpFqs814gG7bGXOfqOBXXS6rpnw7spFtp4pr8J5cSEZYf8A1qyvD3xa1PRbOV9Ms7OK7lYtLdSxljz6EVShGOnUzlUnN3ex7V8OvAw8MWg1vxddQ2lpCu5YpyMj3Y/0rU1D4zaK0ZbQrOW+RTt3cIv4V4Tb3es/EPUov7T1Q365BAkyqp9BxXuegfCnRY9MC3cpluGXKpGRtBp2T96Q4yduWBjat49TxNplxaWGjQRiQfPI4+YGvnyL4ZX15fXcs7QxgSEpGoJL8/pX0HD4bFr4oj0sIY8jc+eDt9aueF1SLV9a1LTrSL7BZZiVpejMOpFW4RaJUp3vc8guPhbpr6dBGbz7LdKMtFj5q80j8KXF54r+wQxySRRybfN28ECvqeCxk1m7Sa6itpFc7mxkMo9q6/TvD+h2MEkotI4yeWd+opSgmODl0Z8VfEFf7IvV017HymiAxuGNw9fpWLowivNwVNkq8jaen0r1f9qrT7WLXdOvLJkZHjKkqevNeH2FybW6SXG4KeR61hOXLM6IUualpubjqz3wklnSRjwXNZurE29yY0I3L3FaUeo2MNy96kGXA+SMngH1rnp5GmmeR/vMcmpnJWsh0YNyu9jufhpqGqXeuLZRCa5idTvCqCUX1rufDVrdaf4luonsZ3sSxIl2fMp9TV39lWxtpbjVbi4AEg2ojt2619ASabDG5ItYWJH+tNb0l7qbZz1o3m+XQ88TTNE1p41vYJpGHVhHnFdZoPgTyHW50KWJkUcbTtZfYirWiAafqnyxq6yHBIGcfStzXre/0y8jutCA3Trh41P3j64rRvsTGOl2ctqthNrFxLZaxEbf+DzIx8w96S3+DUPlQ771bhEOVkBIb8cV0nw+1y91C9v9P8R2fkXkL5jdx94U/wAU+I5tMkuIY5Ykdf7rc4+lS227IpKKV5GM/hawsbpILzUYXh6OpPK1geN/hLJc2rX/AIfuEv4VGfs5PJHsR1rlfEaPfyB2vZIfNbdvDkFqq+HNd1TTLt0S+uXslIX5WJKn3FNpkqUexvf8IuNT8MJpOoWrGQDjcxyCO1eS/Eb4SXvhzS21SKJPsjsEw7neh+npX07oWpR6i3m3tmHuUTMcoyN3Hp61zfxDbSme0k1kSLATiWKUnb7cUSipaMItxV0z4muITBKUYgkdx0p/2WRbYTOjLGxwGI4r7Jn+BnhzUbKPUtLtkcTfvEjLnBzXlfxN8CwaB4a1WVo3imV1AgI4QZ6r7Vz+x3szq+sS0ujwE9aSlIwaSuc7BQcHNesaWo1fw5FGZIgqxYAzzmvJq9B8JSWqaRAZSTN5hA2np9a2ovVo5MWtEzg7mMxTyIeqsRUVbWt2klx4kltrKCWWaaULHEiEs7HoAB1Jr0iy8KeH/hnaRap8RFTUvETqJLTw5E4IT0e5YZAH+z39+cZSVnY6YPmimeY3ugarY6NZateafcwadesy21xIhCylcZ2+o569+cdDWXXSeOPGes+NdW+3a5c79g2wW8Y2w26f3Y07Dp7nHJNc3SKCiiigApaKKACr+jhfte584UHpVCtzwtbrPdSbsYVc5IyKqHxIyru0GUtSdXcAE596pquela2pWr/alQKAeleueAPgTq+uWlvf3s0cFs7AhR94j39Kv2blJmUaqjBHlnhfQbvV9Rggt7aSQM4DEISAPWvuvwH4LtNM8NWsJgQEoDjbjHFdZ4a8OaZ4f0q3stOs4IUiQKSqAFjjqTWuoAyPSmqigrRF7KU3zTOUs9GlsVlNk0abz/EucD2rxjx58J47vx3ZX0U6Mt037+J+Qfevo9olbO4cViy6XZz3zNJCjTKN0cvda1jU5tyJ0rLQ8O+ItmnhA2mm+GoHhmZRvlCfM/sDVbwXYz3+nX41NZIriNS6mXDfyr2fW44dS8MX0t+Iku7HftkAyVK9PzrhNNMMFzZXTSJHFfR7SSRtB9xWsXc55w5X5HzLr2n3d9rVy0ipJliiynrVzwzdtokclrqiIy7s4dc8exrvvGOkxaNqNy+p2rw2sr/u7iL+InvXIarBM1qHg1Bbq0Q7jkfOPY1NrakXvozs7PVLa40xn061hglYYSQKQa7XwF4yfTrm1tdSKh16sx615d4f1s2k0KBYZ7eZcHI5SvWfhT4HsNZ1KXWrgPKqHaA/T8KpyVrsIKXNaJ1ujyjX/HcuozBUjhh8tdp+8tc7Pdw/2nf6VpzKltJMT14rs/EWjWHhjR9T1KA7AUz8x7+grxLwrqcdwZ7xY2RiSShPB96INPYupeOj3PR/Dt3Z22qzW15EgjUYVwTkn2q34qtFvYmhtpmVWXuegrx+w8XX1v4i+exV4S/ynOQ1en3epxarpbXcCbJVX5484xVCT0sfNHxihltZI7RpmlWJiQzHP4V5bXovxav2utQ2iMooPQ9TzXnVcVb4jvwvwBS0lLWR0H0x8CNPhbQbWWLa0kr/ADhT0+tfQwtbO3CxKpLFf4ietfM3wD1oQ6YkFvGXnR/nA9PWvadQ8RSwMY+QAMgkcivQjrFHlX5W7lXXSYPEUQjuCqg8hP5V1Go6qbaHT7wSnEUgG09x7153Ml1d363k24pnKMBXR+MPtC+F1nVCGdOCwwAfWqJTetj0/V9Ng1KzE6IPO2bldeD+deL6vaR3N/KRdBnXIO48ivQPhF4lh8Q+EkgEha9sx5My55yO9edeNor611W7AheDcSVyvUVlSurxNazUkpI5u40p5JFMsqN5TZVmbpV+LUEjvYooLaN3k+QuBwKydJvIJrpoJW3sBnEjYKmvRPh9pmnanqSC7QssYzkjAY9hWl7K5gld2K/w/kv9O8Q3MdwQ9u3zCSThYx6V2HiewtPEVo9vDFFcTHgycEV4r+0h4lfw/q/2HSGe1hkjwwTjP0Nb/wCzVcX2qadELm+MiAsww25iB2NTzK5qk17p73plmujeHobaJARbQ/dB6kDJrlPGmj6b4w8DPNqNqFmljBQ/xA56e9dvdpHJaSQSsVR0Kkg4OCK8Y+IHiex025trawvpJv7OH7wR8gexHc1jSXM7m9ZqKt0sfNnxh0jT9DlgsobaNLpVyWjGAB7+9eXV9Man4WsfHviS3vYpAXmGTCTw31rm7z4GXd/4oTT9PlS33ygODlxGn8TfgO3c4FOtSbfMhYesorlZ4XXbfCvQ9d8ReIBYaBCX43TyOv7uFP7zt/CP19M16Br/AMA28N6/c3PiDXray8F24Eh1JyPOkBz+5WPkmTj6dxk/LXM+KPiMk+njwz4Esv7C8LKcOoP+kXp6F5n6nP8AdzjtyMAc8XZnXUSlFpnU+LfFmifDe4mtfBccOo+K5E8u412VAyWwxgrbqcjPqx/XoPDb27uL67mur2eS4uZmLySysWZ2PUknkmr/AIjbdqBXPKgD9KyaJ/EKjrBBRRRUmgUUUUALRRRQAV0/g6Nm+0urDAXlSM5rmK6HwpIVF2u/YDGaun8RhiPgOi8Nww3/AIu0m3kjEkclwiuT2Ga/QC20+3t7CK3t0CRxqAu0Yr8/vh5OsfjjRckYN0gJPTGa/Q5cbBt6Y4rSUrJWMaMdWn2GxksgzxTwMUingdqdWLOlIR/uEVz/AIqEuneHLy6090imiQv8ylgcdsCt6X7pPcc1We4V0CsAQeCD0q4XWqIqWd0zw3wt4k1C40i5udStWge4Yqcg4dfXFeAfEHxNfaH8RGexuGltICrJbyE+XyORivrz4uXNvpvgbUNRWCP/AEWPcrKAMfSvgDWdRuNU1Ga7u3LyyNkk1tUqe6rHNTpXlZ6o9vTx+fFEEGmTwPdQygFwg5gpNVjiidBbxusCDacoct9eK4zwDoviP+x5dU0CCVJwcRyKOoHXr2rvPDviTWp4d3iV4XvLd8BcYyPRvetYttamE4pPQoeCvBus6n4kEdnp872kjBmlVSqp+dfYPhXRItA0WGxhO7YMs2PvGuA0P4p6dBYQRXNk0b7cbYMY/KqHif446bZoYNJs5pr5h8qzDaB+VZVIyfupaG1KdOHvXuyH9p/xRbaX4RTTQwN5dNlEz1Arj/gH4Z/t3wjdShzG+4q5Yd89BXj/AMQ/Et74g1p7vxA+65bIRB0Qegr6A+BFyPD/AMI9Q1O4BeKDdKVHpVR91WRMpc8rsiufhjc6RBcXqqJVPJ2ZJFcrpsyaZdG3n8w7j9wnHFesD4gzP4astQt47eeO9T5djH5M+teM3uoz3+qytcohRZMbxwTWsW+plPl+yeYfGyz+z61HNEu23nXcv1rzOvavjXah7C12MZTFyCvRBXitcldWkd+Fd4BS0lKKxOk9p/Z7uJYJ7uRF37MEAjg17LdNDqfmPcbo1kODt6j6V45+zz+9bUI0Y7hgkY7V6VrUs1vNbpbxs0bSAkJy1d9L4EeTV+NntXhjRdPbQFKMJo1Xl2HPA71yvxtuZLbwFaTQvthaRV467T3FXLu01i78HC60S5mtBtxNFIgBYDqaofFqzRfhNbJcXAVkVCre+Kl77mj+G1uh5F4M8Vnwh4ja+0t0lsXIW5LNww/xr6MW/wDD3jnSFTzo33rkJkB1PtXx5dMu42yoDE4zhepPqa0dC8SS2dxFCZGiaLgSI2CfahpNkxm4q3Q9t8QfDueyuHntXWQnhGkG3aPwqPRX0fRNTtQNUe8u84kt048s+pxXO6T8YtTt7OOz1GaBizYjknAXI/rXQeB/F+m+IviNJZatY6dbTLHuhlRx+9b3q09NSHZvQ8U/aC1X+1PG0lrcoIUiQGMn35zmt39kr7ZD42uFRZZ7UR4ZoySi/XtVX9rzT7ay8c2Utu6GSe3zIq9sHirf7GZmfx3qaJcFIUs97Rf3zuA/TNYOS5n/AF0OmMHyr1/U+slu3n1Se1mspkCKDHMw+Rx3GfWvHvHPw3ZdXuNS0xJis5JnMa7gn4dxXtGvWn27SLmBZpIXZTtkjbDKe2DU9kmyzhU5yEAOeecUo1OVXRc6XM7M+NtVsfEXg7xLpl/a25niL7QYycMPQ46V9M+GLyGWKKa+itrbWbiMGW1jffJGOwYdR6n/AOtVLxn4bhvHRVcxCSYMyEcN649DVTw74Si8M6/cXy3TbJ1CQxsMsWPY1tJKa3MKd6ctjzn9qzxbaweG5PDVzo8lxJclJYrtpQqwOrZ3AYJJxkduGNfI8RIkXHXNfb3xX+E//CU2c2palePJqSISgThFAHTHeviu8tvsmoywSsQY3KEjtg1zTglZrY66dRyupE2t7HkilQFWZAGU9c1l1qa1IsnkBRwq7Qcdfesupn8RVH4EFFFLUGolFFFAC0UUUAFa/hza14yO21GXBNZFXdIYC9QEj5uOaqHxIyrK8Gb+nXH9m61b3FsQXilVge3Br9C/B2oyap4bsLudNkkkQyD9K/O7TwP7SRVGVVwSo6da/QnwQyy+FNMeLhWhU49K2fws5abtP5HRfWl6UwDBzyTTs5HFYHWhHG5SBVC+ZIbFnIx6+1WppDGR0296oX0P2q1lySFYYwOtaQRlN3OW8YaPH4q+HuuWUwZmaCQxhT3AyP5V+eb/ACMQVwwODmv0y8PoILZ7UqdidC3Ug1+c3imzW08Ua5bSKFMN3KoUdhvOKqpqxU7LU9k+HPxZsdH8MQ293G0N5bJsijjTKyD1Nc9dayL6ed7VR5t7J5ksg/g9q43w2sEsErOEJjXjcOB+NLPfRWWY7Viyv94r1Naqbtqcbj71kdXLqUjzLbyyMYkwAynk1t3Wl3DJFK9uzHgqf6muf8HeHfPiW+nDAhtwjfI4HrXqWpzxrp1vNax+dgbWUf0q4q61M27bHkmu2E9zriTXCK8SIF+le9XWradB8F08P5eGa8QQr5QyxJxXllzYtcasDADG0x+cOOErv44bjRZbaXUUtnW3UPDcZyuPp0pqPcrmaNzwn4d1Xwh4Ce21OISjy90cr9EB9q4610+C7m+1KzTFup//AFV6F478e6Nrfg6C3029Et3Kw8yNDyuBzXF6DIzQbVwuG4JGM046rUU7X0OF+IOmN/Z89yCxQDbszx9a8Pnj8uVl9+K+hvixclYmSSMRgJ0Q8H614RLEJ5SdwVs9MVhWjd6HThp8t7mZg0CtN9OwigE5PQ+tUZY2ilKP1HWudxa3OyNSMtj2L9nS6MesXkZBBMfDY689K9l8Qoba5gaF1im3b1LAHmvn/wCCmofZ/E0USHYsgxj1r2zxbc/abmJY2LugyR3FdlJ+4jzq2k2ek3XxG09fB/7y+j/tQqIzFtALHoeK8/8Aivq9zceDLZYmy64Kxda4aDwlfazrtu8AZLh3GGYdfak+Mdxr3h/U9O0e7svsUEgyJ928T+uD2+lOyimJylI4rTA91eyszrHMBkqx4q1e6fLeadJJahWlHUJ1Fb1pplho7Nf3czXc8q4S3VBhCfU1fvLe7jst6qltvHybFzn2NCjoQ5Hj8l0322O3vjKsaHGWGSp9asaTdONft3uHkkJkAWWN9p+uR0rrda8LLd6NJdPOvnoNzAcn8K4GxWWMnMgj2chm/lUNNPU1TjKOhsfFC/fV/EzMkzTJbxiPezbuldP+zNf2+n+OLy4uL17UizcRlTjc2RxXm0Lo0twZXIL5xjnmvS/2a9FtNT8bv/aI3RIoG3HBz7/hWcdZqRu/dpOPofXF5rj6T4csbnULgXF1Mw2xLwWBP64FdFourQ6raedbbsDhgwwQawPFOjaXc3mnSXsLlIAViWMken+FPWxu7DTpZNMmWNy27LjIx6f/AF60cVKJKcos6PVI0msXLIG2jcCe3vWDBqFtsiuJpEnQHERHJJ/oa0r3VYLfRRcSyR4KjcWcAZ+tcz4W1G11MTCdLa32N+7VGBVh6g+tKmrRdxzldqxn+MviPZaU0tpq8D2ilCVkZuG4r4e8SXkd/wCIr67iVFSeZnCgcYJr7M+L/g2x1LRbqW4uVO5CYkZskNjjBr4nmtZre7dZEA2ttOeaVRJJcuwqd+Z8zHa2mxbcBlYbe1ZNamtoY3hHbbmsusKnxHVQ+BBS0lFQahRRRQAtFFFABUkDFZkYdQRUdKOtAmrqx0MdwFuflj2kgHjpX3P8B9VXVPAFkBJvaIbW9q+GEHmQQTRxl8jaT719WfsjXqT+H9TtZ5iLmCb5YieiHv8AnXQ/hZ58PjVj6CHyj1qvJL5cuDtER6k+tWe9Z+tRhrGXd6fKfQ9qzhZuzOqd0rot+UruHbk9vSqN/dC3cQgYc8qx6VYtZwsMEdxLGZyoztPWqmqzBsxiEP6FhxmrgnzWZEmrXRxXj7V7m1Fnfr5iWsWRKYjgt9faviDx3PFeeNtYnsz+5mnZ0J719u+JbS58RKtn5AAjBwIzwx96+KviVpl9onjXUrW+jEcschIHbB6VdZWikZUm+dmLYXMyQNAjhUY/MK7TwNoUWs3Krbus0wIJVhjbXAWaNLdRpuALsASTwPrXqlq1pocCnRcyTBQJJF/jNTS11YsQuV6dT1GGxTSWVb23aRGXaDGOK7bw3oFncad/yyVzyFY8gfSvNPA/inV47Qy3oRmBym4bv511y/E+S3YxtZ2vmuMNzgj3rqvocsbdTJ8ZaZaaVdkwSeZdv0CDOfavOtRvtaNref2qpj0/BULIxBU+1eu6R4zW5SdpdJtpJ1+4wbcT+dec/F2HUNUtra4t7QoJH+eNev5UpbArXOc8A6H5tvNOz4JPDA8la9H0BNkgi2OUj5Qt/F9awPB2kpFY+VN5kTKBkMCK6jTUeMTSAssCg/Mf6URVkJu5wnxl1kNHHbfdkY8qBnj615fpelT3s52MIlIzvcYFW/iFfvceIpnSVmQHCkjgV33wn0e7vIt10IpIG+6rHkCsvjnY31hBNdShJ4UlvrO2tsiGQdXVc5HrXMeI/CNzYOztFJJCOBKBxX01BpCQGMBAfRtvFUPEdhu0K9SeEGIKcDHBP1rR000ZxnKOx88/DUx2fia1M++NkfjI+9XvOsTST3sBjhViw6jgj6189/aPJ1uKWKULh8Hj7vNet6TdX8uoRqS23aCQ3ceoNTT0Vh1G27s9Ae7awfTrlF8qSN8k/wAI9814d8efHV74l8chXuYprWwASERfdU9Sc9zmvfdQ8LXereD3t7TdJ5y/IQfmzXzh4q+G2seGph/acSI7HgFsNjscUVU2tC6Vo/FsdZ8KfEaarNLYarHEZVXdHIYgdw9Ca9lji0ltFSN5IMZw8Tc4/wB09QK+afB3mWN46NIYw3X1/wD1VvT6hdvqS29m01wzH/WElQvtVRlZambsm7Hot/oOmyatJNpd0rKFwysflriPGfgW3u7Ce7sJAt2OSg+UGux0HT7q/eOKcQoeAzIwA/GvQZfhpbDTmnZpjIU+5uODxVNJqzFDm3ifE3kyQTFX4KnkV9J/sm2a/armeaENuY7WI54FcbrXgFDrGLcjl/mXNe3fCHQW0PHkRqox0B6VjCly3N5VvaNHsc9qt0wWRfunKmpr2xF1ZSW+SisuOKltdxALA8irLkKhPtWEptOx0xgmrs8L13RLjxpLDodoJraO0lzK/mHZweh9fpXbab4DSAxLfTLIsS7USFdq/U11+l2EVlAyRxqhkcyOR1JJzV8KAOK0nXd/dM4YdPWR4f8AFfwTq99os8FpcGGI/wCrkDlsex9BXx1q1rfWeqT213kzQuVcE9wa/TC7hS5t5IpACrAgg1+f3xetbi38fapuAUrKVPHUUnLnjd9A5FTlp1OL15Ti2dm3MyfpWRW/rsTjTLJyMJzjj+tYFZVF7xvh3eCEpaKKg2CiiigAorsrPwXcT+GVv4LPW9QvLhd1vHZabK0CDIyZJWUZPXhAw4+8Kj0PwRqs9+I9Y0bxFa2rKQJoNLklKNj5SVOMrnrjnHQGr5JEe0jucjRXT+JfBGuaDam+nsriXStwQXywSLGGP8LhlDRt/ssAT1GQQTzFS007MpSUldGrprl7OSEMwwdwxXpPwK8Qw+HviHpVxql08FlI3lO2eMnpu9s15Vp85t7pHAB9Qa2JXaN0kVVIzuxnpWsHpfscdWNpW7n6YKwZAykFSMgjvSModCrjINeR/s5+MW8WeEfLnlY3VmRE6t16dR7V64PSolHlehvCfOr2OcNndWviNbtoIWtAnlrIGO/n1FWPFV3b2ulSSXTfJ/CB1J7VJ4nv49NsBLOCUZgmF65NZurWkGtadB5UmWX5lB6fjW8fetJmEvdvFGPoN7Zrp8s0lypuyd20NyK8J+P3w/mukk8YSXSBJQFAJ4PpV7x9rjQ63NpUga2deDMnAIz2pPFmh+IPE3gi202y1qO+01CJAp6qR0BxWskmmjnjPU+c4dMu5boJZ27XEq87UBJP5V6H8PvD1xeXpTXYLq2HRNyEKPrXpnwi8Fy2E6XV7EonjIEgIyCBX0lFpun3lurfZYCCOuwVnZU9WXeVXQ+ZfEXw4v7K3+3aZeyTQquVlg+Yqfp0rxm61PU7PUJYdQkEzbufN+Vv0r7i8U6PHa6ei6cjwuWwDEMhfcj0rwfxP4AHibxFL/atmUnjU4li+UyD1wKv41eJDXI7M4rwr4lmnngBsxGqceapJDfWvTvB66VLq1zLfOWnIyuWLAfQV4v4fig0nxnd6FM80kbP5cb4xg+leg+Fma18RvYPEVMZB3SdSPaqizNqzO61+0tY9Ka6t7hdrNjywo3GuWuNYm0/Rrt9yNGIzjPSvQfEf2S30N5wyfaNvClRyK+ePiZqRbSfstqTGWO5+eGpydlcfLdpHnF5cJPqTSXLAs7biOwya+lvgTZ2E2mBjMrADpnJNfJ5POT1r2D9nbxL/Z/iM6bcyYgn+ZAf7w7CualU963c669G0VLsfUOraZDc+WLdZlRTwVBwPrWN4405LDw428u4lGCey+5rv9OkjDqfvI68isjx54VvPEPh+4stNuEiZgSqseD7Zro5rbmLhdXR8Z3cENp4qgXcjwCQMTgHvXp9td29zrEDLMqRYCkqe30rzPU/CGuaF4nW21q0kjkWT5QTkMAeoNd/4fWOS/gV7cElwuB25pQMpo+qfDltaW2k2r27u8Cxhgx78da+f/jrqcWsarNd2sTTGBfKjUkgHHevd9LnCaCYVUqsUOAAOeleRapa2Ol+F9X1nVYijKGMQk6buaIx1bZrUfupI+e7XW00tNh07frUhwhdshQfar2m+G7/AFu6uN1zdR3AG5zGhVEPpkVzmgmbWvEX2uVl3q5lOOpwegFet+HtavX1Tb5HlQSceWo5OO5NKHvbkT9x2RjaJ4F8Vw5kg1K4VP7gyd/05rqUf4k29k1taLeTxEbC8pbKj6V6hD4ttIrK3sGjHmpjDIORWxN4uR2SCxQsCvzue31q7W2DR6tnmHgnwhf2NvJqniOaR9hLZ56+mK7r4e6xYaj4kkt0LIqglVB6mvMfiv8AFGfTbGXTLSSN7x2wQvRR64rqf2bbBp7X+0bsEXRBdt3fPSk2tUKMbNWPfrO4SaN2GQUJU5GK8ZvvjG3hT4ial4f8YxFtM87zLS/hj+ZInwyh1H3lXJXcOfl5BPNel6lMl6ZILRpFYcMyHHNeC/tV+F2t4/DeswoXkdTYTEDlm+/H9ScyflXLOKirnfTfM+XofSumX1nqljDe6dcw3VpMN0c0ThlYexFW6+a/2UNF1C11HW5rrU7i0FqRDNozgq25gCJZEYccZAxyec4AwfpQ1ib2sMkXcpGSPcV8OfHfTLzT/G11FdMHaZy4cjtn1r7lxXy1+03pcdx4qgnE/lgIFkU+uO1bUtU0cuIVrSPA/Fqk6HYHcGWMleDxmuONd941itYdAtktiCQ+Dzn8q4E0qvxF4b4BKWiisjoCiiigDpIfEoGhiz8q5tbyFQILqyuniB6cSx8q3GcFdpycnd0qLSvE15b3Yl1G61K9hUEiEX8kYZu24jJK+oBBPZh1rAop8zI9nHsbuteK9X1azFjPeSx6YriRbGKRhAG/vFSTubr8zEnnrWFRRQ3fVlJJKyCtS3kY26jymYHjd6Vl1p6Jcm3n+QEv1UdRVQ3M6y9256X8D/HDeD/FJaWXZazjZIT0B7Zr7g0O8bUNNhu8hkmXcuOmK/N/VBJDKsslu8KTcqCMA/Svqr9mr4hS3OhnR9RileO1AWOdRuGOwNa25ly9Tli+VqXRnvtzDDdyiKXDFRkL6e9czqiR6PDPDE0rq+XA6sDXRZM5SdVaNRzyOTVTS0Au7p5XWSV24z2X0qoNxRUveZ8/eO/D974gtXu5l/dxHLOo+YCqfwv13T45RZs8sSxnb5cgxvr6N1TR7SYhvLC7vvqBww+leI/FT4a3WZNV8NAQSQnPpuHpWqkpao55UnE9PgmsYrVnjCCMjO5eaq+CvHFpdX9zp14RBNG37vJ4YV5b8P8AXbyON9M1S2ZGAwzHkE+xrK8VqtnfzT29tNPIR9+MkbBTcVJWYlVcXdH0trFyIrVpPlMTDBOa8C8Z+Nr3TNWj/shY3CNtcu2DiuAv/iLrRtEs4ZHktlyCXYhRXGnxMup3AgvNwjD583PKn/CojaKshzm56mr4p1SOw8WR65JCj3UhBZl6D149a629ubnVJLPUtNkzE4BkfHJHpXmGqPHq/iCGzik+1s2EjdK968F6VbafYxaeF3bEy6nnn+lXHW5nJbGVqHikTrHbkgiFMHd9K8Z+Jd7FeSqIM7VyW4713vjSI22tSmx+Z2PKHoBXmPjJt+MDnHzHGKiq9Gi6Pxo5CrGnXk2n30F3atsngcOh9CKrUVxbHqtXVmfV3w5/aC0aS0itfEUJsrgL80v3kY/Xt+New6Z8VvBFzbr5fiCy8wjJXeM1+eFSROUYFTg1q6vN8SMVQUfhZ9dfFbxjpesXMVzYkSwwfKHGCW964nwpcwT+II1WCWSZmD+dyqAen1rgvh9qMclnc2tzNgkcZGSPpXr/AIGsrdIwXIUJygPBauuDulY86ompNM+gNNiM9pFMg2qYwu3vXy1+1J4j1A3ltoJVoLOImR1H8Z7Zr6e8OXQi0v7UQ0karzt524r44/aL8QXeu+NZZZoRHaxjZFgdR6k+tZ1G0mdMNZRKXwaurS3fUVugpkkUeWT1GM13txfDR7Ge/ccFSELfLzXh2kyvHArW0vlzI27gcmvZi0vinwITDCTdgbREwxlh3FOm/dsZVl77Z5jceK9RszM8dw/2yZs+Zn7o9K9E+F/9qT+H7y4Op+TJMTs89s5b8ar+BPgT4g8Q6xE+oBLWzBDSSE7uPQV9GWnwq0DRdNjtokeRlIIJ6bqULqXvFTgnH3UfPfh/4d+IdY8Xw3/iCxa4s1fc7xjPmY6cDtX1Ro+kzW2nxRabp8dqjLgtI2GX/gOOa2bG18u2gjKrD5YA+UcEVrxneM9AKUqnLsXTp3epmaNpX9nxbZZzcSE5LkYrVZEfbvRWKncuRnB9RS4pa5pScndnXCKjojzP4n6Bf6ZqkHjvwlFv1nT49l9aLwL+1/iU4/iUDIPXjvgCu48La/YeJ9Bs9Y0mXzbS5TcueqnoVYdiDkEe1ateP6grfCbxm2pQgr4H1ycC8jUfLp10eBKB2Ruh/wDrKDJoewV8t/tNXsD+I3SS3DJHEqlg+CzY9Pxr6gaVfK8xWBUjIYcgivhn4039xe+Ob0y5dC+Mlu2a2pLdnJiZaKJ5t4mnjeK2ihVkUDJU9jXPmtHXJhJelUBCqABk1nVE3eRtQVoIKKKKg1F5opM+1FIAooopgFFFFACVNazNbXEcqfeQ5FRUULQTV1ZnR+IPEN3q9vDHM6+RH91Qo4Ndh8EfFlzofiCO1gmihFwwG6Q8Z7V5namMkpLnB6c96fbzta3KvHwyHII9q0U2pcxzSpLlcEfpjas6aQs08plkMe4lRxnHal0eENaLJJFslfknvXzZ8G/jW89vHp2ub3kX5I8Dhvx7V9MaRdx31jHNGwKsM8Hp7VrL4brqZwld2e6JZYN8gIdgV7etUL638+YwTECBxyvrWnJgbdp6d6rX3lysscqnkcGpg3cuSR594j8GWwuTd6fwQOcn5RXlfjCC6tgsbkhScb07ivbPEmpWunWbWbB/NbkIOhHua8H8WXWs+INaSy0WOO3dWHMjZ3fhXUm7HHUSvoa1v8FPt/hWS8sr0x3FwpcA8ivCta8JXOg6hc2Wqu0TqCUkUfK31r6wsX8X+F/D6R6hFBc2oQZKYyv4V4x8dGfUtHi1GJQhTJkHtUNXVyk7WS0Z5D4SCR+IIHaRshuCo5HvXunw+1W7HiCeGO0a4hK8zE8/TFfOOk3zW9/HJ3DZr6E+C/ixLPxKyXcGBKmVUjk8daijJW0KrxcZalXxZbxN4gkieKaPqzPg4x9a83+I1gsSwtaShosY29zXp3xEmOq+J7ryXNtGWyB2NcN44tUNrBHLIqEAfNWk1dMyhLlkmeTt16YptWLxQk7KBwO9V64WrHrxd1cKfGu5gMgfWmVJENzYpA9jtPA0kqXB8uJHQfeO3vXufghytvOkgDSMM7mONteU/DVo4La4kbbtHBB7mu70W5Z45pS6oVBOCcce9d9PRHkVHeTPpfwT5N94RSNWGxlZGK18U/HTT/7L8SzWgujMqOSAfTNer+D/AInal4a0fUIhClzBISYcDoa8D8eapca5qLX9ypSRmIMZOdtZzVk/M3pSUpRXYxNDz/acCg43sFP5196/D7wNpun6Bp9woD74w7buRzXwj4bg8++PzBdi79x6DHNfdfhTxdaD4Z6fcRSxMREEPzZGamlfl0LrOPtNex3do0VszRQKAg6AVzfjzxHZafFDC8h+0u42ojYNcvp/jGOWfZDLjyz1J615b8X9XmTxhpsiMWEjAmTIwe2B6VryJPmZlKreNkfSXh6abUI1mlO2NVGF6810CjjNc14Ak8/wzZyLG8Xy4Ic5J966VeK5qr96x1UV7qYtFHakXnmsjcdVPWNMs9Z0u607UoEuLO5jMcsbdGB/kffsauUUDPCrTxHdfDiK/wDBPiWaSS2jhaTRNQf/AJbW/wDzyY/3k6fT0G3PzP4wul1DU7u9WYmJCSpJzmvdP2r9ct7iWx01wpFtl0YEbt56/hjFfMGrzutsIw3yOc4Fbp8kbM45x9rO8TGkYu7MepOaZSnrSVgdqFopKWgBfxooooEJRRRQMSiiigAooooAUHBzV2URyBJFGCw5FUauWLb28hsbX6E9jVR7GdRac3Yv2t+tvBiNymD95Dhvzr1r4efHfVPDmntp91H9qh/hcn5/xzXit7atZXBjchsehqBuuVzj0q/aSjoZKjCXvI+rvD/x5tZR/p0zxpuzsYZ/UV02p/GbSLqKBrG8jV2OASc7fwr5H05LJYYpmmBJOJIzwRXungj4f+F/EWgG7WTbcleqSE4/Dsa6INyOWV4uyPQPFfimy1XRheW97Abi3XMgDAlq8/8AhFqX9r+NZZ0VlkLDCu2eM15z428NHwtqjRR3MslseUkzyT6Govhj4qbw/wCMLeRgzQSuFfH165pudmkyLN3Z90+JYbmbQZktwrSFMDNfL3xX8I62dLme6uMx7S4jjGAfb3NfTWm69bapYr5Rw7IMhh0rh/H95Z/8I7fFJFKwoxYkZxxRBO1mXUs7STPg8go5ByCDXrHwv8Sw2skbX6q0kC/I4+ZmHpXnmqpDcX8zxfxOSNvTrXT+Dks7W3lF0jJ5nymQcnHt6VjSTjI1rzUoJvc9F1PU4NR1Yz2wLPJyUbtVTxfp63OiI0caySFuvULUfhq2gF06xOzKTw7/AHsV6Zonho6haSMIgIFHUdz9K6d0cfXQ+Wtc02W3uWDIQB0yMZ+lYrKV64r1T4k6dLpt/J9qmR4WJEa4wVry6XAlYr0zxXHVjZnoYabkrMiqxaLulHaoRycdzXR+GtFkv1kZcZj+baepqIRuzWrNQjqdp4TsoTHHmQ7cBmIB6+leqafZafdeG7pVVUnK4wRywrlPClijWgmk2o33dhXGa6SS8NmAsZjPHOB0rvirI8lvU4fV3ms7OK1jhWKJT0xn8a898SwTeQZvKKJnAfPLV6jd6laJqhhusyGTpjnFZXiO2S58J3n2OJAYm3EP97Ge1RJXTLpy5WmeORPJG2UYpu4Jz1FeseAtYsodBXSbq/dIWYuQxIVfpXkzNubJ4rdMP2a3hdcSRyrw2elc9J2bO3ExTSTO2vvF1jo2qAaDLLKm7EvnEkN9Kg1HxHHrviG1mmlKxo67UYZA57V52ymWfCngHGavRia1ZGC/OCCD6VaqNmMqMUlrqfo54JuUufDVgY+AIgv5VumvN/ghqa33g+22sWAUEMTyeOa9HBrOqrSZ00Jc0EHal6Uh6VG7qqFicAc1na5o3YlBrnvHHimy8K6HPe3siqQpEa55Y1gfEH4l6R4P04z3UnmTNkRxKRuY18i+OfHep+M7+aecyLEW+QM2QgraNOzvIwqV1a0TK8f6wfEeuXN/NPJJvJIDn7orjFulmdoZiPKbhT/dPY1Pqt3th+zKwZ8/Ow7+1ZFTUd2Vh4NK7HzxNDK0b9RUdXkxeQeW3/HxGPlP94elUjwcGsjpCitvw5B59pr2ITK0enlxhNxX99EN3twTzWK6sjFXUqw6gjBFO2lxJ3bQlFH4UUgCkoooGFFFFABS0lFABSgkHIpKKALVxIsiqcN06k1XXk89Kmtn4MewMW6Z7GopEZHIYYIpvXUiOnuieta+g6vqmnybdNv5rUH7xjYgH61U06wmv5THCBuwSNxxUbwvbSFZCodTjAOcU1dakzcZXj1PRLq2vr/w89xd3EtzL97LnPHtXFqksdwgjbAzkY45q3pGq38cciCdjFjG08j8quiJZ3tYWiVJmYFtvHB9q6NJK5w603Zn1X8KtOudZ8IW8pupA5QK3PI49azfHsf9kWFxpu13DqQzsCQQfWuz+FkT6X4bgAXy7baBz16Vwnx18bW9raTwWvlNuQqHIyc+1bXtuZ2XKu580anpywajIIE285HOQa6Dw0kd1HGs8iRCNsgEYJ/GuaspE1HUE3TMAx654H4VqwQXP9psEt96L1Y9CKyVt0VO+zPR9BuLL+0m6LIOBnp+Fen6NqrWFpLJC2UIw2Dx+VfP8Us9xexytMkEUXQEV3GjaywsnRXBJ43Z4Naxlcy2Zx3xbkfVdRM64EaAj8a8oYYJB7V6n4xeZpJY2SNUZd3zc5+leXTDErAgA56Cuatvc7sJLRoICVlQj1713/hC4WDUokQb1bBOeMV58oyeOtdj4fHkKsjhpBj+E8g0qTDFrY9bgeO7vTEzFc9F7H3pPFcX2ONGVwseMO4PzfSqPh6OeRElbgHpvU5pfEs+bT7LtE05bGfT6V130ODqcho1neS6uRGWaPO8M3PH17V6/beCynw91fWLsFiYm2nHPANZXg/Snj0+4EkRErjKhud30rs7fxNdap4Rn0KKKFGt1IkUEZA60krIq6e58az/AOuf616Bp+lWtx8Po7tgzXKOxyp7ehri9dh+z6tdR4HDnoPenWGs3tjaTWsEzC2l+9Hng1yRkoydz0akHUgnEro6pdEEFUz+VXLq/bYkedwXpn0qjNKJlXI2sO/rUShnOByanma0RXs1KzkfU/7P3imW30xFuZP3cPyjHUjtX07YXa3NtFLwN4yK+EfhdrkNjd7rllhiSPc5X0rvLr48oj50+KcrDxDubAb610yUZpXZxQlKDdkfXLybAzSYVR0Oa8I+OHxetfD0Uun6VMs1+V42nhD6tXA6t8a/FFnp8Oo6jAvkTDCQJIBnjvXz/wCJdcm13VLi9njSN5n3lU6Cs9KfqbRlKu9FoLq+uX+u6i9xqd3JNLIeWY8D6DtRdTrZWvlQzF5XHJHQCsgYwSabWSmzd0U2uyAnJ5pKKKg2HIxRgyEhgcg0srmSRnbG5jk4FMooAu6VqmoaPdi60m+urG6ClRNbTNE4B6jcpBwaj1C9u9SvJbvUbqe7u5TmSeeQyO56ZLHk1WoouKyvcX8KKKKBiUUUtACUUUUAFLSUUAFFFFAEkOQ4I69qsSDbCfMyWPQ5qtGcMDjOKtGUyp0y/TpVIzne4lnJIWAXt/KpVtRczlopFC553etRwOQzRMNpI7daeSPI2KFV1PbvTW2pnK99NDpdJtre1vUTerHGS3VTVi0VB4pgmkYA+YCD29uKxojG0aKCRJ3OeKurKiXVvPGhLIR155FdCOF3vqfS3iLxjJ4c8Fbyu92jwiZxk18s+IdfvtemkeXcVBJIHIWtnxz4mvryW3guH3QqoOwHj61F4d06xudA1a9R3a5hjJEfTH+NKcud8qNaa5I88l6HHQyvDIHjJDCu98J3t9qsE8FjG0tyq5KE5yK4AHB+YZFdL4O1ybw7fPd2OfNdDGQeRg1lSdn5HRiIKUbpanSpvml23BhjEeVkcj7h9CKg0m8uLbVTGMS2+7AKDAI9amuInuNBn1NYkVpmJkJ7nNSfDWF31M+dGXiPViOBW9tTg6XLfix0ksGJCgH7uRzXldzg3DhR3xXq/wASNiu4hXaqgAYFeTuw3En5ieprOsdWE6sCAmB1bv7V2PgSV31JIzGSD0PrXGqrOwUAkmu78G2z29wHw4O3tU0lrcvEtctup6fqN9Otm/kGMKq/MNvIriJ9WVxGHErSl+ADz+Fat7rbpF5dtGMH5ZA45b61gXif8TD7RbEOIlyB/dPoK6JO5wJHpOka0801vb28xUbMfMeSf8a82urjWdN8W36xzmGaViGdm4KnpTGumtrKHUEJ+0iXcV7de9WLy6HiLUor1olUhQr+lDdxpWOK8VQywXxE7iSRjuLD1rIttgctL90DP1NdN4+WKG+jihYMAo5BrnI7d5FhRFy8rYUetc0172h6NF/u1cdFbNNFLOSqRr60unIDKzEEhVJ4NWNWP2fZZgf6v75Hc1SicxLIV4LDFS7JjTc4t9zX8PGB7sjUJpIrYj5hF94j2r0fRfBGi63JHPoF75tjGP3sF0fnU+2MV5jZW7GzL4KHPysOtdx4WjjsvC19qUrSJJ92Jwetb09tUctZ6tpmB8RJIE1L7Has/lW/yEMc5Pt7VykWzdmTOKmvJGnd5nYMzMSf8aq5rCbvK52UocsOUfMylvlztHSo6KKg0SsFLSUUDCilHXmigBKKU0lABRRRQAUUUvpQAUlFFAC0lFFABRRRQA5eozwD6VqSvFDHGImU49qy1xkZ6VIz5AAH51SdjOcOZouySRtMqIQVYcsBzVV96sccDOMU6xJ84hVBbHftRKrhCTx83NO91chLldi0JGEQDFQe3Fb+gRhhJvlUM64wRx+Nc3bxiUKMkFRn2NdjoCqli7Pa+Yr/AChQP1rWGpzVrLQ5jxHFsuBghlX5dwqvot7LaTuI2xHIpDr2Iq/4ih2Ax4DMhzlR09qxoY2AEnRemcVEtJXNqdpUrMbcOHlZl6Z4qbTSfPG1seoPeqrHLHJzV/Sl5kkJXCjo1THWRrU0geiW11IuhGFoVa0fpjjBrrvCWneXpbOsi+cRlVHAxXCWV/Fc6RBaKCW3ZJB5P/1q7jSJXtzGmxPOkG0KAcKP8a647nlvscd46lkEhjd2Jbrjpn3rzyeAKm4kc9BXtvinwvcTKm3DBuSq9c+tctf/AA/uZCWtzu2rliw5zUTg5G1GryHAaerCReRkdjXqvhG1uFtTOx2gDnjt7VkeH/h9qFzOplQ/KeQB1FeqLpkel6CYJ4yARgKop04NLUmtNTeh5NdXcsmr3IjYmHnLEcmqmmswtbmd1+SM8Eda6m+t7NbiWU4V14ANTT6JHDpjJbFJJZlyxPYU7EXRxcssT6PKQ4Uu3BOcZ9K2/BKwnSbp5grMoJx6DFY9xpxdCkL7RGSCvqa0XgOh+D7jax33B+bPUf8A1qF3DpY4TX5RcapI8ecE8Va0qXyNUSVQv+jIcBuRnFZ1oPtFyXmY4HJqazm2faW25R+Mn0rnT1ud0laPL2RWv5muLuSR23EnqKhRS7BV5YnFI2CxK5AzxVzR7c3N/HGAT34qN2bu0IehpNEYY0gU5IUE+xrrNaMmneBrSApgTckdyfesW30zffqjN8pbGGrT+It5BKttZw4jWJPmI6V07Js85PmkkcZLEH08uyhXU5yO4rOq1JLuhEZbhTxmqprmk0z0KaaTuJRRRUmgUUUUAL2pKcTTaANjwzoU3iC9mgiu7CySGFp5bi+nEMSKCByx7ksoAAJJNVdZsP7L1Oez+1Wl55TbfPtJPMifjOVbHIrX8AatcaPrck9nrzaDcSQPEt4Ymkj5xlZAqs2wgHorHO3juIPG19bal4kubqzkWVHSISzohRZ5hEqyygEAgPIHcZAOG5APAvTl8zNc3P5GDRRRUGgUtFFABSUUUAFFFFABRRRQAoNOQEnj8qaOtPRyhyOKBM0NGhZ7raDhzxtNX7mxDTBH+Uk/dHaqOlsZLlHwu4GtrU0ME2SQzuc/QVvBLlOGrKSmVI4grsFOdoxx3rrdCVLa3RDMUDjIIH6Vzdup+0pGgUM3613Gmr/obieBS0QBGw5I9cjt+taxRzydzLuo7a1mljliSQTj5i3r7ViaxDDFpuIlRGUnjHOPejxHfh5sxsxRejHtVIvNcaXPLG58thhyeoqW+hUU9GcuTk5q3prRiRhKuQRVQ9akhZgx2NgmuZOzuenNXjY6zQbZftMdwmAqN90n/PFeu+G7+Pz/ADGWFmUckDj8K8e0aCQxowChF5Zj1NeieD7uLy2aGMy84bHRRXZBnlT3Z6eNk91FL5eVYdv4a6nRIdPuPkkiUtnBJHJrl7SOMwxFCRkZAWt3SMJOGVtpXjg1sRE9A0rSdMgwyWseRznArkPiKljHKTFGgyvKjpmtUTO0qsnAx8xzXF+NZpI5P4Sjnt1qba3NZS0seT6qLSe6WO8gUkvkMOBVm6ENwkgCgtGuEReMVHrlqkmqZWYEIufLI6UBDb6PL5sWHwTv7mkZHFiXF81vMpMTn/WJ94H0p/jiaKLw/Fb7iJwcbT1I9azp5/LZ3MWze3b731FZHiTUjd7VUkKg2jd1NZSdos1px5poxomVLSXP3mOBTSVW1UKfnJJNMcjyVGctk1H0Fc1z0VHqXLO3WSGSRudv6Vq+DvJTUpJpvuKpA+tQ6FAZ7W4CBSyAt15xUuk2zrazToQMHDDFaRjsznqT+JM7TR7eG6uY5YxvKH5y3TFc34uY/wBo3O8DaDgAdhW5pF7DDbRQbQoHJkH3h9awfE7xea7RtvRud56mtZbHND4kcpI3AUDgVFT3IJJ70yuQ9RbBRRRQMKWkooAU0lFFABS0lFABRRRQAUUUUAOzwOKSkooAKKKKACiiigApwxj3ptKDigC1ZzeVIrAd+latzcgzB3UqmO1YcWDIobOM81oNhnJyQq9MdK0g2kc1WC5rmhazHKTQg5B4avQ9EvUis5UmUkyplgnbjqa8tglLSBSAwBzgV0Vldsq/ODlxtQ56fWtoSuclWFmZGt3JkZwgIVWIz7VPpV0Dpc0KhmDDn2rN1nelw6Nwc8ir/hOOS4S6ijJGEySKhP37Grhalc51vvH61NZjMoIXcey0y4ULPIB2Y1Y0uMPcYPA9fSsktbHXN2hc3bKUxxbJMpjlQD3ruvhxdBrx4ZFxH95jmuAaDy4SSrBAe/erejX81hOZIQyk9fcV1J2Z5sknqj6BTUoEQvnjp7Y9aoTeLrPSgFjLFc8nPWvJLvxLcmFo/mWNhyDXI6hqF3dShd7HsAKcqlghScmfWWn+JrSdYJ45lbeOBmsPxn4it7fCyEtJIeoryHwVdX1hZyzSqW8scY7Vha1reqXV47TuzAnIVuuPam56CUW3a57LctFM0EkURMrKM4PT61Yu7aN9LkVyEO0kMT3ryzSfEkk0KRXHmLE3ynH3ia6i81qZNNNtGqgBernnFNSTJcbM851ueXz5UlbJBxuXuK5pnV3dWJ29jWtrcpknkl2AZJxg8ZqhY42yPIhIIxkVzz1djspJRjzFBjnjHTvTam8lirsVIUdCahrFnYmuhs6ErskhjBDDOGyRnjp710GlfLA0e6PexywPWuW0+4VF8twxye3auheRIo9yQleOGPWt6fwnn101MkhukFxJvTfJ/AcYrL8QzmRlJAJxglRxSxSO0qup35PLelVNXdlchjnceopyfuipxtNGQTzSU449KbXMekFFFFABRRRQAUUUUAFLSUtACUUUUALSUUUAFFFFABRRRQAUUUUAFLSUtAD4wpb5849q1kISxAXqR3FZCYJGTj3rUR2MOM7s8CrgYVlsM0oKbkls8dMVsMUgVXVvM+bO3tWPAu1i27BXuKsXLn7KGPr1HetIuyOeouaQ3xFI8l15hULvGcelXfBN8LO8kPl72KkY/CqF9Ot1ZI/GU4JPU0mhzC3u2Zcn5eoHSp+3cu37lpoo35zezE9SxNa3ha1+0zSY+9jjPSsWd/Mmdj3JNehfDCwSf7Uk2wq6fKc9KKavIuu+WlYzhDIsbebiSMcEDtVaGWNDICcqBwpq/Ohtbq4twrHBIG3msSaBULrMdpfk89fatmcUUnoxlxOxIWJ1aM+vSpLSJ3lQsoPPQd6p2MTPMwVVK/3Se3tW9o9kZrkB9wKHKhefwqI3erNZ2joju9KsJpNGcsvkLt+UjnP1rjtaj8l1DoGJH367v7RDa6cDIrLuwGVjXL+LBBcYZY1jTaNu05FaswRyUDqLkkBkC9+1a5uvNUPkuMYy3WsCKbaHBHGccVaiuGjbC9eu70qEzScWR6xbukDP95TzxSWCrHpZWQFvM6Y7Ut1MtzGqZJYfeNNkmeKIJGyqvTml1uWr8qiU7pw1tJx0OBWYau53W0zgBucZPaqXesJHZSVk0WbPiZMgkE1t31xIsKKCSo6k/e/KsaI/KgABK/xDtVuS5zGFBznrnrVxdkY1Y80kwtSz3O5OIwM59aj1B/NyVzwec9qsWeHuIwi/KOuDzS3KKtxIzDEfYU2rxJTSmYxGO9MqR8Fzg5HamVidiEooooGFFFFABRRRQAUUUUAFFFFAH//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    MRI coronal STIR sequence shows markedly enlarged parotids with irregular signal pattern. A number of globular high signal areas are seen bilaterally, particularly on the left (arrows), representing fluid-filled, sialectatic cavities.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Creamer, MD, MRCP.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_18_24869=[""].join("\n");
var outline_f24_18_24869=null;
var title_f24_18_24870="X-ray incomplete stable fracture proximal phalanx";
var content_f24_18_24870=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RADIOL%2F83504&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RADIOL%2F83504&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 474px\">",
"   <div class=\"ttl\">",
"    X-ray incomplete stable fracture of proximal phalanx",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 454px; height: 598px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The AP view of the left 4th proximal phalanx (A, magnified in B) reveals an incomplete complex fracture of the proximal diaphysis with mild overlying soft tissue swelling. The oblique image confirms a nondisplaced fracture that is barely visible (D, red arrow). The fracture was not obvious on the lateral examination.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_18_24870=[""].join("\n");
var outline_f24_18_24870=null;
var title_f24_18_24871="Skin biopsy NSF CD34 cells II";
var content_f24_18_24871=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F56673&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F56673&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Low power image showing immunohistochemical staining for CD34 of a skin biopsy from a patient with nephrogenic systemic fibrosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A lower magnification of the same image shows a dense network of CD34+ dendritic processes (brown) among thickened collagen bundles (magenta).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     With permission from: Shawn E Cowper, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_18_24871=[""].join("\n");
var outline_f24_18_24871=null;
var title_f24_18_24872="Intestinal gas and bloating";
var content_f24_18_24872=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Intestinal gas and bloating",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/18/24872/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/18/24872/contributors\">",
"     Diane Abraczinskas, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/18/24872/contributors\">",
"     Stephen E Goldfinger, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/18/24872/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/18/24872/contributors\">",
"     Nicholas J Talley, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/18/24872/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/18/24872/contributors\">",
"     Shilpa Grover, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?24/18/24872/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 27, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of gastrointestinal complaints, such as belching, bloating, abdominal pain, constipation, or flatulence, are commonly attributed by the patient to \"excess gas,\" even though this perception is usually incorrect. When excessive intestinal gas does occur, it may be due to excessive air swallowing, increased intraluminal production from malabsorbed nutrients, decreased gas absorption due to obstruction, or expansion of intraluminal gas due to changes in atmospheric pressure (",
"    <a class=\"graphic graphic_table graphicRef81749 \" href=\"UTD.htm?38/38/39531\">",
"     table 1",
"    </a>",
"    ). The understanding of intestinal gas syndromes has been aided by studies of intestinal gas composition and volume in normal individuals and in those with complaints of \"too much gas.\"",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     AMOUNT OF GAS IN THE INTESTINE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The volume of gas in the intestinal tract, as determined by body plethysmography or argon washout techniques, is approximately 200 mL in both the fasting and postprandial states [",
"    <a class=\"abstract\" href=\"UTD.htm?24/18/24872/abstract/1,2\">",
"     1,2",
"    </a>",
"    ], and in subjects who complain of gaseous distention [",
"    <a class=\"abstract\" href=\"UTD.htm?24/18/24872/abstract/3\">",
"     3",
"    </a>",
"    ]. Quantitative measurement of bowel gas has also been performed with digitized abdominal radiographs [",
"    <a class=\"abstract\" href=\"UTD.htm?24/18/24872/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     COMPOSITION OF INTESTINAL GAS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nitrogen (N",
"    <sub>",
"     2",
"    </sub>",
"    ), oxygen (O",
"    <sub>",
"     2",
"    </sub>",
"    ), carbon dioxide (CO",
"    <sub>",
"     2",
"    </sub>",
"    ), hydrogen (H",
"    <sub>",
"     2",
"    </sub>",
"    ), and methane (CH",
"    <sub>",
"     4",
"    </sub>",
"    ) account for more that 99 percent of expelled intestinal gas [",
"    <a class=\"abstract\" href=\"UTD.htm?24/18/24872/abstract/1\">",
"     1",
"    </a>",
"    ]. One investigation using a gas washout technique revealed the composition of gas within the intestinal tract of 10 normal subjects to be predominantly N",
"    <sub>",
"     2",
"    </sub>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?24/18/24872/abstract/1\">",
"     1",
"    </a>",
"    ]. Oxygen was present in very low concentrations, and the concentrations of CO",
"    <sub>",
"     2",
"    </sub>",
"    , H",
"    <sub>",
"     2",
"    </sub>",
"    , and CH",
"    <sub>",
"     4",
"    </sub>",
"    were variable.",
"   </p>",
"   <p>",
"    The composition of gas may vary in a given compartment of the gastrointestinal tract. As an example, stomach gas contains high concentrations of N",
"    <sub>",
"     2",
"    </sub>",
"    and O",
"    <sub>",
"     2",
"    </sub>",
"    similar to the atmosphere, while flatus contains less O",
"    <sub>",
"     2",
"    </sub>",
"    and more CH",
"    <sub>",
"     4",
"    </sub>",
"    .",
"   </p>",
"   <p>",
"    None of the principal gases has an odor. Minor constituents of flatus, to which odor may be attributable, include sulfur-containing compounds such as methanethiol, dimethyl sulfide, hydrogen sulfide [",
"    <a class=\"abstract\" href=\"UTD.htm?24/18/24872/abstract/5,6\">",
"     5,6",
"    </a>",
"    ], as well as short-chain fatty acids, skatoles, indoles, volatile amines, and ammonia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     SOURCES OF INTESTINAL GAS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Air swallowing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Air swallowing or aerophagia is the major source of stomach gas. Several milliliters of air, mostly N",
"    <sub>",
"     2",
"    </sub>",
"    , are incorporated into each normal swallow. Larger amounts are swallowed when food is gulped. Aerophagia can be a manifestation of anxiety, and may also be enhanced by gum chewing and smoking. Most swallowed air appears to be eructated.",
"   </p>",
"   <p>",
"    The most common symptoms of aerophagia in a series of 79 patients were belching (56 percent), bloating (27 percent) abdominal pain (19 percent), and abdominal distension (19 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/18/24872/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A study evaluating the source of air in patients with excessive belching found that such patients tended to expel air that had reached the esophagus during swallowing rather than air that had reached the stomach. A study using cineradiography demonstrated that patients relax their upper esophageal sphincter, swallow air, and then release it from the esophagus before it reaches the stomach [",
"    <a class=\"abstract\" href=\"UTD.htm?24/18/24872/abstract/8\">",
"     8",
"    </a>",
"    ]. Some achieve this by creating a negative intrathoracic pressure, possibly by inspiring against a closed glottis, and then relaxing the upper esophageal sphincter to allow air to enter the esophagus. Others force air into their esophagus by simultaneously contracting the muscles of their pharynx, palate, and tongue [",
"    <a class=\"abstract\" href=\"UTD.htm?24/18/24872/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Posture may influence the amount of swallowed air passing from the stomach into the small intestine. This occurs because in the supine position, gastric air is located above gastric liquid that overlies the GE junction, causing air to pass preferentially into the small intestine.",
"   </p>",
"   <p>",
"    Swallowed air is the major source of O",
"    <sub>",
"     2",
"    </sub>",
"    and N",
"    <sub>",
"     2",
"    </sub>",
"    in intestinal gas. Diffusion of these gases between the intestinal lumen and the bloodstream is determined by partial pressure gradients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Intraluminal production",
"    </span>",
"    &nbsp;&mdash;&nbsp;Three of the five principal gases, CO",
"    <sub>",
"     2",
"    </sub>",
"    , H",
"    <sub>",
"     2",
"    </sub>",
"    , and CH",
"    <sub>",
"     4",
"    </sub>",
"    , are produced within the bowel lumen.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     CO2",
"    </span>",
"    &nbsp;&mdash;&nbsp;CO",
"    <sub>",
"     2",
"    </sub>",
"    is derived from digestion of fat and protein in the upper gastrointestinal tract, from bacterial fermentation of intraluminal substrates, or may be liberated from the interaction of acid and bicarbonate [",
"    <a class=\"abstract\" href=\"UTD.htm?24/18/24872/abstract/10\">",
"     10",
"    </a>",
"    ]. Much of the CO",
"    <sub>",
"     2",
"    </sub>",
"    produced in the upper small intestine is probably absorbed before it reaches the colon; CO",
"    <sub>",
"     2",
"    </sub>",
"    that is present in flatus is likely due to bacterial fermentation reactions in the colon. Increased CO",
"    <sub>",
"     2",
"    </sub>",
"    in flatus can result from specific dietary substrates, such as nondigestible carbohydrates [",
"    <a class=\"abstract\" href=\"UTD.htm?24/18/24872/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     H2",
"    </span>",
"    &nbsp;&mdash;&nbsp;H",
"    <sub>",
"     2",
"    </sub>",
"    production occurs predominantly in the colon, except under conditions of small intestine bacterial overgrowth when it is produced by bacterial fermentation in that portion of the gut [",
"    <a class=\"abstract\" href=\"UTD.htm?24/18/24872/abstract/12\">",
"     12",
"    </a>",
"    ]. Ingested carbohydrate and protein are sources for H",
"    <sub>",
"     2",
"    </sub>",
"    production. Small intestinal carbohydrate malabsorption leads to increased delivery of carbohydrate to the colon and increased H",
"    <sub>",
"     2",
"    </sub>",
"    gas production (see",
"    <a class=\"local\" href=\"#H1307548188\">",
"     'Carbohydrate malabsorption'",
"    </a>",
"    below). In healthy individuals, certain foods with high concentrations of oligosaccharides such as stachyose and raffinose found in legumes, or resistant starches (flours made from wheat, oats, potatoes, and corn) cannot be completely digested by enzymes within the normal small bowel, leading to increased H",
"    <sub>",
"     2",
"    </sub>",
"    production [",
"    <a class=\"abstract\" href=\"UTD.htm?24/18/24872/abstract/13\">",
"     13",
"    </a>",
"    ]. Increased colonic H",
"    <sub>",
"     2",
"    </sub>",
"    production following carbohydrate ingestion forms the basis for the H",
"    <sub>",
"     2",
"    </sub>",
"    breath test for carbohydrate malabsorption [",
"    <a class=\"abstract\" href=\"UTD.htm?24/18/24872/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    H",
"    <sub>",
"     2",
"    </sub>",
"    is both produced and consumed by fecal bacteria; the net H",
"    <sub>",
"     2",
"    </sub>",
"    excretion is determined by these two processes. H",
"    <sub>",
"     2",
"    </sub>",
"    consumption occurs in the bacterial production of CH",
"    <sub>",
"     4",
"    </sub>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?24/18/24872/abstract/15\">",
"     15",
"    </a>",
"    ], sulfide [",
"    <a class=\"abstract\" href=\"UTD.htm?24/18/24872/abstract/16\">",
"     16",
"    </a>",
"    ], and acetate [",
"    <a class=\"abstract\" href=\"UTD.htm?24/18/24872/abstract/17\">",
"     17",
"    </a>",
"    ]. H",
"    <sub>",
"     2",
"    </sub>",
"    is excreted in the breath (after absorption into the bloodstream) or passed in flatus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Methane",
"    </span>",
"    &nbsp;&mdash;&nbsp;Methane, like H",
"    <sub>",
"     2",
"    </sub>",
"    , is exclusively a product of bacterial metabolism. The principal methanogenic bacterium is Methanobrevibacter smithii. Because M. smithii catalyzes the reaction: 4H",
"    <sub>",
"     2",
"    </sub>",
"    + CO",
"    <sub>",
"     2",
"    </sub>",
"    &rarr; CH",
"    <sub>",
"     4",
"    </sub>",
"    + 2H",
"    <sub>",
"     2",
"    </sub>",
"    0, it reduces the volume of gas that would otherwise be present in the colon. CH",
"    <sub>",
"     4",
"    </sub>",
"    may be absorbed into the portal circulation and excreted in expired air, or excreted in flatus.",
"   </p>",
"   <p>",
"    The tendency to produce CH",
"    <sub>",
"     4",
"    </sub>",
"    is determined by the concentration of methanogens in the colon, and may be related to genetic or early environmental factors. The presence of bile acid in the colon may be important in the regulation of methanogenesis [",
"    <a class=\"abstract\" href=\"UTD.htm?24/18/24872/abstract/18\">",
"     18",
"    </a>",
"    ]. The incidence of methane production is increased in individuals with colorectal cancer, extensive ulcerative colitis, and colonic polyps compared with individuals with other diseases of the colon or healthy volunteers [",
"    <a class=\"abstract\" href=\"UTD.htm?24/18/24872/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1307548188\">",
"    <span class=\"h3\">",
"     Carbohydrate malabsorption",
"    </span>",
"    &nbsp;&mdash;&nbsp;Malabsorption of carbohydrates can lead to increased intraluminal gas and result in complaints of gas, abdominal pain, and flatulence. Unabsorbed carbohydrates provide a substrate for rapid bacterial fermentation (causing gas), and have other physiological consequences including an increased osmotic load, alteration of gastrointestinal motility, and a change in the profile of the bacterial flora. Patients with functional bowel disorders (such as irritable bowel syndrome) may have a heightened sensitivity to the effects of malabsorbed carbohydrate, even though the rates of carbohydrate malabsorption may not differ from healthy subjects.",
"   </p>",
"   <p>",
"    Diagnosis of specific forms of carbohydrate malabsorption can be established with a breath test, although an empirical trial of dietary restriction may be sufficient. Thus, dietary evaluation and modification are useful approaches to medical management. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/14/40169?source=see_link&amp;anchor=H5#H5\">",
"     \"Treatment of irritable bowel syndrome\", section on 'Dietary modification'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/50/41765?source=see_link\">",
"     \"Mechanisms of nutrient absorption and malabsorption\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Lactose restriction or ingestion of oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?13/62/14306?source=see_link\">",
"       lactase",
"      </a>",
"      preparations often benefits individuals with symptoms of lactose intolerance. However, one blinded study of patients with self-reported \"severe lactose intolerance\" showed no difference in bloating or perceived severity or frequency of flatus after patients ingested 240 mL of conventional milk as compared with lactose-hydrolyzed milk [",
"      <a class=\"abstract\" href=\"UTD.htm?24/18/24872/abstract/20\">",
"       20",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/32/5641?source=see_link\">",
"       \"Lactose intolerance\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Using H",
"      <sub>",
"       2",
"      </sub>",
"      breath testing in healthy subjects, one group found that as much as 20 percent of carbohydrate from flours of whole wheat, oats, potatoes, and corn was malabsorbed [",
"      <a class=\"abstract\" href=\"UTD.htm?24/18/24872/abstract/21\">",
"       21",
"      </a>",
"      ]. In contrast, rice and gluten-free wheat were absorbed completely.",
"     </li>",
"     <li>",
"      Bacterial fermentation of raffinose, stachyose, and verbascose, the undigestible oligosaccharides abundant in legumes, causes increased intestinal gas.",
"     </li>",
"     <li>",
"      Fructose malabsorption may be an underappreciated cause of gastrointestinal symptoms. Up to one-half of the population cannot completely absorb a load of 25 g of fructose while daily intake varies from about 11 to 54 g per day [",
"      <a class=\"abstract\" href=\"UTD.htm?24/18/24872/abstract/22-26\">",
"       22-26",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Diffusion from the blood",
"    </span>",
"    &nbsp;&mdash;&nbsp;The partial pressure of intestinal gases determines the direction of diffusion of the gas between the intestinal lumen and the bloodstream.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      H",
"      <sub>",
"       2",
"      </sub>",
"      and CH",
"      <sub>",
"       4",
"      </sub>",
"      have high partial pressures in the intestinal lumen as compared to the bloodstream and therefore diffuse readily out of the intestine.",
"     </li>",
"     <li>",
"      Gastric luminal oxygen is absorbed into the bloodstream since it has a relatively high partial pressure (due to its concentration in swallowed air). On the other hand, colonic luminal oxygen has a low partial pressure; it tends to diffuse from the blood into the lumen.",
"     </li>",
"     <li>",
"      CO",
"      <sub>",
"       2",
"      </sub>",
"      has a variable pattern of diffusion. The partial pressure of CO",
"      <sub>",
"       2",
"      </sub>",
"      in the gastric lumen is lower than that of the blood; thus, CO",
"      <sub>",
"       2",
"      </sub>",
"      tends to diffuse into the gastric lumen. As it reaches the duodenum, the partial pressure of CO",
"      <sub>",
"       2",
"      </sub>",
"      becomes higher in the lumen than in the bloodstream, and its direction of diffusion reverses.",
"     </li>",
"     <li>",
"      N",
"      <sub>",
"       2",
"      </sub>",
"      has a relatively high partial pressure in the stomach with resultant diffusion into the blood, but its partial pressure falls below that of the blood in the duodenum, and the direction of diffusion reverses.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     GAS DISORDERS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Eructation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Belching or eructation is defined as the retrograde passage of esophageal or gastric gas out of the mouth [",
"    <a class=\"abstract\" href=\"UTD.htm?24/18/24872/abstract/27\">",
"     27",
"    </a>",
"    ]. It may be voluntary or involuntary. Involuntary belching typically follows a meal and is caused by the release of swallowed air after gastric distention.",
"   </p>",
"   <p>",
"    Belching may be facilitated by foods that relax the lower esophageal sphincter, such as chocolate, fats, and mints [",
"    <a class=\"abstract\" href=\"UTD.htm?24/18/24872/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Chronic, repetitive belching is a disorder caused by habitual air swallowing (aerophagia) in which air may transit only to the esophagus before being vented (see",
"    <a class=\"local\" href=\"#H5\">",
"     'Air swallowing'",
"    </a>",
"    above). In these patients, belching frequently becomes habitual and may be incorrectly regarded as indicative of underlying digestive problems.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diagnostic evaluation of patients with chronic eructation should be reserved for those patients who have additional symptoms suggesting underlying pathology. Diagnostic criteria for aerophagia (Rome III) include [",
"    <a class=\"abstract\" href=\"UTD.htm?24/18/24872/abstract/29\">",
"     29",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Troublesome repetitive belching at least several times a week",
"     </li>",
"     <li>",
"      Air swallowing that is objectively observed or measured",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Rome III criteria also recognized a separate disorder of \"unspecified excessive belching\":",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Troublesome repetitive belching at least several times a week",
"     </li>",
"     <li>",
"      No evidence that excessive air swallowing underlies the symptoms",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These criteria should be fulfilled for the last three months with symptom onset at least six months before diagnosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of chronic eructation consists of breaking the vicious cycle of aerophagia by explaining the process to the patient and making specific recommendations where appropriate. These include discontinuation of such habits as gum chewing, smoking, drinking carbonated beverages, and gulping food and liquids. Specific treatment of anxiety should be considered if this is a prominent symptom. Reassurance that isolated belching is a benign condition may help relieve underlying anxiety.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Flatulence",
"    </span>",
"    &nbsp;&mdash;&nbsp;The volume of gas passed per rectum varies from about 500 to 1500 mL per day [",
"    <a class=\"abstract\" href=\"UTD.htm?24/18/24872/abstract/3\">",
"     3",
"    </a>",
"    ]. The frequency of flatus released varies between 10 and 20 times per day in healthy subjects [",
"    <a class=\"abstract\" href=\"UTD.htm?24/18/24872/abstract/30\">",
"     30",
"    </a>",
"    ]. Most patients who report excessive flatulence fall within this range.",
"   </p>",
"   <p>",
"    Although excessive passage of flatus or its foul odor may be a source of embarrassment to the patient, it is rarely associated with serious illness. Offensive odor, when present, may be due to sulfur-containing compounds, such as methanethiol, dimethyl sulfide, and hydrogen sulfide, as well as short-chain fatty acids, skatoles, indoles, volatile amines, and ammonia.",
"   </p>",
"   <p>",
"    A number of factors may account for a patient's awareness of bothersome flatus:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An alteration of intestinal motility or bacteria.",
"     </li>",
"     <li>",
"      Dietary factors, such as an increased intake of lactose, fructose,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/0/29699?source=see_link\">",
"       sorbitol",
"      </a>",
"      , undigestible starches in fruits, vegetables, and legumes, and carbonated beverages. Products such as pork, upon digestion, may release trace concentrations of malodorous gases.",
"     </li>",
"     <li>",
"      Psychological factors that may create a heightened sensitivity to normal flatal passage.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evaluation of the patient complaining of flatulence should be guided by the history and physical examination.",
"   </p>",
"   <p>",
"    New onset flatulence associated with symptoms such as weight loss, diarrhea, abdominal pain, and distention or anorexia usually deserves a work-up for malabsorption (",
"    <a class=\"graphic graphic_table graphicRef50363 \" href=\"UTD.htm?4/11/4283\">",
"     table 2",
"    </a>",
"    ). This may include stool examination for fat and Giardia, a lactose tolerance test, celiac serology, and a small bowel radiograph or upper endoscopy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/21/38232?source=see_link\">",
"     \"Clinical features and diagnosis of malabsorption\"",
"    </a>",
"    .) For the patient with no \"alarm\" signals, such studies rarely uncover a specific underlying problem.",
"   </p>",
"   <p>",
"    Hydrogen breath testing may be useful in identifying or confirming a relationship between symptoms and specific foods.",
"   </p>",
"   <p>",
"    Gas chromatography studies, which can help identify the source of \"excessive gas\" by determining its composition, are generally reserved for clinical trials; they are not recommended for routine clinical practice.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several measures can be undertaken to reduce annoying flatus.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The avoidance of foods that may contribute to the problem is an obvious initial step. Limiting dietary ingestion of known gas-producing foods such as cabbage, onions, broccoli, brussel sprouts, wheat, and potatoes should be recommended as a therapeutic trial.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/35/33332?source=see_link\">",
"       Simethicone",
"      </a>",
"      , which causes gas bubbles to break and coalesce, is widely used for treating gaseous complaints. However, it has not been shown to be of benefit [",
"      <a class=\"abstract\" href=\"UTD.htm?24/18/24872/abstract/31\">",
"       31",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The purported value of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/52/39750?source=see_link\">",
"       activated charcoal",
"      </a>",
"      has been supported by some studies and refuted by others [",
"      <a class=\"abstract\" href=\"UTD.htm?24/18/24872/abstract/32-35\">",
"       32-35",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/13/26834?source=see_link\">",
"       Beano",
"      </a>",
"      &trade;, an alpha-galactosidase preparation, is often tried by patients on their own. This over-the-counter agent reduced gas production and frequency in subjects challenged with baked beans [",
"      <a class=\"abstract\" href=\"UTD.htm?24/18/24872/abstract/36\">",
"       36",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      If bacterial overgrowth or an altered flora is strongly suspected, a two-week trial of antibiotic treatment may be helpful. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/50/28454?source=see_link\">",
"       \"Treatment of small intestinal bacterial overgrowth\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/29/35285?source=see_link\">",
"       Bismuth",
"      </a>",
"      subsalicylate reduces the odor arising from hydrogen sulfide as well as other pungent components of flatus [",
"      <a class=\"abstract\" href=\"UTD.htm?24/18/24872/abstract/37\">",
"       37",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A variety of external devices to deodorize flatus (such as charcoal lined cushion) are commercially available [",
"      <a class=\"abstract\" href=\"UTD.htm?24/18/24872/abstract/6\">",
"       6",
"      </a>",
"      ]. Their efficacy has not been well established [",
"      <a class=\"abstract\" href=\"UTD.htm?24/18/24872/abstract/38\">",
"       38",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Abdominal bloating and distension",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bloating refers to a person's sensation of abdominal fullness, whereas distension connotes visible or measureable increase in abdominal girth.",
"   </p>",
"   <p>",
"    The feeling of abdominal bloating is often attributed to excessive gas by patients. However, the relationship between the amount of intestinal gas and symptoms is not straightforward. In one study, the composition and average volume of intestinal gas in patients with complaints of chronic gaseousness and controls was similar (176 and 199 mL, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/18/24872/abstract/39\">",
"     39",
"    </a>",
"    ]. Radiographic studies with plain films and CT have also shown no evidence of increased gas in patients complaining of gaseous distension [",
"    <a class=\"abstract\" href=\"UTD.htm?24/18/24872/abstract/40\">",
"     40",
"    </a>",
"    ], although discordant data have also been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?24/18/24872/abstract/4\">",
"     4",
"    </a>",
"    ]. One study found that patients with a history of abdominal bloating had significantly delayed transit of small intestinal gas compared with a healthy control population [",
"    <a class=\"abstract\" href=\"UTD.htm?24/18/24872/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other studies have suggested that gut hyperalgesia occurs in some patients with irritable bowel syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?24/18/24872/abstract/42\">",
"     42",
"    </a>",
"    ], suggesting that many patients with chronic complaints of gaseousness have a similar underlying bowel dysfunction with heightened sensitivity to gaseous distension or an exaggerated motor response to normal amounts of gas. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/25/12697?source=see_link\">",
"     \"Pathophysiology of irritable bowel syndrome\"",
"    </a>",
"    .) Studies have shown that infusion of gas into the small intestine [",
"    <a class=\"abstract\" href=\"UTD.htm?24/18/24872/abstract/3\">",
"     3",
"    </a>",
"    ], or balloon-induced bowel distension [",
"    <a class=\"abstract\" href=\"UTD.htm?24/18/24872/abstract/43\">",
"     43",
"    </a>",
"    ], caused an enhanced pain response in patients with chronic bloating as compared to controls.",
"   </p>",
"   <p>",
"    Some investigators have suggested that patients with IBS or functional bloating may have impaired transit of intestinal gas. One report, for example, compared the effects of intestinal gas infusion in 20 patients with IBS to 20 controls [",
"    <a class=\"abstract\" href=\"UTD.htm?24/18/24872/abstract/44\">",
"     44",
"    </a>",
"    ]. IBS patients were significantly more likely to develop gas retention and increased gastrointestinal symptoms or abdominal distension. Lipid perfusion into the duodenum retards gas transit time more in patients with IBS than in normal controls [",
"    <a class=\"abstract\" href=\"UTD.htm?24/18/24872/abstract/45\">",
"     45",
"    </a>",
"    ]. Pharmacologic stimulation of gut motility in IBS patients has been reported to reduce gas retention and improve symptoms suggesting that a motility disturbance underlies this complaint in some patients [",
"    <a class=\"abstract\" href=\"UTD.htm?24/18/24872/abstract/46-48\">",
"     46-48",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/25/12697?source=see_link\">",
"     \"Pathophysiology of irritable bowel syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Abdominal distension has been well documented in a subset of patients with irritable bowel syndrome by both plethysmography [",
"    <a class=\"abstract\" href=\"UTD.htm?24/18/24872/abstract/49\">",
"     49",
"    </a>",
"    ] and abdominal CT imaging [",
"    <a class=\"abstract\" href=\"UTD.htm?24/18/24872/abstract/40\">",
"     40",
"    </a>",
"    ]. One proposed mechanism for abdominal distention is incoordination of the abdominophrenic reflex. Investigators found that subjects with bloating and distention respond to modest increases in intraluminal gas by evidencing downward rather than upward displacement of their diaphragm, resulting in visible protrusion of the anterior abdominal wall. &nbsp;In contrast, patients with measureable gut dysmotility harbor larger volumes of intraluminal gas during bloating episodes, resulting in excessive abdominal bulging despite normal cephalic displacement of the diaphragm [",
"    <a class=\"abstract\" href=\"UTD.htm?24/18/24872/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Trapping of gas at the colonic flexures may result in distension, spasm, and subsequent pain, the so-called hepatic and splenic flexure syndromes. In these syndromes, the segment of bowel proximal to the colonic flexure may be distended with air on abdominal plain film, but subsequent evaluation by",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/17/12564?source=see_link\">",
"     barium",
"    </a>",
"    enema reveals no focal lesions, thereby implicating spasm as the etiology [",
"    <a class=\"abstract\" href=\"UTD.htm?24/18/24872/abstract/51\">",
"     51",
"    </a>",
"    ]. Instillation of air or barium may reproduce the symptoms. These syndromes are probably variants of irritable bowel syndrome, and anticonstipation therapy is sometimes effective.",
"   </p>",
"   <p>",
"    Nissen fundoplication for GERD may result in the inability to belch because of tightness of the wrap created by the surgeon. As a result of gastric distention, many postoperative patients experience bloating, abdominal pain, and excessive flatus, known as the gas-bloat syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?24/18/24872/abstract/52\">",
"     52",
"    </a>",
"    ], which may slowly improve with time.",
"   </p>",
"   <p>",
"    These observations underscore that many patients with bloating often have no clearly identifiable abnormality and thus can be classified as having a functional disorder.",
"   </p>",
"   <p>",
"    According to consensus criteria (Rome III), functional bloating can be distinguished from other causes of abdominal distention by its diurnal pattern [",
"    <a class=\"abstract\" href=\"UTD.htm?24/18/24872/abstract/29\">",
"     29",
"    </a>",
"    ]. It may follow ingestion of specific foods and sometimes be accompanied by excessive burping or flatus (but these may be unrelated to the sensation of bloating). Diarrhea, weight loss, or nutritional deficiency should prompt evaluation for other conditions.",
"   </p>",
"   <p>",
"    Clinical criteria for establishing the diagnosis of functional bloating include both of the following (for at least three months with symptom onset at least six months prior to diagnosis).",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Recurrent feeling of bloating or visible distension at least three",
"      <span class=\"nowrap\">",
"       days/month",
"      </span>",
"      in three months",
"     </li>",
"     <li>",
"      Insufficient criteria for a diagnosis of functional dyspepsia, IBS, or other functional GI disorder",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1307547838\">",
"    <span class=\"h3\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approach to treatment of abdominal distension and gaseousness is similar to that used in irritable bowel syndrome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/14/40169?source=see_link\">",
"     \"Treatment of irritable bowel syndrome\"",
"    </a>",
"    .) However, anticholinergic agents should be avoided in these patients because of their potential to exacerbate symptoms. A few specific approaches have been studied.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/35/33332?source=see_link\">",
"       Simethicone",
"      </a>",
"      has not been shown to be of benefit [",
"      <a class=\"abstract\" href=\"UTD.htm?24/18/24872/abstract/31\">",
"       31",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      There is contradictory evidence for the use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/52/39750?source=see_link\">",
"       activated charcoal",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      Improvement in symptoms was observed in a placebo-controlled trial evaluating",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/17/37140?source=see_link\">",
"       rifaximin",
"      </a>",
"      (a nonabsorbable antibiotic), a finding that awaits confirmation in additional studies [",
"      <a class=\"abstract\" href=\"UTD.htm?24/18/24872/abstract/53\">",
"       53",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H60523464\">",
"    <span class=\"h2\">",
"     Others",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H60523382\">",
"    <span class=\"h3\">",
"     Pneumatosis cystoides intestinalis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Excessive H",
"    <sub>",
"     2",
"    </sub>",
"    concentrations in the small bowel and colon are rarely associated with pneumatosis cystoides intestinalis, a condition in which gas-filled cysts are present in the bowel wall [",
"    <a class=\"abstract\" href=\"UTD.htm?24/18/24872/abstract/54,55\">",
"     54,55",
"    </a>",
"    ]. This condition is usually asymptomatic, diagnosed by an incidental finding on imaging or colonoscopy, although it may be associated with spontaneous pneumoperitoneum, intussusception, or volvulus. The mechanism by which excessive intraluminal H",
"    <sub>",
"     2",
"    </sub>",
"    produces this condition is controversial [",
"    <a class=\"abstract\" href=\"UTD.htm?24/18/24872/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Treatment can include antibiotics to decrease H",
"    <sub>",
"     2",
"    </sub>",
"    production, dietary restriction of carbohydrates, which act as substrates for H",
"    <sub>",
"     2",
"    </sub>",
"    production, or administration of inhaled O",
"    <sub>",
"     2",
"    </sub>",
"    , which may alter concentrations of colonic gases and gases in the cyst [",
"    <a class=\"abstract\" href=\"UTD.htm?24/18/24872/abstract/56\">",
"     56",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/31/31223?source=see_link\">",
"     \"Pneumatosis intestinalis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H60523389\">",
"    <span class=\"h3\">",
"     Colonic explosions during colonoscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Combustible concentrations of H",
"    <sub>",
"     2",
"    </sub>",
"    and CH",
"    <sub>",
"     4",
"    </sub>",
"    have occurred in the setting of inadequate bowel preparation or inappropriate choice of purgative before colonoscopy (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/42/3752?source=see_link\">",
"     mannitol",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/0/29699?source=see_link\">",
"     sorbitol",
"    </a>",
"    may serve as substrates for H",
"    <sub>",
"     2",
"    </sub>",
"    -producing bacteria), and have resulted in colonic trauma and perforation triggered by electrocauterization during sigmoidoscopy or colonoscopy [",
"    <a class=\"abstract\" href=\"UTD.htm?24/18/24872/abstract/57\">",
"     57",
"    </a>",
"    ]. This problem is now virtually extinct, however, since the commonly used bowel preparations containing electrolytes or polyethylene glycol cannot be fermented by bacteria and does not produce excessive concentrations of H",
"    <sub>",
"     2",
"    </sub>",
"    or CH",
"    <sub>",
"     4",
"    </sub>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?21/31/22002?source=see_link\">",
"       \"Patient information: Gas and bloating (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?11/26/11684?source=see_link\">",
"       \"Patient information: Lactose intolerance (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?6/14/6371?source=see_link\">",
"       \"Patient information: Gas and bloating (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A variety of gastrointestinal complaints, such as belching, bloating, abdominal pain, constipation, or flatulence, are commonly attributed by the patient to \"excess gas,\" even though this perception is usually incorrect. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      When excessive intestinal gas occurs, it may be due to excessive air swallowing, increased intraluminal production from malabsorbed nutrients, decreased gas absorption due to obstruction, or expansion of intraluminal gas due to changes in atmospheric pressure (",
"      <a class=\"graphic graphic_table graphicRef81749 \" href=\"UTD.htm?38/38/39531\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Sources of intestinal gas'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The medical history should begin by determining whether there is actually passage of excessive gas (belching or flatus) or just a subjective sensation of bloating.",
"     </li>",
"     <li>",
"      In patients who complain predominantly of belching, we suggest behavioral changes, which include avoidance of carbonated beverages, stress management, discontinuation of gum-chewing (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Eructation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If patients who complain predominantly of flatus, we suggest dietary changes (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). These include a temporary trial of lactose and fructose avoidance, avoidance of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/0/29699?source=see_link\">",
"       sorbitol",
"      </a>",
"      (which may be contained in diet foods and chewing gum), and avoidance of ingestion of foods known to promote gaseousness (such as legumes and cruciferous vegetables). (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Flatulence'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Various preparations promoted to reduce gas, such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/35/33332?source=see_link\">",
"       simethicone",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/52/39750?source=see_link\">",
"       activated charcoal",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/13/26834?source=see_link\">",
"       Beano",
"      </a>",
"      are usually of minimal benefit and we generally do not suggest their use. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with suspected bacterial overgrowth should undergo breath testing and treatment if positive. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/45/11990?source=see_link\">",
"       \"Clinical manifestations and diagnosis of small intestinal bacterial overgrowth\"",
"      </a>",
"      .) Diagnosis of specific forms of carbohydrate malabsorption can also be established with a breath test, although an empirical trial of dietary restriction may be sufficient. (See",
"      <a class=\"local\" href=\"#H1307548188\">",
"       'Carbohydrate malabsorption'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      New onset flatulence associated with symptoms such as weight loss, diarrhea, abdominal pain, and distention or anorexia usually deserves a work-up for malabsorption. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/21/38232?source=see_link\">",
"       \"Clinical features and diagnosis of malabsorption\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/18/24872/abstract/1\">",
"      Lasser RB, Bond JH, Levitt MD. The role of intestinal gas in functional abdominal pain. N Engl J Med 1975; 293:524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/18/24872/abstract/2\">",
"      BEDELL GN, MARSHALL R, DUBOIS AB, HARRIS JH. Measurement of the volume of gas in the gastrointestinal tract; values in normal subjects and ambulatory patients. J Clin Invest 1956; 35:336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/18/24872/abstract/3\">",
"      Tomlin J, Lowis C, Read NW. Investigation of normal flatus production in healthy volunteers. Gut 1991; 32:665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/18/24872/abstract/4\">",
"      Koide A, Yamaguchi T, Odaka T, et al. Quantitative analysis of bowel gas using plain abdominal radiograph in patients with irritable bowel syndrome. Am J Gastroenterol 2000; 95:1735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/18/24872/abstract/5\">",
"      Moore JG, Jessop LD, Osborne DN. Gas-chromatographic and mass-spectrometric analysis of the odor of human feces. Gastroenterology 1987; 93:1321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/18/24872/abstract/6\">",
"      Suarez FL, Springfield J, Levitt MD. Identification of gases responsible for the odour of human flatus and evaluation of a device purported to reduce this odour. Gut 1998; 43:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/18/24872/abstract/7\">",
"      Chitkara DK, Bredenoord AJ, Rucker MJ, Talley NJ. Aerophagia in adults: a comparison with functional dyspepsia. Aliment Pharmacol Ther 2005; 22:855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/18/24872/abstract/8\">",
"      Bredenoord AJ, Weusten BL, Sifrim D, et al. Aerophagia, gastric, and supragastric belching: a study using intraluminal electrical impedance monitoring. Gut 2004; 53:1561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/18/24872/abstract/9\">",
"      Bredenoord AJ, Smout AJ. Physiologic and pathologic belching. Clin Gastroenterol Hepatol 2007; 5:772.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/18/24872/abstract/10\">",
"      Levitt MD. Intestinal gas production. J Am Diet Assoc 1972; 60:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/18/24872/abstract/11\">",
"      Steggerda FR. Gastrointestinal gas following food consumption. Ann N Y Acad Sci 1968; 150:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/18/24872/abstract/12\">",
"      Levitt MD. Production and excretion of hydrogen gas in man. N Engl J Med 1969; 281:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/18/24872/abstract/13\">",
"      Olesen M, Rumessen JJ, Gudmand-H&oslash;yer E. Intestinal transport and fermentation of resistant starch evaluated by the hydrogen breath test. Eur J Clin Nutr 1994; 48:692.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/18/24872/abstract/14\">",
"      Newcomer AD, McGill DB, Thomas PJ, Hofmann AF. Prospective comparison of indirect methods for detecting lactase deficiency. N Engl J Med 1975; 293:1232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/18/24872/abstract/15\">",
"      Wolin MJ. Fermentation in the rumen and human large intestine. Science 1981; 213:1463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/18/24872/abstract/16\">",
"      Gibson GR, Macfarlane GT, Cummings JH. Occurrence of sulphate-reducing bacteria in human faeces and the relationship of dissimilatory sulphate reduction to methanogenesis in the large gut. J Appl Bacteriol 1988; 65:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/18/24872/abstract/17\">",
"      Lajoie SF, Bank S, Miller TL, Wolin MJ. Acetate production from hydrogen and [13C]carbon dioxide by the microflora of human feces. Appl Environ Microbiol 1988; 54:2723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/18/24872/abstract/18\">",
"      Florin TH, Woods HJ. Inhibition of methanogenesis by human bile. Gut 1995; 37:418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/18/24872/abstract/19\">",
"      Piqu&eacute; JM, Pallar&eacute;s M, Cus&oacute; E, et al. Methane production and colon cancer. Gastroenterology 1984; 87:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/18/24872/abstract/20\">",
"      Suarez FL, Savaiano DA, Levitt MD. A comparison of symptoms after the consumption of milk or lactose-hydrolyzed milk by people with self-reported severe lactose intolerance. N Engl J Med 1995; 333:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/18/24872/abstract/21\">",
"      Levitt MD, Hirsh P, Fetzer CA, et al. H2 excretion after ingestion of complex carbohydrates. Gastroenterology 1987; 92:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/18/24872/abstract/22\">",
"      Gibson PR, Newnham E, Barrett JS, et al. Review article: fructose malabsorption and the bigger picture. Aliment Pharmacol Ther 2007; 25:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/18/24872/abstract/23\">",
"      Choi YK, Johlin FC Jr, Summers RW, et al. Fructose intolerance: an under-recognized problem. Am J Gastroenterol 2003; 98:1348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/18/24872/abstract/24\">",
"      Ravich WJ, Bayless TM, Thomas M. Fructose: incomplete intestinal absorption in humans. Gastroenterology 1983; 84:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/18/24872/abstract/25\">",
"      Rumessen JJ, Gudmand-H&oslash;yer E. Functional bowel disease: malabsorption and abdominal distress after ingestion of fructose, sorbitol, and fructose-sorbitol mixtures. Gastroenterology 1988; 95:694.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/18/24872/abstract/26\">",
"      Nelis GF, Vermeeren MA, Jansen W. Role of fructose-sorbitol malabsorption in the irritable bowel syndrome. Gastroenterology 1990; 99:1016.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/18/24872/abstract/27\">",
"      MCNALLY EF, KELLY JE Jr, INGELFINGER FJ. MECHANISM OF BELCHING: EFFECTS OF GASTRIC DISTENSION WITH AIR. Gastroenterology 1964; 46:254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/18/24872/abstract/28\">",
"      Richter JE, Castell DO. Gastroesophageal reflux. Pathogenesis, diagnosis, and therapy. Ann Intern Med 1982; 97:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/18/24872/abstract/29\">",
"      Tack J, Talley NJ, Camilleri M, et al. Functional gastroduodenal disorders. Gastroenterology 2006; 130:1466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/18/24872/abstract/30\">",
"      Olsson S, Furne J, Levitt MD. Relationship of gaseous symptoms to intestinal gas production: Symptoms do not equal increased production. Gastroenterology 1995; 108 Suppl:A28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/18/24872/abstract/31\">",
"      Friis H, Bod&eacute; S, Rumessen JJ, Gudmand-H&oslash;yer E. Effect of simethicone on lactulose-induced H2 production and gastrointestinal symptoms. Digestion 1991; 49:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/18/24872/abstract/32\">",
"      Hall RG Jr, Thompson H, Strother A. Effects of orally administered activated charcoal on intestinal gas. Am J Gastroenterol 1981; 75:192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/18/24872/abstract/33\">",
"      Jain NK, Patel VP, Pitchumoni S. Activated charcoal, simethicone, and intestinal gas: a double-blind study. Ann Intern Med 1986; 105:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/18/24872/abstract/34\">",
"      Potter T, Ellis C, Levitt M. Activated charcoal: in vivo and in vitro studies of effect on gas formation. Gastroenterology 1985; 88:620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/18/24872/abstract/35\">",
"      Suarez FL, Furne J, Springfield J, Levitt MD. Failure of activated charcoal to reduce the release of gases produced by the colonic flora. Am J Gastroenterol 1999; 94:208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/18/24872/abstract/36\">",
"      Ganiats TG, Norcross WA, Halverson AL, et al. Does Beano prevent gas? A double-blind crossover study of oral alpha-galactosidase to treat dietary oligosaccharide intolerance. J Fam Pract 1994; 39:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/18/24872/abstract/37\">",
"      Suarez FL, Furne JK, Springfield J, Levitt MD. Bismuth subsalicylate markedly decreases hydrogen sulfide release in the human colon. Gastroenterology 1998; 114:923.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/18/24872/abstract/38\">",
"      Ohge H, Furne JK, Springfield J, et al. Effectiveness of devices purported to reduce flatus odor. Am J Gastroenterol 2005; 100:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/18/24872/abstract/39\">",
"      Levitt MD. Volume and composition of human intestinal gas determined by means of an intestinal washout technic. N Engl J Med 1971; 284:1394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/18/24872/abstract/40\">",
"      Maxton DG, Martin DF, Whorwell PJ, Godfrey M. Abdominal distension in female patients with irritable bowel syndrome: exploration of possible mechanisms. Gut 1991; 32:662.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/18/24872/abstract/41\">",
"      Salvioli B, Serra J, Azpiroz F, et al. Origin of gas retention and symptoms in patients with bloating. Gastroenterology 2005; 128:574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/18/24872/abstract/42\">",
"      Schuster MM, Whitehead WE. Physiologic insights into irritable bowel syndrome. Clin Gastroenterol 1986; 15:839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/18/24872/abstract/43\">",
"      Ritchie J. Pain from distension of the pelvic colon by inflating a balloon in the irritable colon syndrome. Gut 1973; 14:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/18/24872/abstract/44\">",
"      Serra J, Azpiroz F, Malagelada JR. Impaired transit and tolerance of intestinal gas in the irritable bowel syndrome. Gut 2001; 48:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/18/24872/abstract/45\">",
"      Serra J, Salvioli B, Azpiroz F, Malagelada JR. Lipid-induced intestinal gas retention in irritable bowel syndrome. Gastroenterology 2002; 123:700.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/18/24872/abstract/46\">",
"      Caldarella MP, Serra J, Azpiroz F, Malagelada JR. Prokinetic effects in patients with intestinal gas retention. Gastroenterology 2002; 122:1748.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/18/24872/abstract/47\">",
"      Johnson AG. Controlled trial of metoclopramide in the treatment of flatulent dyspepsia. Br Med J 1971; 2:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/18/24872/abstract/48\">",
"      Van Outryve M, Milo R, Toussaint J, Van Eeghem P. \"Prokinetic\" treatment of constipation-predominant irritable bowel syndrome: a placebo-controlled study of cisapride. J Clin Gastroenterol 1991; 13:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/18/24872/abstract/49\">",
"      Lewis MJ, Reilly B, Houghton LA, Whorwell PJ. Ambulatory abdominal inductance plethysmography: towards objective assessment of abdominal distension in irritable bowel syndrome. Gut 2001; 48:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/18/24872/abstract/50\">",
"      Accarino A, Perez F, Azpiroz F, et al. Abdominal distention results from caudo-ventral redistribution of contents. Gastroenterology 2009; 136:1544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/18/24872/abstract/51\">",
"      MACHELLA TE, DWORKEN HJ, BIEL FJ. Observations on the splenic flexure syndrome. Ann Intern Med 1952; 37:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/18/24872/abstract/52\">",
"      Walls AD, Gonzales JG. The incidence of gas bloat syndrome and dysphagia following fundoplication for hiatus hernia. J R Coll Surg Edinb 1977; 22:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/18/24872/abstract/53\">",
"      Sharara AI, Aoun E, Abdul-Baki H, et al. A randomized double-blind placebo-controlled trial of rifaximin in patients with abdominal bloating and flatulence. Am J Gastroenterol 2006; 101:326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/18/24872/abstract/54\">",
"      Gillon J, Tadesse K, Logan RF, et al. Breath hydrogen in pneumatosis cystoides intestinalis. Gut 1979; 20:1008.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/18/24872/abstract/55\">",
"      Levitt MD, Olsson S. Pneumatosis cystoides intestinalis and high breath H2 excretion: insights into the role of H2 in this condition. Gastroenterology 1995; 108:1560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/18/24872/abstract/56\">",
"      Forgacs P, Wright PH, Wyatt AP. Treatment of intestinal gas cysts by oxygen breathing. Lancet 1973; 1:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/18/24872/abstract/57\">",
"      Bond JH Jr, Levitt MD. Factors affecting the concentration of combustible gases in the colon during colonoscopy. Gastroenterology 1975; 68:1445.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2607 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-91.202.164.29-FFA7B79098-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_18_24872=[""].join("\n");
var outline_f24_18_24872=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H23\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      AMOUNT OF GAS IN THE INTESTINE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      COMPOSITION OF INTESTINAL GAS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      SOURCES OF INTESTINAL GAS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Air swallowing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Intraluminal production",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - CO2",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - H2",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Methane",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1307548188\">",
"      - Carbohydrate malabsorption",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Diffusion from the blood",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      GAS DISORDERS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Eructation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Flatulence",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Abdominal bloating and distension",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1307547838\">",
"      - Treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H60523464\">",
"      Others",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H60523382\">",
"      - Pneumatosis cystoides intestinalis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H60523389\">",
"      - Colonic explosions during colonoscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/2607\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2607|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?38/38/39531\" title=\"table 1\">",
"      Differential diagnosis of excess intestinal gas",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?4/11/4283\" title=\"table 2\">",
"      Alarm signs and symptoms in a patient with excessive flatulence",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/21/38232?source=related_link\">",
"      Clinical features and diagnosis of malabsorption",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/45/11990?source=related_link\">",
"      Clinical manifestations and diagnosis of small intestinal bacterial overgrowth",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/32/5641?source=related_link\">",
"      Lactose intolerance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/50/41765?source=related_link\">",
"      Mechanisms of nutrient absorption and malabsorption",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/25/12697?source=related_link\">",
"      Pathophysiology of irritable bowel syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?6/14/6371?source=related_link\">",
"      Patient information: Gas and bloating (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?21/31/22002?source=related_link\">",
"      Patient information: Gas and bloating (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?11/26/11684?source=related_link\">",
"      Patient information: Lactose intolerance (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/31/31223?source=related_link\">",
"      Pneumatosis intestinalis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/14/40169?source=related_link\">",
"      Treatment of irritable bowel syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/50/28454?source=related_link\">",
"      Treatment of small intestinal bacterial overgrowth",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_18_24873="Bacterial endophthalmitis";
var content_f24_18_24873=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Bacterial endophthalmitis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/18/24873/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/18/24873/contributors\">",
"     Marlene L Durand, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/18/24873/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/18/24873/contributors\">",
"     Stephen B Calderwood, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/18/24873/contributors\">",
"     Jonathan Trobe, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/18/24873/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/18/24873/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?24/18/24873/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 23, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endophthalmitis refers to bacterial or fungal infection within the eye, including involvement of the vitreous",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    aqueous humors. It is not caused by viruses or parasites; by convention, infections due to these organisms are included in the term &lsquo;uveitis&rsquo; (eg, cytomegalovirus [CMV] retinitis, toxoplasma chorioretinitis). Most cases of endophthalmitis are exogenous, resulting from inoculation of organisms from the outside, via trauma, eye surgery, or as an extension of keratitis (corneal infection). In such cases, the aqueous humor may be seeded first before extension into the vitreous. The remaining cases are endogenous, resulting from bacteremic or fungemic seeding of the eye. In endogenous endophthalmitis, organisms usually seed the highly vascular choroid first, then extend anteriorly into the vitreous.",
"   </p>",
"   <p>",
"    Most cases of endophthalmitis are due to bacteria and present acutely. Acute bacterial endophthalmitis is a vision-threatening condition and must be managed as an emergency. The clinical outcome depends both upon the virulence of the infecting organism and the speed with which appropriate therapy is initiated.",
"   </p>",
"   <p>",
"    Bacterial endophthalmitis can be divided into five categories:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Acute postcataract surgery",
"     </li>",
"     <li>",
"      Chronic pseudophakic",
"     </li>",
"     <li>",
"      Bleb-related",
"     </li>",
"     <li>",
"      Posttraumatic",
"     </li>",
"     <li>",
"      Endogenous",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The epidemiology, clinical features, diagnosis, and treatment of bacterial endophthalmitis will be reviewed here. Fungal endophthalmitis is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/33/13849?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of fungal endophthalmitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/12/39112?source=see_link\">",
"     \"Treatment of endogenous endophthalmitis due to Candida species\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/16/36102?source=see_link\">",
"     \"Treatment of exogenous endophthalmitis due to Candida species\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ACUTE POSTCATARACT ENDOPHTHALMITIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute postcataract endophthalmitis is the most common form of endophthalmitis and, in the United States, is almost always due to bacteria. This complication occurs within six weeks of cataract surgery, with 75 percent of cases presenting in the first postoperative week.",
"   </p>",
"   <p>",
"    Series from the 1990s noted an incidence of endophthalmitis of 0.1 to 0.2 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?24/18/24873/abstract/1-3\">",
"     1-3",
"    </a>",
"    ], whereas a nationwide prospective study in Sweden from 2002 to 2004 found a somewhat lower incidence of 0.05 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?24/18/24873/abstract/4\">",
"     4",
"    </a>",
"    ]. Despite the low rate, endophthalmitis represents an important clinical problem, since over two million cataract operations are performed annually in the United States.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The vitreous is much more susceptible than the aqueous humor to infection by exogenously introduced bacteria (",
"    <a class=\"graphic graphic_figure graphicRef57690 \" href=\"UTD.htm?41/35/42549\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?24/18/24873/abstract/5\">",
"     5",
"    </a>",
"    ]. Cataract surgery, which is performed through the anterior chamber, often results in transient bacterial contamination of the aqueous by the patient's conjunctival flora.",
"   </p>",
"   <p>",
"    Several studies have shown that bacteria can be isolated from the anterior chamber at the end of cataract surgery in 7 to 43 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?24/18/24873/abstract/6-8\">",
"     6-8",
"    </a>",
"    ]. The organism burden in the aqueous is usually low, as demonstrated by quantitative cultures [",
"    <a class=\"abstract\" href=\"UTD.htm?24/18/24873/abstract/6\">",
"     6",
"    </a>",
"    ]. None of the study patients developed endophthalmitis, suggesting that the immune system is usually able to clear a small inoculum of relatively avirulent organisms.",
"   </p>",
"   <p>",
"    If a communication with the vitreous is inadvertently created during surgery (eg, break in the posterior lens capsule), the risk of endophthalmitis is much higher (14 times higher in one report) than in patients without a vitreous communication [",
"    <a class=\"abstract\" href=\"UTD.htm?24/18/24873/abstract/4,9\">",
"     4,9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Additional risk factors were evaluated in a retrospective case-control series of 57 patients with postcataract endophthalmitis and 220 controls [",
"    <a class=\"abstract\" href=\"UTD.htm?24/18/24873/abstract/10\">",
"     10",
"    </a>",
"    ]. Implantation of an intraocular lens without a heparinized surface, immunosuppressive therapy, and wound abnormality were risk factors for infection by logistic regression analysis. Risk factors noted in other studies include diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?24/18/24873/abstract/2\">",
"     2",
"    </a>",
"    ], wound dehiscence or leak [",
"    <a class=\"abstract\" href=\"UTD.htm?24/18/24873/abstract/11\">",
"     11",
"    </a>",
"    ], age &ge;85 [",
"    <a class=\"abstract\" href=\"UTD.htm?24/18/24873/abstract/4\">",
"     4",
"    </a>",
"    ], and lens implants made of polypropylene (Prolene) instead of polymethyl methacrylate [",
"    <a class=\"abstract\" href=\"UTD.htm?24/18/24873/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Advances in surgery, such as phacoemulsification and foldable synthetic intraocular lenses, have allowed incisions so small that they are considered self-sealing. These &lsquo;sutureless&rsquo; incisions may be made in the traditional way through the sclera (&lsquo;scleral tunnel incision&rsquo;), or with a newer technique through the cornea (&lsquo;clear cornea incision&rsquo;).",
"   </p>",
"   <p>",
"    Although the risk of endophthalmitis after sutureless surgery using a scleral tunnel incision is not increased [",
"    <a class=\"abstract\" href=\"UTD.htm?24/18/24873/abstract/13\">",
"     13",
"    </a>",
"    ], the risk using a clear cornea incision appears to be increased [",
"    <a class=\"abstract\" href=\"UTD.htm?24/18/24873/abstract/14-17\">",
"     14-17",
"    </a>",
"    ]. There is evidence that clear corneal incisions gape intermittently during the first few days after cataract surgery. This may allow external colonizing flora to enter the eye and account for the increased risk of endophthalmitis [",
"    <a class=\"abstract\" href=\"UTD.htm?24/18/24873/abstract/18,19\">",
"     18,19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Symptoms and signs",
"    </span>",
"    &nbsp;&mdash;&nbsp;The onset of symptoms occurs within one week of surgery in 75 percent of cases. Patients usually give a 12 to 24 hour history of decreasing vision and eye &lsquo;ache&rsquo; (they may deny eye &lsquo;pain&rsquo;). Patients feel otherwise well and are afebrile.",
"   </p>",
"   <p>",
"    On physical examination, findings are confined to the affected eye. The lids often appear normal, although they may be swollen. The conjunctiva may be injected or edematous (conjunctival chemosis), although these findings can also represent residual postoperative changes. Visual acuity is decreased, and a hypopyon (layering of white blood cells in the anterior chamber) is often present (",
"    <a class=\"graphic graphic_picture graphicRef59911 \" href=\"UTD.htm?1/45/1745\">",
"     picture 1",
"    </a>",
"    ). The view of the retina is usually hazy, and, in 80 percent of patients, no retinal vessels can be seen [",
"    <a class=\"abstract\" href=\"UTD.htm?24/18/24873/abstract/16\">",
"     16",
"    </a>",
"    ]. Slit lamp examination reveals intraocular white blood cells and protein (called &lsquo;cells&rsquo; and &lsquo;flare,&rsquo; respectively, by ophthalmologists).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major entity in the differential diagnosis of endophthalmitis is sterile postoperative inflammation. This can result from various causes, including a reaction to retained native lens fragments, extensive iris manipulation, or prolonged and complicated surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?24/18/24873/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The sterile inflammation can mimic early endophthalmitis, although the manifestations are typically greatest on the first postoperative day, whereas bacterial endophthalmitis usually develops on day two or later. However, timing of the onset of symptoms or findings cannot be relied upon to differentiate these entities. Sterile inflammation must be a diagnosis of exclusion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Laboratory findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laboratory findings are usually normal. Only one-third of patients with endophthalmitis have a white blood cell count greater than",
"    <span class=\"nowrap\">",
"     10,000/microL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?24/18/24873/abstract/20\">",
"     20",
"    </a>",
"    ]. The erythrocyte sedimentation rate is usually normal. An ultrasound of the eye (&lsquo;B-scan&rsquo;) usually shows increased echogenicity of the vitreous due to intraocular inflammation. This test can be helpful when the view of the vitreous is obscured by abnormalities in the anterior segment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endophthalmitis is a clinical diagnosis that is confirmed by positive aqueous or vitreous culture. However, a negative culture does not exclude the diagnosis.",
"   </p>",
"   <p>",
"    The ophthalmologist can aspirate the aqueous (0.1 mL sample)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    vitreous (0.2 to 0.3 mL) with a needle in the office or perform a pars plana vitrectomy in the operating room. A vitrectomy entails the use of a vitrector, an instrument inserted into the vitreous that simultaneously cuts and aspirates some of the 4 mL of gel-like vitreous into a canister. During this process, another catheter irrigates the vitreous with saline. By the end of the case, the vitrectomy canister contains 50 to 100 mL of dilute vitreous washings (",
"    <a class=\"graphic graphic_figure graphicRef59512 \" href=\"UTD.htm?30/11/30899\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Vitrectomy has the highest yield for a positive culture (90 percent of specimens), whereas only 75 percent of vitreous aspirate specimens are positive [",
"    <a class=\"abstract\" href=\"UTD.htm?24/18/24873/abstract/20\">",
"     20",
"    </a>",
"    ]. An aqueous aspirate has the lowest yield for a positive culture. In cases with positive vitreous cultures, simultaneous aqueous cultures are positive in only 40 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?24/18/24873/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Aspirates should be cultured on blood agar, chocolate agar, anaerobic media, meat broth, and Sabouraud agar. One drop should be placed on a slide for Gram stain. Gram stain is positive in approximately 45 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?24/18/24873/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If a vitrectomy is performed, 3 mL of the vitreous washings should be aspirated from the canister, centrifuged, and the pellet smeared on a slide for Gram stain. The remainder of the canister contents should be vacuum filtered through a 0.45 micron filter; the filter paper should then be cut up and placed on the media listed above.",
"   </p>",
"   <p>",
"    It is not yet clear what role molecular diagnostic techniques, such as polymerase chain reaction (PCR), will have in the diagnosis of bacterial endophthalmitis. These methods may amplify bacteria that are conjunctival contaminants and lead to false-positive results. The value of PCR was evaluated in a study that used eubacterial primers to examine aqueous and vitreous samples from endophthalmitis cases and noninfectious controls [",
"    <a class=\"abstract\" href=\"UTD.htm?24/18/24873/abstract/21\">",
"     21",
"    </a>",
"    ]. PCR was positive in all 20 culture-positive cases, but also in one of the 20 controls. The use of PCR to diagnose endophthalmitis is being evaluated in a large multicenter European study [",
"    <a class=\"abstract\" href=\"UTD.htm?24/18/24873/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Bacteriology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since coagulase-negative staphylococci are the predominant organisms colonizing the surface of the eye, and since most cases of postcataract endophthalmitis are due to the patient's own conjunctival flora [",
"    <a class=\"abstract\" href=\"UTD.htm?24/18/24873/abstract/23\">",
"     23",
"    </a>",
"    ], it is not surprising that coagulase-negative staphylococci are the major pathogens in postcataract endophthalmitis. The best microbiologic data have been provided by the Endophthalmitis Vitrectomy Study (EVS), a multicenter, National Institutes of Health (NIH)-sponsored, prospective study of 420 patients with postcataract endophthalmitis [",
"    <a class=\"abstract\" href=\"UTD.htm?24/18/24873/abstract/24\">",
"     24",
"    </a>",
"    ]. Thirty-one percent of patients had negative or equivocal cultures. Organisms isolated in the confirmed culture-positive group included:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Coagulase-negative staphylococci &mdash; 70 percent",
"     </li>",
"     <li>",
"      Staphylococcus aureus &mdash; 10 percent",
"     </li>",
"     <li>",
"      Streptococci &mdash; 9 percent",
"     </li>",
"     <li>",
"      Other gram-positive organisms &mdash; 5 percent",
"     </li>",
"     <li>",
"      Gram-negative organisms &mdash; 6 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute endophthalmitis is a medical emergency. The most important component of treatment of postcataract endophthalmitis is direct injection of antibiotics into the vitreous. Vitrectomy is important in severe cases. The role of adjunctive systemic antibiotics is unknown.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17914123\">",
"    <span class=\"h3\">",
"     Intravitreal antibiotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ophthalmologist first obtains a vitreous sample for culture, and then injects antibiotics into the vitreous. Intravitreal antibiotics can be injected either as an office procedure (vitreous aspiration and antibiotic injection, also called &lsquo;tap and inject&rsquo;) or in the operating room following vitrectomy (a debridement procedure of the vitreous).",
"   </p>",
"   <p>",
"    The empiric intravitreal antibiotics used are",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    1 mg plus either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/0/17415?source=see_link\">",
"     ceftazidime",
"    </a>",
"    2.25 mg or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/16/34056?source=see_link\">",
"     amikacin",
"    </a>",
"    0.4 mg. Each agent is diluted in 0.1 mL of sterile water or saline. Ceftazidime is usually preferred over amikacin because of the small risk of macular infarction with injected aminoglycosides. Antibiotic concentrations in the vitreous decline rapidly following injection, so most last only 24 to 48 hours. Thus, one injection of antibiotics may not maintain levels in the vitreous long enough to kill all bacteria. A repeat injection of vancomycin or ceftazidime may be indicated after 48 hours if there is persistent or worsening intraocular inflammation; a second injection of amikacin is avoided given concerns for retinal toxicity. The choice of antibiotic for repeat intravitreal injection is based on the culture result.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17914148\">",
"    <span class=\"h3\">",
"     Vitrectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vitrectomy is an important component of treatment in eyes with severe infection. Vitrectomy debrides the inflamed vitreous, similar to incision and drainage of an abscess. Vitrectomy leads to better visual outcomes in patients who present with severe vision loss. Whether vitrectomy should also be used in less severe cases is unclear. Similarly, the role of adjunctive oral or intravenous antibiotics in treating exogenous endophthalmitis is unclear.",
"   </p>",
"   <p>",
"    The Endophthalmitis Vitrectomy Study (EVS) was a multicenter trial that evaluated the role of vitrectomy and the value of adjunctive systemic antibiotics in treating postcataract endophthalmitis [",
"    <a class=\"abstract\" href=\"UTD.htm?24/18/24873/abstract/20\">",
"     20",
"    </a>",
"    ]. This study changed the practice of treating postcataract endophthalmitis. However, flaws in study design led to controversy regarding the interpretation of some of the results. Four hundred and twenty patients with postcataract endophthalmitis were randomly assigned to four treatment arms (2x2 design): vitrectomy versus vitreous &lsquo;tap&rsquo; (aspirate or biopsy) and systemic antibiotics versus none [",
"    <a class=\"abstract\" href=\"UTD.htm?24/18/24873/abstract/20\">",
"     20",
"    </a>",
"    ]. The systemic antibiotics used were intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/0/17415?source=see_link\">",
"     ceftazidime",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/16/34056?source=see_link\">",
"     amikacin",
"    </a>",
"    . All patients received intravitreal antibiotics and all patients assigned to the vitrectomy group received a vitrectomy in the operating room under local anesthesia.",
"   </p>",
"   <p>",
"    It is important to note that the vitreous &lsquo;tap&rsquo; group in the EVS was not homogeneous. Although a vitreous &lsquo;tap&rsquo; is understood by ophthalmologists to mean needle aspiration of the vitreous (an office procedure using topical anesthesia), the &lsquo;tap&rsquo; group included patients who received the usual needle aspiration of the vitreous, but also those who received a vitreous biopsy. Two-thirds of the patients had a vitreous &lsquo;biopsy,&rsquo; which was really a &lsquo;mini-vitrectomy&rsquo; and was performed with a vitrector in the operating room [",
"    <a class=\"abstract\" href=\"UTD.htm?24/18/24873/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. The EVS authors concluded that there was no difference in visual outcome between the vitrectomy and &lsquo;tap&rsquo; groups, except in patients who presented with the worst vision (light perception only). In these patients, vitrectomy was superior and significantly decreased the chance of severe visual loss compared with vitreous &lsquo;tap&rsquo; (20 versus 47 percent). In patients who presented with hand motion or better vision, the authors concluded that vitreous &lsquo;tap&rsquo; was sufficient. However, objections have been raised to this conclusion, since the comparison was really vitrectomy versus mini-vitrectomy in the majority of patients. The question remains whether patients who present with hand motion or better vision, especially those who present with a rapidly worsening course, might also benefit from vitrectomy (plus intravitreal antibiotics), rather than intravitreal antibiotics alone.",
"   </p>",
"   <p>",
"    The EVS demonstrated that vitrectomy sterilizes the vitreous more quickly than intravitreal antibiotics alone. Approximately 10 percent of each group had a second procedure and vitreous culture during the first week due to persistent inflammation. Of these patients, vitreous cultures were persistently positive more often in the &lsquo;tap&rsquo; group than the vitrectomy group (71 versus 13 percent), even though both groups had received the same intravitreal antibiotics [",
"    <a class=\"abstract\" href=\"UTD.htm?24/18/24873/abstract/25\">",
"     25",
"    </a>",
"    ]. Therefore, a vitrectomy should be considered for patients with endophthalmitis who received only an initial &lsquo;tap and inject&rsquo; on presentation but are failing to improve by 48 hours (or 24 hours in severe cases), since these patients may have persistent infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17914227\">",
"    <span class=\"h3\">",
"     Adjunctive systemic antibiotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Systemic antibiotics alone are not effective in treating exogenous bacterial endophthalmitis. Whether systemic antibiotics provide any benefit as adjunctive therapy to intravitreal antibiotics is unknown. Systemic antibiotics that cross the blood-eye barrier may prolong intravitreal antibiotic concentrations achieved following intravitreal antibiotic injection. This may be helpful in killing bacteria in the vitreous. However, there are no studies that have adequately evaluated this. The EVS concluded that adjunctive systemic antibiotics did not improve visual outcome and were not necessary to treat postcataract endophthalmitis [",
"    <a class=\"abstract\" href=\"UTD.htm?24/18/24873/abstract/20\">",
"     20",
"    </a>",
"    ]. However, staphylococci accounted for 80 percent of the study isolates [",
"    <a class=\"abstract\" href=\"UTD.htm?24/18/24873/abstract/24\">",
"     24",
"    </a>",
"    ], but the systemic antibiotics used in the study (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/16/34056?source=see_link\">",
"     amikacin",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/0/17415?source=see_link\">",
"     ceftazidime",
"    </a>",
"    ), have poor activity against staphylococci. In addition, amikacin does not cross the blood-eye barrier, so it is ineffective in treating endophthalmitis. It has been suggested that more effective systemic antibiotics (eg, a regimen that included intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    ) might have demonstrated a benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?24/18/24873/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Since the EVS, only retrospective reviews of adjunctive systemic antibiotics have been published. A study from western Australia that reviewed 213 cases of postcataract endophthalmitis from 1980 to 2000 found that patients who received various adjunctive oral antibiotics had better visual outcomes compared with those who did not receive adjunctive antibiotics [",
"    <a class=\"abstract\" href=\"UTD.htm?24/18/24873/abstract/26\">",
"     26",
"    </a>",
"    ]. However, it is difficult to draw any conclusions from this study given the lack of a uniform antibiotic regimen and the retrospective study design. Another study reviewed 72 cases of postcataract endophthalmitis between 2000 and 2009, excluding patients treated with primary vitrectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?24/18/24873/abstract/27\">",
"     27",
"    </a>",
"    ]. All patients received an oral fluoroquinolone for 10 days after intravitreal injection of antibiotics;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    was used between 2000 and 2004 (in 48 patients) and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/51/33584?source=see_link\">",
"     moxifloxacin",
"    </a>",
"    was used between 2005 and 2009 (in 24 patients). There were no significant differences in patient or surgical characteristics between the two groups. After controlling for potentially confounding factors such as ciprofloxacin resistance, moxifloxacin use was significantly associated with a good visual outcome",
"    <span class=\"nowrap\">",
"     (20/40",
"    </span>",
"    or better; adjusted odds ratio 4.07, 95% CI 1.11-14.9).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Approach to therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;We recommend the following approach to therapy for patients with postcataract bacterial endophthalmitis:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cultures of the vitreous should be obtained by needle aspiration or vitrectomy as soon as endophthalmitis is suspected.",
"     </li>",
"     <li>",
"      Antibiotics should be injected into the vitreous as soon as endophthalmitis is suspected and vitreous cultures are obtained. Intravitreal antibiotics are the most important component of endophthalmitis therapy. Empiric intravitreal antibiotics are usually given when the etiology is unknown, and these include",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"       vancomycin",
"      </a>",
"      1 mg plus either",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/0/17415?source=see_link\">",
"       ceftazidime",
"      </a>",
"      2.25 mg or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/16/34056?source=see_link\">",
"       amikacin",
"      </a>",
"      0.4 mg. Ceftazidime is favored over amikacin because of toxicity concerns.",
"     </li>",
"     <li>",
"      Vitrectomy should be performed for eyes with severe vision loss on presentation (light perception vision only or worse), and should be considered for cases that fail to improve after 24 to 48 hours. Vitreous aspiration (&lsquo;tap and inject&rsquo;) may be used initially for other cases. Intravitreal antibiotics are injected at the end of the vitrectomy as above.",
"     </li>",
"     <li>",
"      The intraocular lens implant does not need to be removed, except in cases of chronic endophthalmitis or those due to fungi. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Chronic pseudophakic endophthalmitis'",
"      </a>",
"      below and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/16/36102?source=see_link\">",
"       \"Treatment of exogenous endophthalmitis due to Candida species\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The value of adjunctive systemic antibiotics in treating postcataract endophthalmitis is unknown. We recommend adjunctive systemic antibiotics for severe cases (see",
"      <a class=\"local\" href=\"#H17914227\">",
"       'Adjunctive systemic antibiotics'",
"      </a>",
"      above).",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/51/33584?source=see_link\">",
"       Moxifloxacin",
"      </a>",
"      (400 mg orally once daily) achieves excellent vitreous levels [",
"      <a class=\"abstract\" href=\"UTD.htm?24/18/24873/abstract/28\">",
"       28",
"      </a>",
"      ] and, as noted above, a retrospective study using 10 days of therapy suggested some benefit [",
"      <a class=\"abstract\" href=\"UTD.htm?24/18/24873/abstract/27\">",
"       27",
"      </a>",
"      ]. Oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/3/14393?source=see_link\">",
"       linezolid",
"      </a>",
"      (600 mg twice daily) can be used as adjunctive therapy in staphylococcal endophthalmitis but it has been inadequately studied for this indication. Linezolid achieves therapeutic intraocular levels [",
"      <a class=\"abstract\" href=\"UTD.htm?24/18/24873/abstract/29\">",
"       29",
"      </a>",
"      ], and has excellent coverage of gram-positive bacteria. Whether intravenous antibiotics are indicated as adjunctive therapy in fulminant postcataract endophthalmitis cases has not been studied. In practice, few ophthalmologists use them.",
"     </li>",
"     <li>",
"      If the eye is not improving by 48 hours after the initial intravitreal antibiotic injection (ie, unchanged or worsening intraocular inflammation based on the ophthalmologist's examination), there are two things one should consider: a second injection of intravitreal antibiotics, and vitrectomy (if this has not already been performed). In fulminant cases, these should be considered at 24 rather than 48 hours. For this second injection of intravitreal antibiotics, either intravitreal",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"       vancomycin",
"      </a>",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/0/17415?source=see_link\">",
"       ceftazidime",
"      </a>",
"      should be given, based on culture results. A second injection of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/16/34056?source=see_link\">",
"       amikacin",
"      </a>",
"      is avoided, if possible, due to toxicity concerns. A repeat culture of the vitreous should also be obtained. In rare cases, a third injection of intravitreal antibiotics may be indicated 24 to 48 hours after the second injection, especially if repeat vitreous cultures are positive.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Visual outcome",
"    </span>",
"    &nbsp;&mdash;&nbsp;About half of eyes with postcataract endophthalmitis will eventually recover",
"    <span class=\"nowrap\">",
"     20/40",
"    </span>",
"    vision, whereas 10 percent will lose useful vision",
"    <span class=\"nowrap\">",
"     (5/200",
"    </span>",
"    or worse) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/18/24873/abstract/20\">",
"     20",
"    </a>",
"    ]. The outcome of postcataract endophthalmitis depends on the virulence of the pathogen: the worst outcomes are seen in cases due to streptococci of any type and the best outcomes occur in cases due to coagulase-negative staphylococci or cases that are culture-negative.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     CHRONIC PSEUDOPHAKIC ENDOPHTHALMITIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic pseudophakic-related endophthalmitis is a rare complication of cataract surgery. During cataract surgery, most of the opacified native lens (cataract) is removed, leaving behind some residual native lens and the posterior portion of the lens capsule. An artificial intraocular lens (IOL) is placed in front of this in the posterior chamber, the space between the lens and iris. &ldquo;Pseudophakic&rdquo; refers to the intraocular lens. Chronic pseudophakic endophthalmitis is usually caused by Propionibacterium acnes. A few cases have been caused by coagulase-negative staphylococci and diphtheroids. This infection is characterized by low-grade intraocular inflammation that may persist for months. It is often misdiagnosed as non-infectious iritis, and typically improves initially with topical corticosteroid therapy, but flares each time corticosteroids are stopped. It may be months before the correct diagnosis is made.",
"   </p>",
"   <p>",
"    Symptoms include decreased vision in nearly all patients, and eye pain (usually mild) in approximately half of patients. Eye examination with a slit lamp reveals white blood cells in the anterior chamber and, in nearly all patients, a characteristic white plaque in the posterior lens capsule. A hypopyon and white blood cells in the anterior vitreous (anterior vitritis) are also seen in some patients.",
"   </p>",
"   <p>",
"    For years, this process was thought to be a reaction to the remaining native lens tissue and was called toxic lens syndrome or phacoanaphylactic endophthalmitis. That the inflammation typically decreased with topical corticosteroid therapy added support to this misdiagnosis. Vitreous culture was negative or grew only P. acnes, initially thought to be a contaminant. Subsequent Gram stain and electron microscopy studies of the removed lens capsule showed small gram-positive rods, consistent with P. acnes, adherent to the capsular remnants [",
"    <a class=\"abstract\" href=\"UTD.htm?24/18/24873/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Diagnosis is often difficult, and is based on clinical suspicion supported by cultures of the aqueous or posterior lens capsule. However, cultures of the aqueous are often negative, even in cases where subsequent electron microscopy of the removed lens or lens capsule demonstrates organisms [",
"    <a class=\"abstract\" href=\"UTD.htm?24/18/24873/abstract/31\">",
"     31",
"    </a>",
"    ]. Anaerobic cultures should be included if possible. The highest yield for culture is usually by sampling the white plaque in the posterior lens capsule, but this can only be obtained by surgery (removal of the intraocular lens [IOL] and posterior lens capsule). Aspirate of the aqueous can be performed in an outpatient ophthalmology procedure room using a topical anesthetic.",
"   </p>",
"   <p>",
"    Treatment requires at least vitrectomy and intravitreal",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    , although 50 percent of cases recur with this treatment alone [",
"    <a class=\"abstract\" href=\"UTD.htm?24/18/24873/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. Removing part of the lens capsule (partial capsulectomy), in addition to vitrectomy and intravitreal vancomycin, reduced the recurrence rate in one study to 14 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?24/18/24873/abstract/33\">",
"     33",
"    </a>",
"    ]. However, in another study, this treatment was associated with a 44 percent recurrence rate [",
"    <a class=\"abstract\" href=\"UTD.htm?24/18/24873/abstract/34\">",
"     34",
"    </a>",
"    ]. Exchanging the IOL for a new one improved outcomes considerably. The combination of total capsulectomy, IOL exchange or removal, vitrectomy, and intravitreal antibiotics cured all cases in both studies. This was true whether this treatment was used as initial therapy or as treatment of recurrence after other therapy had failed. Systemic antimicrobial therapy is",
"    <strong>",
"     not",
"    </strong>",
"    indicated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     BLEB-RELATED ENDOPHTHALMITIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A filtering bleb is used to treat severe glaucoma that has failed medical management. It is a surgically created defect in the sclera, covered only by conjunctiva, which allows excess aqueous humor to leak out of the anterior chamber and be absorbed into the systemic circulation. It is usually placed in the superior portion of the eye, and when the upper lid is raised, it may be seen as a small bump in the sclera. A bleb can also rarely occur as a complication of other types of eye surgery.",
"   </p>",
"   <p>",
"    A bleb may become infected (blebitis) (",
"    <a class=\"graphic graphic_picture graphicRef82722 \" href=\"UTD.htm?18/16/18690\">",
"     picture 2",
"    </a>",
"    ), and bacteria may enter the eye, resulting in endophthalmitis. The onset of endophthalmitis is usually abrupt and typically occurs months to years following surgery. In a retrospective study of late-onset bleb-related endophthalmitis, infection developed suddenly an average of two years postoperatively (range one month to eight years) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/18/24873/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The incidence of endophthalmitis after bleb surgery in various studies depends on the duration of follow-up and ranges from 0.06 to 13.2 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?24/18/24873/abstract/2,36\">",
"     2,36",
"    </a>",
"    ]. One study used a Kaplan-Meier method to calculate incidence following bleb surgery, based on retrospective data on 239 eyes in 198 patients. The probability of developing endophthalmitis was 1.3 percent per patient-year, with a five year probability of 7.5 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?24/18/24873/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with bleb-related endophthalmitis present with sudden onset of eye pain and decreased vision. The eye is often red with purulence over the bleb, although bleb-related endophthalmitis may occur without any signs of blebitis.",
"   </p>",
"   <p>",
"    The clinical diagnosis of endophthalmitis is confirmed by vitreous cultures, although vitreous cultures were negative in 45 percent of cases in one study [",
"    <a class=\"abstract\" href=\"UTD.htm?24/18/24873/abstract/38\">",
"     38",
"    </a>",
"    ]. Cultures of the infected bleb should also be obtained. Most studies of late-onset endophthalmitis report that 50 percent of culture-positive cases are due to streptococci (viridans streptococci or S. pneumoniae). Haemophilus influenzae and Moraxella catarrhalis are other major pathogens [",
"    <a class=\"abstract\" href=\"UTD.htm?24/18/24873/abstract/38,39\">",
"     38,39",
"    </a>",
"    ]. In contrast, one study found that streptococci caused only about 20 percent of cases, whereas S. aureus and Staphylococcus epidermidis caused approximately 30 percent each [",
"    <a class=\"abstract\" href=\"UTD.htm?24/18/24873/abstract/35\">",
"     35",
"    </a>",
"    ]. Cases of late-onset endophthalmitis due to Enterococcus faecalis or gram-negative bacilli other than H. influenzae or M. catarrhalis (eg, Serratia) have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?24/18/24873/abstract/38\">",
"     38",
"    </a>",
"    ], although these cases are unusual. Early-onset bleb-related endophthalmitis, developing within 4 to 6 weeks of surgery, is uncommon, and all four culture-positive cases were caused by S. epidermidis in one study [",
"    <a class=\"abstract\" href=\"UTD.htm?24/18/24873/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The outcome of bleb-related endophthalmitis is typically poor, with only 13 percent of 32 patients in one study achieving",
"    <span class=\"nowrap\">",
"     20/40",
"    </span>",
"    or better visual acuity [",
"    <a class=\"abstract\" href=\"UTD.htm?24/18/24873/abstract/39\">",
"     39",
"    </a>",
"    ]. Almost one-half of patients in this study were left with minimal vision",
"    <span class=\"nowrap\">",
"     (5/200",
"    </span>",
"    or worse), including 10 patients (31 percent) who lost all vision in the infected eye.",
"   </p>",
"   <p>",
"    No prospective study has determined optimal therapy. Although the Endophthalmitis Vitrectomy Study (EVS) is often cited for treatment approaches to all types of endophthalmitis, this study was of postcataract endophthalmitis only. In addition, there were design flaws in the study and results should be interpreted with caution even for postcataract endophthalmitis. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Treatment'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    For treatment of bleb-related endophthalmitis, the author recommends a three-pronged approach:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Vitrectomy, rather than vitreous aspirate, based on the likelihood that infection will be caused by bacteria (eg, streptococci) known to cause fulminant infections in the eye.",
"     </li>",
"     <li>",
"      Intravitreal",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"       vancomycin",
"      </a>",
"      (1 mg) plus either",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/0/17415?source=see_link\">",
"       ceftazidime",
"      </a>",
"      (2.25 mg) or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/16/34056?source=see_link\">",
"       amikacin",
"      </a>",
"      (0.4 mg). Intravitreal antibiotics may be repeated after 48 hours if marked vitreous inflammation persists, although repeat injections of aminoglycosides should be avoided due to concern for toxicity (macular infarction). Injection of corticosteroids may also be considered in cases with marked vitritis, although the possible benefit is uncertain.",
"     </li>",
"     <li>",
"      The role of adjunctive systemic antibiotics in exogenous endophthalmitis is unknown (see",
"      <a class=\"local\" href=\"#H11\">",
"       'Approach to therapy'",
"      </a>",
"      above). In bleb-related endophthalmitis, however, most patients have severe infection and we recommend adding oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/51/33584?source=see_link\">",
"       moxifloxacin",
"      </a>",
"      400 mg daily for 7 to 10 days. The value of adjunctive IV antibiotics has not been evaluated and ophthalmologists rarely use them, but IV antibiotics should be considered for fulminant cases.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     POSTTRAUMATIC ENDOPHTHALMITIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endophthalmitis occurs after penetrating trauma to the globe of the eye in 3 to 10 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?24/18/24873/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]. Endophthalmitis is much more likely to occur after lacerating injury with a metal object than after injury from glass or blunt trauma. The risk of endophthalmitis is also increased by the presence of retained intraocular foreign bodies, delay in primary repair of more than 24 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?24/18/24873/abstract/42\">",
"     42",
"    </a>",
"    ], and disruption of the lens [",
"    <a class=\"abstract\" href=\"UTD.htm?24/18/24873/abstract/42-44\">",
"     42-44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Bacillus cereus is one of the major pathogens in most studies and causes a fulminant endophthalmitis [",
"    <a class=\"abstract\" href=\"UTD.htm?24/18/24873/abstract/45\">",
"     45",
"    </a>",
"    ]. B. cereus endophthalmitis is characterized by abrupt onset of symptoms 12 to 24 hours after eye injury, and a ring corneal infiltrate. Most eyes lose all vision even with prompt treatment. Other causes of posttraumatic endophthalmitis include coagulase-negative staphylococci, streptococci, and gram-negative bacilli such as Klebsiella and Pseudomonas, and molds [",
"    <a class=\"abstract\" href=\"UTD.htm?24/18/24873/abstract/46,47\">",
"     46,47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Because of the fulminant nature of posttraumatic endophthalmitis, we advocate the same aggressive treatment as described above for bleb-related endophthalmitis. To prevent endophthalmitis after eye trauma, we recommend initial systemic prophylactic antibiotics (eg, intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    plus either intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/0/17415?source=see_link\">",
"     ceftazidime",
"    </a>",
"    or oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    ). A review of 558 cases of open globe injuries revealed a very low rate (0.9 percent) of endophthalmitis following a protocol that included two days of prophylactic systemic antibiotics [",
"    <a class=\"abstract\" href=\"UTD.htm?24/18/24873/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Molds may cause posttraumatic endophthalmitis, although this is rare in temperate climates. The presentation of mold endophthalmitis is usually subacute. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/33/13849?source=see_link&amp;anchor=H27883763#H27883763\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of fungal endophthalmitis\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     ENDOGENOUS BACTERIAL ENDOPHTHALMITIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endogenous bacterial endophthalmitis is rare in the United States and results from bacterial seeding of the eye during bacteremia. A retrospective review of a 10 year period at a large acute care hospital and an adjoining eye specialty hospital identified only 28 cases [",
"    <a class=\"abstract\" href=\"UTD.htm?24/18/24873/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Sources of bacteremia include endocarditis, urinary tract infections, abdominal abscesses (including liver), meningitis, indwelling catheters, procedures such as endoscopy that cause transient bacteremia, and illicit injection drug use. In the US, endocarditis is a major cause of endogenous endophthalmitis, causing 40 percent of cases in one series [",
"    <a class=\"abstract\" href=\"UTD.htm?24/18/24873/abstract/49\">",
"     49",
"    </a>",
"    ]. However, in Taiwan, Singapore, and other East Asian nations, Klebsiella pneumoniae is the major cause of endophthalmitis associated with liver abscess, accounting for up to 60 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?24/18/24873/abstract/50\">",
"     50",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/33/38426?source=see_link&amp;anchor=H6013720#H6013720\">",
"     \"Clinical features, diagnosis, and treatment of Klebsiella pneumoniae infection\", section on 'Endophthalmitis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with endogenous bacterial endophthalmitis may present with symptoms of their bacteremia, or may only complain of eye pain and decreased vision. Half of patients in one series reported no systemic symptoms, and over half saw an ophthalmologist first [",
"    <a class=\"abstract\" href=\"UTD.htm?24/18/24873/abstract/49\">",
"     49",
"    </a>",
"    ]. In another series, fewer than 20 percent of patients had fever on presentation, and 40 percent had an unremarkable general physical examination [",
"    <a class=\"abstract\" href=\"UTD.htm?24/18/24873/abstract/51\">",
"     51",
"    </a>",
"    ]. Patients who do not have systemic symptoms may initially be misdiagnosed as having noninfectious uveitis. Endophthalmitis should be considered in any patient complaining of decreased vision or eye pain in the setting of possible bacteremia or injection drug use.",
"   </p>",
"   <p>",
"    The diagnosis of endogenous endophthalmitis is established by clinical findings consistent with endophthalmitis (eg, vitritis, hypopyon) in the setting of positive blood cultures, or by positive vitreous or aqueous cultures in patients presenting with endophthalmitis but who do not have a history of recent eye trauma or surgery. Blood cultures are positive in 75 percent of those tested, as are vitreous cultures [",
"    <a class=\"abstract\" href=\"UTD.htm?24/18/24873/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The microbiology of endogenous endophthalmitis varies with the patient population. In North America and Europe, streptococci (S. pneumoniae, S. milleri group, Group A, Group B) cause 30 to 50 percent of cases, S. aureus causes 25 percent, and gram-negative bacilli cause 30 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?24/18/24873/abstract/49,51\">",
"     49,51",
"    </a>",
"    ]. In Asia, gram-negative bacilli, especially Klebsiella, cause the majority of cases of endogenous endophthalmitis [",
"    <a class=\"abstract\" href=\"UTD.htm?24/18/24873/abstract/50,52\">",
"     50,52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The treatment of endogenous endophthalmitis includes intravitreal and systemic antibiotics. The duration of systemic antibiotics should be determined by the need to treat the underlying source of bacteremia (eg, six weeks in many cases of endocarditis). Systemic antibiotics alone will not effectively treat endophthalmitis, however, and all patients with endogenous endophthalmitis require intravitreal antibiotic injection. Vitrectomy plus intravitreal antibiotic injection is indicated in most cases, rather than intravitreal antibiotic injection alone, because of the virulent nature of most of the pathogens involved. Vitrectomy debrides the vitreous and leads to better visual outcome in severe cases of endophthalmitis. If the eye worsens over the next 24 to 48 hours, a second intravitreal antibiotic injection should be given. A third injection may also be given if there is still no improvement after a similar time interval, or if cultures from the second vitreous sample were positive. The basis for this approach is discussed above. (See",
"    <a class=\"local\" href=\"#H17914123\">",
"     'Intravitreal antibiotics'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H11\">",
"     'Approach to therapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     FUNGAL ENDOPHTHALMITIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fungal endophthalmitis due to yeasts (eg, Candida albicans) is very different from that due to molds (eg, Aspergillus or Fusarium). While Candida endophthalmitis is usually treated successfully, mold endophthalmitis often results in the loss of vision. Fungal endophthalmitis is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/33/13849?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of fungal endophthalmitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/12/39112?source=see_link\">",
"     \"Treatment of endogenous endophthalmitis due to Candida species\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/16/36102?source=see_link\">",
"     \"Treatment of exogenous endophthalmitis due to Candida species\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H365247411\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Endophthalmitis refers to bacterial or fungal infection within the eye, including involvement of the vitreous",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      aqueous humors. Most cases of endophthalmitis are exogenous, resulting from inoculation of organisms from the outside, via trauma, eye surgery, or as an extension of keratitis (corneal infection). In such cases, the aqueous humor may be seeded first before extension into the vitreous. The remaining cases are endogenous, resulting from bacteremic or fungemic seeding of the eye. In endogenous endophthalmitis, organisms usually seed the highly vascular choroid first, then extend anteriorly into the vitreous. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most cases of endophthalmitis are due to bacteria and present acutely. Acute bacterial endophthalmitis is a vision-threatening condition and must be managed as an emergency. The clinical outcome depends both upon the virulence of the infecting organism and the speed with which appropriate therapy is initiated. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Bacterial endophthalmitis can be divided into five categories:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Acute postcataract surgery",
"     </li>",
"     <li>",
"      Chronic pseudophakic",
"     </li>",
"     <li>",
"      Bleb-related",
"     </li>",
"     <li>",
"      Posttraumatic",
"     </li>",
"     <li>",
"      Endogenous (see",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H365247985\">",
"    <span class=\"h2\">",
"     Acute postcataract endophthalmitis",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acute postcataract endophthalmitis is the most common form of endophthalmitis and, in the United States, is almost always due to bacteria. Approximately 95 percent of cases are caused by gram-positive bacteria, particularly coagulase-negative staphylococci (70 percent). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Diagnosis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H8\">",
"       'Bacteriology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most important component of treatment is direct injection of antibiotics into the vitreous. For severe cases, immediate vitrectomy (followed by intravitreal injection of antibiotics) is also essential. Specific recommendations are reviewed above. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Approach to therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2139528\">",
"    <span class=\"h2\">",
"     Chronic pseudophakic endophthalmitis",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Chronic pseudophakic-related endophthalmitis is a rare complication of cataract surgery; &lsquo;pseudophakic&rsquo; refers to the intraocular lens. Chronic pseudophakic endophthalmitis is usually caused by Propionibacterium acnes. Treatment requires at least vitrectomy and intravitreal",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"       vancomycin",
"      </a>",
"      , although 50 percent of cases recur with this treatment alone. Removal of the residual lens capsule and exchange or removal of the intraocular lens may also be necessary for cure. Systemic antibiotics are not indicated. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Chronic pseudophakic endophthalmitis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H365248000\">",
"    <span class=\"h2\">",
"     Bleb-related endophthalmitis",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A filtering bleb is a surgically created defect in the sclera that is used to treat severe glaucoma that has failed medical management. Bleb-related endophthalmitis can be caused by a range of gram-positive and gram-negative bacteria, but streptococci, Haemophilus influenzae, and Moraxella catarrhalis are major pathogens. For treatment, we recommend a three-pronged approach that includes vitrectomy, intravitreal",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"       vancomycin",
"      </a>",
"      plus either",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/0/17415?source=see_link\">",
"       ceftazidime",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/16/34056?source=see_link\">",
"       amikacin",
"      </a>",
"      , and a systemic antibiotic that achieves good intravitreal concentrations and treats the most likely pathogens (eg, oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/51/33584?source=see_link\">",
"       moxifloxacin",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Bleb-related endophthalmitis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H365248008\">",
"    <span class=\"h2\">",
"     Posttraumatic endophthalmitis",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Posttraumatic endophthalmitis occurs after penetrating trauma to the globe of the eye in 3 to 10 percent of cases. Bacillus cereus is one of the major pathogens in most studies and causes a fulminant endophthalmitis. Because of the fulminant nature of posttraumatic endophthalmitis, we recommend immediate vitrectomy, intravitreal",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"       vancomycin",
"      </a>",
"      plus either",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/0/17415?source=see_link\">",
"       ceftazidime",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/16/34056?source=see_link\">",
"       amikacin",
"      </a>",
"      , and a systemic antibiotic that achieves good intravitreal concentrations. For initial empiric treatment, the systemic antibiotic chosen should cover B. cereus. To prevent endophthalmitis after eye trauma, we recommend initial systemic prophylactic antibiotics (eg, intravenous vancomycin plus either intravenous ceftazidime or oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"       ciprofloxacin",
"      </a>",
"      for 48 hours). (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Posttraumatic endophthalmitis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H365248016\">",
"    <span class=\"h2\">",
"     Endogenous endophthalmitis",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Endogenous bacterial endophthalmitis is rare in the United States and results from bacterial seeding of the eye during bacteremia. In North America and Europe, streptococci (Streptococcus pneumoniae, S. milleri group, Group A, Group B) cause 30 to 50 percent of cases, Staphylococcus aureus causes 25 percent, and gram-negative bacilli cause 30 percent. In Asia, gram-negative bacilli (especially Klebsiella) cause the majority of cases. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Endogenous bacterial endophthalmitis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The treatment of endogenous endophthalmitis includes intravitreal and systemic antibiotics. Systemic antibiotics alone will not effectively treat endophthalmitis, however, and all patients with endogenous endophthalmitis require intravitreal antibiotic injection. Vitrectomy plus intravitreal antibiotic injection is indicated in most cases, rather than intravitreal antibiotic injection alone, because of the virulent nature of most of the pathogens involved. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Endogenous bacterial endophthalmitis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/18/24873/abstract/1\">",
"      Javitt JC, Vitale S, Canner JK, et al. National outcomes of cataract extraction. Endophthalmitis following inpatient surgery. Arch Ophthalmol 1991; 109:1085.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/18/24873/abstract/2\">",
"      Kattan HM, Flynn HW Jr, Pflugfelder SC, et al. Nosocomial endophthalmitis survey. Current incidence of infection after intraocular surgery. Ophthalmology 1991; 98:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/18/24873/abstract/3\">",
"      Aaberg TM Jr, Flynn HW Jr, Schiffman J, Newton J. Nosocomial acute-onset postoperative endophthalmitis survey. A 10-year review of incidence and outcomes. Ophthalmology 1998; 105:1004.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/18/24873/abstract/4\">",
"      Lundstr&ouml;m M, Wejde G, Stenevi U, et al. Endophthalmitis after cataract surgery: a nationwide prospective study evaluating incidence in relation to incision type and location. Ophthalmology 2007; 114:866.",
"     </a>",
"    </li>",
"    <li>",
"     Mandelbaum S, Forster RK. Exogenous endophthalmitis. In: Ocular Immunology and Infection, Pepose JS, Holland GN, Wilhelmus KR (Eds), Mosby, St. Louis 1996. p.1298.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/18/24873/abstract/6\">",
"      Dickey JB, Thompson KD, Jay WM. Anterior chamber aspirate cultures after uncomplicated cataract surgery. Am J Ophthalmol 1991; 112:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/18/24873/abstract/7\">",
"      Sherwood DR, Rich WJ, Jacob JS, et al. Bacterial contamination of intraocular and extraocular fluids during extracapsular cataract extraction. Eye (Lond) 1989; 3 ( Pt 3):308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/18/24873/abstract/8\">",
"      Tervo T, Ljungberg P, Kautiainen T, et al. Prospective evaluation of external ocular microbial growth and aqueous humor contamination during cataract surgery. J Cataract Refract Surg 1999; 25:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/18/24873/abstract/9\">",
"      Menikoff JA, Speaker MG, Marmor M, Raskin EM. A case-control study of risk factors for postoperative endophthalmitis. Ophthalmology 1991; 98:1761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/18/24873/abstract/10\">",
"      Montan PG, Koranyi G, Setterquist HE, et al. Endophthalmitis after cataract surgery: risk factors relating to technique and events of the operation and patient history: a retrospective case-control study. Ophthalmology 1998; 105:2171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/18/24873/abstract/11\">",
"      Bainbridge JW, Teimory M, Tabandeh H, et al. Intraocular lens implants and risk of endophthalmitis. Br J Ophthalmol 1998; 82:1312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/18/24873/abstract/12\">",
"      Driebe WT Jr, Mandelbaum S, Forster RK, et al. Pseudophakic endophthalmitis. Diagnosis and management. Ophthalmology 1986; 93:442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/18/24873/abstract/13\">",
"      Turkalj JW, Carlson AN, Manos JP, Apple DJ. Is the sutureless cataract incision a valve for bacterial inoculation? J Cataract Refract Surg 1995; 21:472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/18/24873/abstract/14\">",
"      Cooper BA, Holekamp NM, Bohigian G, Thompson PA. Case-control study of endophthalmitis after cataract surgery comparing scleral tunnel and clear corneal wounds. Am J Ophthalmol 2003; 136:300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/18/24873/abstract/15\">",
"      Nagaki Y, Hayasaka S, Kadoi C, et al. Bacterial endophthalmitis after small-incision cataract surgery. effect of incision placement and intraocular lens type. J Cataract Refract Surg 2003; 29:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/18/24873/abstract/16\">",
"      Taban M, Behrens A, Newcomb RL, et al. Acute endophthalmitis following cataract surgery: a systematic review of the literature. Arch Ophthalmol 2005; 123:613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/18/24873/abstract/17\">",
"      Lalwani GA, Flynn HW Jr, Scott IU, et al. Acute-onset endophthalmitis after clear corneal cataract surgery (1996-2005). Clinical features, causative organisms, and visual acuity outcomes. Ophthalmology 2008; 115:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/18/24873/abstract/18\">",
"      Behrens A, Stark WJ, Pratzer KA, McDonnell PJ. Dynamics of small-incision clear cornea wounds after phacoemulsification surgery using optical coherence tomography in the early postoperative period. J Refract Surg 2008; 24:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/18/24873/abstract/19\">",
"      Taban M, Sarayba MA, Ignacio TS, et al. Ingress of India ink into the anterior chamber through sutureless clear corneal cataract wounds. Arch Ophthalmol 2005; 123:643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/18/24873/abstract/20\">",
"      Results of the Endophthalmitis Vitrectomy Study. A randomized trial of immediate vitrectomy and of intravenous antibiotics for the treatment of postoperative bacterial endophthalmitis. Endophthalmitis Vitrectomy Study Group. Arch Ophthalmol 1995; 113:1479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/18/24873/abstract/21\">",
"      Therese KL, Anand AR, Madhavan HN. Polymerase chain reaction in the diagnosis of bacterial endophthalmitis. Br J Ophthalmol 1998; 82:1078.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/18/24873/abstract/22\">",
"      Seal D, Reischl U, Behr A, et al. Laboratory diagnosis of endophthalmitis: comparison of microbiology and molecular methods in the European Society of Cataract &amp; Refractive Surgeons multicenter study and susceptibility testing. J Cataract Refract Surg 2008; 34:1439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/18/24873/abstract/23\">",
"      Speaker MG, Milch FA, Shah MK, et al. Role of external bacterial flora in the pathogenesis of acute postoperative endophthalmitis. Ophthalmology 1991; 98:639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/18/24873/abstract/24\">",
"      Han DP, Wisniewski SR, Wilson LA, et al. Spectrum and susceptibilities of microbiologic isolates in the Endophthalmitis Vitrectomy Study. Am J Ophthalmol 1996; 122:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/18/24873/abstract/25\">",
"      Doft BH, Kelsey SF, Wisniewski SR. Additional procedures after the initial vitrectomy or tap-biopsy in the Endophthalmitis Vitrectomy Study. Ophthalmology 1998; 105:707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/18/24873/abstract/26\">",
"      Ng JQ, Morlet N, Pearman JW, et al. Management and outcomes of postoperative endophthalmitis since the endophthalmitis vitrectomy study: the Endophthalmitis Population Study of Western Australia (EPSWA)'s fifth report. Ophthalmology 2005; 112:1199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/18/24873/abstract/27\">",
"      Hooper CY, Lightman SL, Pacheco P, et al. Adjunctive antibiotics in the treatment of acute bacterial endophthalmitis following cataract surgery. Acta Ophthalmol 2012; 90:e572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/18/24873/abstract/28\">",
"      Lott MN, Fuller JJ, Hancock HA, et al. Vitreal penetration of oral moxifloxacin in humans. Retina 2008; 28:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/18/24873/abstract/29\">",
"      Fiscella RG, Lai WW, Buerk B, et al. Aqueous and vitreous penetration of linezolid (Zyvox) after oral administration. Ophthalmology 2004; 111:1191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/18/24873/abstract/30\">",
"      Piest KL, Kincaid MC, Tetz MR, et al. Localized endophthalmitis: a newly described cause of the so-called toxic lens syndrome. J Cataract Refract Surg 1987; 13:498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/18/24873/abstract/31\">",
"      Ad&aacute;n A, Casaroli-Marano RP, Gris O, et al. Pathological findings in the lens capsules and intraocular lens in chronic pseudophakic endophthalmitis: an electron microscopy study. Eye (Lond) 2008; 22:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/18/24873/abstract/32\">",
"      Winward KE, Pflugfelder SC, Flynn HW Jr, et al. Postoperative Propionibacterium endophthalmitis. Treatment strategies and long-term results. Ophthalmology 1993; 100:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/18/24873/abstract/33\">",
"      Clark WL, Kaiser PK, Flynn HW Jr, et al. Treatment strategies and visual acuity outcomes in chronic postoperative Propionibacterium acnes endophthalmitis. Ophthalmology 1999; 106:1665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/18/24873/abstract/34\">",
"      Aldave AJ, Stein JD, Deramo VA, et al. Treatment strategies for postoperative Propionibacterium acnes endophthalmitis. Ophthalmology 1999; 106:2395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/18/24873/abstract/35\">",
"      Waheed S, Ritterband DC, Greenfield DS, et al. New patterns of infecting organisms in late bleb-related endophthalmitis: a ten year review. Eye (Lond) 1998; 12 ( Pt 6):910.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/18/24873/abstract/36\">",
"      Greenfield DS, Su&ntilde;er IJ, Miller MP, et al. Endophthalmitis after filtering surgery with mitomycin. Arch Ophthalmol 1996; 114:943.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/18/24873/abstract/37\">",
"      DeBry PW, Perkins TW, Heatley G, et al. Incidence of late-onset bleb-related complications following trabeculectomy with mitomycin. Arch Ophthalmol 2002; 120:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/18/24873/abstract/38\">",
"      Ciulla TA, Beck AD, Topping TM, Baker AS. Blebitis, early endophthalmitis, and late endophthalmitis after glaucoma-filtering surgery. Ophthalmology 1997; 104:986.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/18/24873/abstract/39\">",
"      Kangas TA, Greenfield DS, Flynn HW Jr, et al. Delayed-onset endophthalmitis associated with conjunctival filtering blebs. Ophthalmology 1997; 104:746.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/18/24873/abstract/40\">",
"      Soheilian M, Rafati N, Mohebbi MR, et al. Prophylaxis of acute posttraumatic bacterial endophthalmitis: a multicenter, randomized clinical trial of intraocular antibiotic injection, report 2. Arch Ophthalmol 2007; 125:460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/18/24873/abstract/41\">",
"      Sabaci G, Bayer A, Mutlu FM, et al. Endophthalmitis after deadly-weapon-related open-globe injuries: risk factors, value of prophylactic antibiotics, and visual outcomes. Am J Ophthalmol 2002; 133:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/18/24873/abstract/42\">",
"      Thompson JT, Parver LM, Enger CL, et al. Infectious endophthalmitis after penetrating injuries with retained intraocular foreign bodies. National Eye Trauma System. Ophthalmology 1993; 100:1468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/18/24873/abstract/43\">",
"      Thompson WS, Rubsamen PE, Flynn HW Jr, et al. Endophthalmitis after penetrating trauma. Risk factors and visual acuity outcomes. Ophthalmology 1995; 102:1696.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/18/24873/abstract/44\">",
"      Jonas JB, Budde WM. Early versus late removal of retained intraocular foreign bodies. Retina 1999; 19:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/18/24873/abstract/45\">",
"      Miller JJ, Scott IU, Flynn HW Jr, et al. Endophthalmitis caused by Bacillus species. Am J Ophthalmol 2008; 145:883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/18/24873/abstract/46\">",
"      Abu el-Asrar AM, al-Amro SA, al-Mosallam AA, al-Obeidan S. Post-traumatic endophthalmitis: causative organisms and visual outcome. Eur J Ophthalmol 1999; 9:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/18/24873/abstract/47\">",
"      Alfaro DV, Roth DB, Laughlin RM, et al. Paediatric post-traumatic endophthalmitis. Br J Ophthalmol 1995; 79:888.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/18/24873/abstract/48\">",
"      Andreoli CM, Andreoli MT, Kloek CE, et al. Low rate of endophthalmitis in a large series of open globe injuries. Am J Ophthalmol 2009; 147:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/18/24873/abstract/49\">",
"      Okada AA, Johnson RP, Liles WC, et al. Endogenous bacterial endophthalmitis. Report of a ten-year retrospective study. Ophthalmology 1994; 101:832.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/18/24873/abstract/50\">",
"      Wong JS, Chan TK, Lee HM, Chee SP. Endogenous bacterial endophthalmitis: an east Asian experience and a reappraisal of a severe ocular affliction. Ophthalmology 2000; 107:1483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/18/24873/abstract/51\">",
"      Binder MI, Chua J, Kaiser PK, et al. Endogenous endophthalmitis: an 18-year review of culture-positive cases at a tertiary care center. Medicine (Baltimore) 2003; 82:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/18/24873/abstract/52\">",
"      Jackson TL, Eykyn SJ, Graham EM, Stanford MR. Endogenous bacterial endophthalmitis: a 17-year prospective series and review of 267 reported cases. Surv Ophthalmol 2003; 48:403.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3418 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-115.25.216.6-12D3B89698-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_18_24873=[""].join("\n");
var outline_f24_18_24873=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H365247411\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ACUTE POSTCATARACT ENDOPHTHALMITIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Risk factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Symptoms and signs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Laboratory findings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Bacteriology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17914123\">",
"      - Intravitreal antibiotics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17914148\">",
"      - Vitrectomy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17914227\">",
"      - Adjunctive systemic antibiotics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Approach to therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Visual outcome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      CHRONIC PSEUDOPHAKIC ENDOPHTHALMITIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      BLEB-RELATED ENDOPHTHALMITIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      POSTTRAUMATIC ENDOPHTHALMITIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      ENDOGENOUS BACTERIAL ENDOPHTHALMITIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      FUNGAL ENDOPHTHALMITIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H365247411\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H365247985\">",
"      Acute postcataract endophthalmitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2139528\">",
"      Chronic pseudophakic endophthalmitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H365248000\">",
"      Bleb-related endophthalmitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H365248008\">",
"      Posttraumatic endophthalmitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H365248016\">",
"      Endogenous endophthalmitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/3418\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/3418|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?41/35/42549\" title=\"figure 1\">",
"      Eye anatomy in cross section",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?30/11/30899\" title=\"figure 2\">",
"      Vitreous aspirate vitrectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/3418|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?1/45/1745\" title=\"picture 1\">",
"      Hypopyon",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?18/16/18690\" title=\"picture 2\">",
"      Blebitis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/33/38426?source=related_link\">",
"      Clinical features, diagnosis, and treatment of Klebsiella pneumoniae infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/33/13849?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of fungal endophthalmitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/12/39112?source=related_link\">",
"      Treatment of endogenous endophthalmitis due to Candida species",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/16/36102?source=related_link\">",
"      Treatment of exogenous endophthalmitis due to Candida species",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_18_24874="Management of the potential pediatric organ donor";
var content_f24_18_24874=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Management of the potential pediatric organ donor",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/18/24874/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/18/24874/contributors\">",
"     Harish Vyas, DM, FRCP, FRCPCH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/18/24874/contributors\">",
"     Shaun Wilson, DCH, MRCPCH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/18/24874/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/18/24874/contributors\">",
"     George B Mallory, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/18/24874/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/18/24874/contributors\">",
"     Alison G Hoppin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?24/18/24874/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 16, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of potential donors is as complex as that of any other patient cared for in an intensive care unit. A major paradigm shift in strategy occurs after brain death. The goal of antemortem management is to maintain cerebral perfusion pressure, while the postmortem goal is to maintain the perfusion of all potential donor organs (",
"    <a class=\"graphic graphic_table graphicRef64564 \" href=\"UTD.htm?1/36/1611\">",
"     table 1",
"    </a>",
"    ). Without intervention following neurologic death, circulatory collapse occurs within hours.",
"   </p>",
"   <p>",
"    The pathophysiology of brain death and management of the potential pediatric organ donor are discussed here. The diagnosis of brain death and assessment of the pediatric patient for potential organ donation are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/2/30761?source=see_link\">",
"     \"Diagnosis of brain death\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/1/7193?source=see_link\">",
"     \"Assessment of the pediatric patient for potential organ donation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGIC CONSEQUENCES OF BRAIN DEATH",
"    </span>",
"    &nbsp;&mdash;&nbsp;Regardless of the initial insult to the brain, the end point of brain death is complete ischemia and irreversible loss of brainstem function. In some countries (eg, the United States) the term and medicolegal definitions focus on whole \"brain death\", while in others (eg, the United Kingdom) the term and concept of \"brainstem death\" is used. However, because brainstem death is associated with loss of any higher brain functions, the terms are essentially synonymous. It is important to understand the pathophysiology of brain death so that appropriate supportive management strategies can be offered to the potential donor. Brain death unleashes a cascade of autonomic, endocrine, hematological, and cardiorespiratory responses that threaten organ viability. Most, if not all, donors will develop this cascade as brain death occurs.",
"   </p>",
"   <p>",
"    Experimental models of induced brain death have demonstrated an orderly rostrocaudal march of ischemia and related autonomic symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?24/18/24874/abstract/1\">",
"     1",
"    </a>",
"    ]. Once the ischemic threshold of the brain is exceeded, death of the cerebrum is followed by progression to the brainstem.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Widespread cerebral damage is associated with increased vagal activity, manifested by signs of bradycardia, hypotension and decreased cardiac output.",
"     </li>",
"     <li>",
"      Pontine ischemia leads to a mixture of vagal and sympathetic signs.",
"     </li>",
"     <li>",
"      In a final attempt to maintain cerebral perfusion, Cushing's triad of hypertension, bradycardia and abnormal breathing patterns is elicited. When the ischemic process extends into the brainstem, an \"autonomic storm\" occurs.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In humans, the physiological events associated with brain death are less predictable, and depend in part upon the cause and rate of progression of the neurologic injury. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/56/19337?source=see_link\">",
"     \"Hypoxic-ischemic brain injury: Evaluation and prognosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/37/44633?source=see_link\">",
"     \"Elevated intracranial pressure in children\"",
"    </a>",
"    .) Nonetheless, many patients will display predictable pathophysiological patterns in the minutes and hours leading up to and following brain death. Understanding and anticipating these events will allow for optimal management of the patient.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Autonomic storm",
"    </span>",
"    &nbsp;&mdash;&nbsp;Necrosis of the parasympathetic nuclei in the medulla oblongata and unchallenged sympathetic activation is often the final event in brain death, leading to an outpouring of catecholamines. In animal models, this occurs within minutes after brain death [",
"    <a class=\"abstract\" href=\"UTD.htm?24/18/24874/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Elevated levels of epinephrine,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?1/25/1429?source=see_link\">",
"       norepinephrine",
"      </a>",
"      and",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?12/54/13157?source=see_link\">",
"       dopamine",
"      </a>",
"      lead to increased heart rate, mean arterial pressure, cardiac output, and massive peripheral vasoconstriction [",
"      <a class=\"abstract\" href=\"UTD.htm?24/18/24874/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Although cardiac contractility is increased, the massively increased systemic vascular resistance will functionally reduce left ventricular output [",
"      <a class=\"abstract\" href=\"UTD.htm?24/18/24874/abstract/3,4\">",
"       3,4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Increases of catecholamine levels of up to 1200-fold have been described; maximal levels are directly proportional to the rate of onset of brain death [",
"      <a class=\"abstract\" href=\"UTD.htm?24/18/24874/abstract/1,2\">",
"       1,2",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The entire hyperdynamic response is short lived, after which heart rate, blood pressure and contractility begin to decrease [",
"      <a class=\"abstract\" href=\"UTD.htm?24/18/24874/abstract/5\">",
"       5",
"      </a>",
"      ]. This may result in coronary artery hypoperfusion and myocardial ischemic damage.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Cardiovascular",
"    </span>",
"    &nbsp;&mdash;&nbsp;The massive outpouring of catecholamines induces ischemic changes to the myocardial and conductive tissue, impairing cardiac output [",
"    <a class=\"abstract\" href=\"UTD.htm?24/18/24874/abstract/1,2\">",
"     1,2",
"    </a>",
"    ] and potentiating arrhythmias. Other causes of myocardial dysfunction include cytolysis [",
"    <a class=\"abstract\" href=\"UTD.htm?24/18/24874/abstract/6\">",
"     6",
"    </a>",
"    ], abnormal cardiac receptor function [",
"    <a class=\"abstract\" href=\"UTD.htm?24/18/24874/abstract/7\">",
"     7",
"    </a>",
"    ] and production of a myocardial inhibitory protein [",
"    <a class=\"abstract\" href=\"UTD.htm?24/18/24874/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Following this catecholamine storm, hemodynamic compromise is the greatest risk to potential donor organs. As the spinal cord becomes ischemic, the sympathetic overdrive stops. Destruction of the sympathetic spinal cord tracts leads to loss of autonomic regulation resulting in peripheral vasodilation. The blood pressure drops, resulting in hypoperfusion of organs. Intrinsic damage to the myocardium compounds this hemodynamic instability.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Pulmonary",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pulmonary edema may occur during the hyperdynamic phase of brain death, and is caused by systemic vasoconstriction and pulmonary volume overload, leading to pulmonary edema [",
"    <a class=\"abstract\" href=\"UTD.htm?24/18/24874/abstract/9,10\">",
"     9,10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Endocrine abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Brain death leads to alteration and destruction of the hypothalamic-pituitary axes. The most commonly described endocrine abnormality following brain death in adults is diabetes insipidus (DI), which has been described in up to 87 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?24/18/24874/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. DI is somewhat less common in pediatric patients after brain death (38 to 41 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/18/24874/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. Although not pathognomonic, the onset of DI in severely brain-injured patients should raise the consideration of mid brain dysfunction and brain death.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Levels of anti-diuretic hormone (ADH), cortisol, and adrenocorticotropic hormone (ACTH) fall dramatically following brain death, and are undetectable within hours [",
"      <a class=\"abstract\" href=\"UTD.htm?24/18/24874/abstract/2,5\">",
"       2,5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Depletion of ADH and ACTH causes hypovolemia and further aggravates hemodynamic instability. Treatment of DI with IV",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/9/22678?source=see_link\">",
"       vasopressin",
"      </a>",
"      may allow weaning of inotropic support required to maintain cardiac output in brain dead patients [",
"      <a class=\"abstract\" href=\"UTD.htm?24/18/24874/abstract/15-17\">",
"       15-17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Levels of triiodothyronine (T3) drop and become very low within hours of brain death. Thyroxine (T4) levels are typically normal or low and thyroid stimulating hormone (TSH) does not rise in response. This rapid decline of free T3 levels and peripheral conversion to inactive reverse T3 (rT3) leads to a \"sick euthyroid syndrome\" [",
"      <a class=\"abstract\" href=\"UTD.htm?24/18/24874/abstract/18\">",
"       18",
"      </a>",
"      ]. It remains unclear whether this condition contributes to the cardiomyopathy often seen after brain death and whether thyroid hormone treatment is helpful [",
"      <a class=\"abstract\" href=\"UTD.htm?24/18/24874/abstract/17-20\">",
"       17-20",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Hormone management'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      The loss of hormonal regulation leads to changes in metabolism, most notably a shift from aerobic to anaerobic metabolism [",
"      <a class=\"abstract\" href=\"UTD.htm?24/18/24874/abstract/21\">",
"       21",
"      </a>",
"      ]. Some of these changes may be caused by decreased levels of thyroid hormone and can be reversed with hormonal replacement therapy, specifically thyroid hormone [",
"      <a class=\"abstract\" href=\"UTD.htm?24/18/24874/abstract/21\">",
"       21",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Hematological",
"    </span>",
"    &nbsp;&mdash;&nbsp;The hematocrit often rises acutely within minutes after brain death [",
"    <a class=\"abstract\" href=\"UTD.htm?24/18/24874/abstract/5\">",
"     5",
"    </a>",
"    ]. This is most likely due to acute vascular depletion and transcapillary fluid shifts, caused by acute increases in hydrostatic pressure. The hematocrit may fall later, most likely because of fluid redistribution, hemolysis, and the dilutional effect of resuscitation fluids.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Inflammatory changes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Brain death results in activation of platelets, leukocytes and endothelial cells. Production of cytokines, chemokines, adhesion molecules, tumor necrosis factor, and interleukin 6 typically increases after brain death, as measured by messenger RNA expression. These cytokines along with the massive catecholamine storm are thought to cause decreased myocardial contractility and contribute to hemodynamic instability after brain death [",
"    <a class=\"abstract\" href=\"UTD.htm?24/18/24874/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Coagulation disturbances can occur following brain death. A hypercoagulable state can arise as large amounts of pro-thrombotic agents are released into the circulation. Cerebral gangliosides and thromboplastin release can lead to disseminated intravascular coagulopathy.",
"   </p>",
"   <p>",
"    The organs of brain dead donors are more immunogenic than live donors, possibly as there is upregulation of the expression of major histocompatibility complex class I and II antigens. This may predispose to earlier and more severe rejection as compared to grafts from live donors [",
"    <a class=\"abstract\" href=\"UTD.htm?24/18/24874/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Mobility",
"    </span>",
"    &nbsp;&mdash;&nbsp;The concept of death has been synonymous with immobility. However, abnormal movements can occur in brain dead patients. The classic described movement is the \"Lazarus sign\". It consists of flexion at the elbows, shoulder adduction, lifting of the arms, dystonic hand posturing and crossing of the hands [",
"    <a class=\"abstract\" href=\"UTD.htm?24/18/24874/abstract/24\">",
"     24",
"    </a>",
"    ]. These abnormal movements occur most often in the first 24 hours and do not exclude the diagnosis of brain death [",
"    <a class=\"abstract\" href=\"UTD.htm?24/18/24874/abstract/25\">",
"     25",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/2/30761?source=see_link&amp;anchor=H4#H4\">",
"     \"Diagnosis of brain death\", section on 'Neurologic examination'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     HEMODYNAMIC MONITORING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following the autonomic storm in the first hour(s) after brain death, hypotension becomes the overriding hemodynamic issue (",
"    <a class=\"graphic graphic_table graphicRef79594 \" href=\"UTD.htm?18/1/18459\">",
"     table 2",
"    </a>",
"    ). Because of autonomic paralysis, beat-to-beat variability of heart rate is abolished. Therefore, brain dead patients cannot become tachycardic in response to hypovolemia. Invasive central venous pressure (CVP) and arterial blood pressure monitoring are mandatory. Hemodynamic parameters vary with age and should be taken into account when monitoring and treating the potential pediatric organ donor (",
"    <a class=\"graphic graphic_table graphicRef63033 \" href=\"UTD.htm?16/41/17051\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Pulmonary artery catheters (PAC) are rarely used in children. Placement of a PAC must be weighed against the potential risks for an individual patient, in consultation with the transplant surgeon and medical director of the organ procurement organization. A PAC may provide information that is useful in guiding treatment for older adolescents or adults with the following indications:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Evaluation for thoracic organ donation",
"     </li>",
"     <li>",
"      Echocardiography indicates ejection fraction &lt;45 percent",
"     </li>",
"     <li>",
"      CVP &gt;15 mmHg",
"     </li>",
"     <li>",
"      High PEEP &gt;10 cm H2O",
"     </li>",
"     <li>",
"      Coexisting valvular disease, cardiomyopathy, severe lung disease, persistent hypotension",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Urinary catheterization and meticulous measurement of fluid input and output measurement is required to assess response to therapies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     INOTROPES AND VASOPRESSORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Brain death is associated with peripheral vasodilatation, resulting in hypotension. Hypotension is typically treated with a combination of fluids and inotropes. Commonly used vasopressors are shown in the table (",
"    <a class=\"graphic graphic_table graphicRef76583 \" href=\"UTD.htm?26/22/26988\">",
"     table 4",
"    </a>",
"    ). This combined approach helps prevent excessive volume administration which can result in pulmonary edema, making the lungs less suitable for transplantation.",
"   </p>",
"   <p>",
"    Some centers have theoretical concerns that catecholamine treatment may induce cardiomyopathy and deplete endogenous catecholamines in the myocardium, which could attenuate the tissue's subsequent responsiveness to catecholamines [",
"    <a class=\"abstract\" href=\"UTD.htm?24/18/24874/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. However, animal studies have suggested that catecholamine administration may down-regulate immunogenicity of the graft, thus contributing to graft survival [",
"    <a class=\"abstract\" href=\"UTD.htm?24/18/24874/abstract/28,29\">",
"     28,29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Studies of catecholamine use in human donors show conflicting outcomes. Some studies suggest that",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?12/54/13157?source=see_link\">",
"     dopamine",
"    </a>",
"    usage may decrease early and late kidney graft survival [",
"    <a class=\"abstract\" href=\"UTD.htm?24/18/24874/abstract/30\">",
"     30",
"    </a>",
"    ]. However, another study showed that catecholamine treatment had minimal detrimental effect on organ function after renal or liver transplantation, and in fact showed improved renal graft survival [",
"    <a class=\"abstract\" href=\"UTD.htm?24/18/24874/abstract/31\">",
"     31",
"    </a>",
"    ], perhaps because of the effects on immunogenicity noted above. Vasopressor use has been associated with nonfunction of cardiac grafts [",
"    <a class=\"abstract\" href=\"UTD.htm?24/18/24874/abstract/32\">",
"     32",
"    </a>",
"    ], suggesting that vasopressor use may cause, or is a marker for, cardiac damage. In an early study, increased mortality was seen among recipients of hearts from organ donors who received dopamine infusions [",
"    <a class=\"abstract\" href=\"UTD.htm?24/18/24874/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite these uncertainties and caveats, the use of pharmacologic agents to maintain adequate blood pressure and organ perfusion is generally well accepted and is routinely used by many centers to support cardiac output and oxygen delivery to the tissues. A consensus conference recommended adjustment of fluids, inotropes, and pressors every 15 minutes based on serial hemodynamic measurements to minimize use of alpha-agonists. Most centers attempt to meet these parameters while keeping",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?12/54/13157?source=see_link\">",
"     dopamine",
"    </a>",
"    infusions below 10",
"    <span class=\"nowrap\">",
"     mcg/kg/minute",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?24/18/24874/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The following are appropriate targets for systolic blood pressure (SBP) and diastolic blood pressure (DBP) for the pediatric organ donor [",
"    <a class=\"abstract\" href=\"UTD.htm?24/18/24874/abstract/35\">",
"     35",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Neonate: SBP 60-90; DBP 35-60",
"     </li>",
"     <li>",
"      Infant: SBP 80-95; DBP 50-65",
"     </li>",
"     <li>",
"      Toddler: SBP 85-100; DBP 50-65",
"     </li>",
"     <li>",
"      School age: SBP 90-115; DBP 60-70",
"     </li>",
"     <li>",
"      Adolescent: SBP 110-130; DBP 65-80",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If a pulmonary artery catheter is placed, we suggest the following target ranges. These criteria were suggested for adult patients, and are also appropriate ranges for most older children or adolescents who are potential donors [",
"    <a class=\"abstract\" href=\"UTD.htm?24/18/24874/abstract/34\">",
"     34",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Mean arterial pressure &gt;60 mm Hg",
"     </li>",
"     <li>",
"      Central venous pressure 4 to 12 mm Hg",
"     </li>",
"     <li>",
"      Pulmonary capillary wedge pressure 8 to 12 mm Hg",
"     </li>",
"     <li>",
"      Systemic vascular resistance 800 to 1200 dynes x",
"      <span class=\"nowrap\">",
"       sec/cm(5)",
"      </span>",
"     </li>",
"     <li>",
"      Cardiac index &gt;2.4",
"      <span class=\"nowrap\">",
"       L/min/m(2)",
"      </span>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?12/54/13157?source=see_link\">",
"       Dopamine",
"      </a>",
"      &lt;10",
"      <span class=\"nowrap\">",
"       &micro;g/kg/min",
"      </span>",
"      or",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?24/48/25348?source=see_link\">",
"       dobutamine",
"      </a>",
"      &lt;10",
"      <span class=\"nowrap\">",
"       &micro;g/kg/min",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Dopamine",
"    </span>",
"    &nbsp;&mdash;&nbsp;If fluid resuscitation alone is unsuccessful,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?12/54/13157?source=see_link\">",
"     dopamine",
"    </a>",
"    is often the first line therapy because of its combined inotropic and vasopressor activity. Low dose dopamine has predominantly beta-adrenergic action. In animal models, doses less than 6",
"    <span class=\"nowrap\">",
"     micrograms/kg/min",
"    </span>",
"    increase splanchnic and renal perfusion. Low dose dopamine has also been shown to stimulate alveolar fluid clearance in brain dead patients [",
"    <a class=\"abstract\" href=\"UTD.htm?24/18/24874/abstract/36\">",
"     36",
"    </a>",
"    ]. In higher doses, alpha-adrenergic effects predominate and vasoconstrict tissue beds.",
"   </p>",
"   <p>",
"    Because of these considerations, management protocols recommend that",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?12/54/13157?source=see_link\">",
"     dopamine",
"    </a>",
"    infusion rates be kept to less than 10",
"    <span class=\"nowrap\">",
"     micrograms/kg/minute",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?24/18/24874/abstract/34\">",
"     34",
"    </a>",
"    ]. If the combination of fluid and dopamine up to maximum dose of 10",
"    <span class=\"nowrap\">",
"     micrograms/kg/min",
"    </span>",
"    is not sufficient to maintain BP, a vasopressor can be added to counteract the peripheral vasodilatation that occurs after brain death.",
"   </p>",
"   <p>",
"    Many transplant programs are reluctant to transplant a heart from a donor treated with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?12/54/13157?source=see_link\">",
"     dopamine",
"    </a>",
"    doses higher than 10",
"    <span class=\"nowrap\">",
"     micrograms/kg/minute.",
"    </span>",
"    However, in view of organ shortages, some authors have questioned the restriction to low doses of dopamine. There are a few reports of acceptable outcomes for heart transplantation from donors treated with higher doses of dopamine [",
"    <a class=\"abstract\" href=\"UTD.htm?24/18/24874/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. Retrospective studies demonstrate that hormone replacement therapy may increase the functional resuscitation of organs in donors treated with dopamine at doses that are higher than this threshold [",
"    <a class=\"abstract\" href=\"UTD.htm?24/18/24874/abstract/20,39\">",
"     20,39",
"    </a>",
"    ]. However, these observations have not been confirmed with prospective clinical trials.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Vasopressors",
"    </span>",
"    &nbsp;&mdash;&nbsp;If peripheral vasodilatation is the main concern,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?1/25/1429?source=see_link\">",
"     norepinephrine",
"    </a>",
"    infusions can be used to control the mean arterial pressure. The concern with the use of alpha-agonists is the possible occurrence of excessive peripheral vasoconstriction. This may compromise perfusion of the donor organs, limiting the potential for transplantation. The choices of alpha-agonists are epinephrine, norepinephrine, or",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/46/41696?source=see_link\">",
"     phenylephrine",
"    </a>",
"    . Epinephrine is commonly used in smaller children for both alpha and beta agonist effects.",
"   </p>",
"   <p>",
"    In patients with DI and hemodynamic instability,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/9/22678?source=see_link\">",
"     vasopressin",
"    </a>",
"    should be the primary agent used to control DI, titrated to decrease urine output. This is because vasopressin also may increase systemic vascular resistance and improve circulating volume, improving hemodynamic stability and allowing weaning of other inotropic agents. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Diabetes insipidus'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/9/22678?source=see_link\">",
"     Vasopressin",
"    </a>",
"    or",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?14/45/15062?source=see_link\">",
"     desmopressin",
"    </a>",
"    also may be considered in patients without DI as a second-line agent for hemodynamic support. As an example, these agents may be used if excessive doses of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?1/25/1429?source=see_link\">",
"     norepinephrine",
"    </a>",
"    or epinephrine are required (eg, norepinephrine in excess of 0.05",
"    <span class=\"nowrap\">",
"     micrograms/kg/min),",
"    </span>",
"    using doses similar to those used to treat shock [",
"    <a class=\"abstract\" href=\"UTD.htm?24/18/24874/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Beta-agonists",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of pure beta-agonist inotropes alone is contraindicated, because these agents cause vasodilatation. However, they can be used in conjunction with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?12/54/13157?source=see_link\">",
"     dopamine",
"    </a>",
"    , epinephrine and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?1/25/1429?source=see_link\">",
"     norepinephrine",
"    </a>",
"    to augment heart rate in patients with problematic bradycardia.",
"   </p>",
"   <p>",
"    The hypertensive crisis that occurs during the \"autonomic storm\" can cause serious damage to the end organs. Opinions are divided as to whether antihypertensive management should be instituted. Many experts feel that the surge is too short to require management, and judging when to start medication would be difficult. Short acting and titratable medications such as sodium",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?39/52/40773?source=see_link\">",
"     nitroprusside",
"    </a>",
"    or",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?5/48/5895?source=see_link\">",
"     esmolol",
"    </a>",
"    may be suitable candidates [",
"    <a class=\"abstract\" href=\"UTD.htm?24/18/24874/abstract/41-43\">",
"     41-43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although hypotension is the most common hemodynamic problem in brain dead patients, hypertension can occur intraoperatively during organ recovery. This is initiated via a sympathetic spinal reflex to the stimulus of surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?24/18/24874/abstract/44,45\">",
"     44,45",
"    </a>",
"    ] and an inhalational anesthetic agent can be used to control the blood pressure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     ARRHYTHMIAS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A baseline 12-lead ECG should be performed to assess the intrinsic conduction of the donor's heart. A variety of atrial and ventricular arrhythmias can occur after brain death. Hypovolemia, hypothermia, electrolyte abnormalities, increased intracranial pressure, myocardial ischemia, oxygenation issues, acid base disturbances, and myocardial contusions may contribute to the development of these arrhythmias. The use of inotropes and vasopressors can also predispose to arrhythmias, especially in the presence of an ischemic myocardium.",
"   </p>",
"   <p>",
"    Maintenance of normal body temperature and fluid and electrolyte balance is important to prevent arrhythmias. Any electrolyte abnormalities should be aggressively treated. Hypokalemia commonly occurs in this patient population secondary to excessive diuresis with DI and hyperglycemia. Hypothermia is a potent pro-arrhythmic stimulus and should be prevented. Respiratory alkalosis may be desirable as it can reduce arrhythmias, especially ventricular arrhythmias [",
"    <a class=\"abstract\" href=\"UTD.htm?24/18/24874/abstract/12\">",
"     12",
"    </a>",
"    ]. However, excessive alkalosis may reduce oxygen delivery to tissues by shifting the hemoglobin oxygen dissociation curve to the left (",
"    <a class=\"graphic graphic_figure graphicRef81216 \" href=\"UTD.htm?2/26/2479\">",
"     figure 1",
"    </a>",
"    ). Therefore, most providers try to maintain the pH between 7.3 and 7.45. Careful interpretation of the ECG is required as ST-segment change and J-waves are commonly seen in brain dead patients with electrolyte abnormalities and hypothermia.",
"   </p>",
"   <p>",
"    Bradycardia is the most common arrhythmia and only requires treatment if it is associated with hypotension.",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?25/13/25816?source=see_link\">",
"     Atropine",
"    </a>",
"    is ineffective in brain dead patients, as the inhibitory effect it normally exhibits on the vagus nerve is lost.",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?12/54/13157?source=see_link\">",
"     Dopamine",
"    </a>",
"    or epinephrine are the agents of choice. If chronotropic support does not treat the bradycardia, the patient may need transvenous pacing.",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/25/38291?source=see_link\">",
"     Isoproterenol",
"    </a>",
"    is effective in treating symptomatic bradycardia [",
"    <a class=\"abstract\" href=\"UTD.htm?24/18/24874/abstract/46\">",
"     46",
"    </a>",
"    ]. However, it may induce hypotension or paradoxical bradycardia, so pacing is usually safer [",
"    <a class=\"abstract\" href=\"UTD.htm?24/18/24874/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Electrolyte imbalances or hypotension may be heralded by tachyarrhythmias and ventricular arrhythmia. If",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?12/54/13157?source=see_link\">",
"     dopamine",
"    </a>",
"    or epinephrine is the presumptive cause of the dysrhythmia, stopping these drugs and commencing",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?1/25/1429?source=see_link\">",
"     norepinephrine",
"    </a>",
"    may help. Body temperature below 28&deg;C may cause resistant ventricular arrhythmias. If ventricular arrhythmias occur,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?36/57/37776?source=see_link\">",
"     lidocaine",
"    </a>",
"    or",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?9/41/9882?source=see_link\">",
"     amiodarone",
"    </a>",
"    are used. Correction of temperature, electrolyte and acid base disturbances and hypoxia may reduce arrhythmias as well.",
"   </p>",
"   <p>",
"    Hypotensive patients are especially at risk of a cardiac arrest. A cardiac arrest does not preclude a patient from successfully donating organs [",
"    <a class=\"abstract\" href=\"UTD.htm?24/18/24874/abstract/11\">",
"     11",
"    </a>",
"    ]. Resuscitation procedures are similar to protocols used for other patients. The idea of \"resuscitating\" an already dead child may be extremely distressing to parents coming to terms with recent loss. Occasionally, parents may oppose the continuation of aggressive donor management even after explanation, and their wishes should be respected.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     RESPIRATORY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ventilatory settings for the brain dead patient should be carefully adjusted to maintain a relatively normal physiologic state. The strategy differs from that used prior to brain death, in which the most important goal of mechanical ventilation was to diminish cerebral edema. However, such ante mortem strategies can cause damage to the donor organs, because a low PaCO2 causes peripheral vasoconstriction and can alter perfusion to tissues. With the onset of brain death, the consumption of oxygen is greatly decreased, and anaerobic metabolism gradually ensues. Following brain death, the main goals are to prevent hypoxemia, atelectasis, and ventilator-induced lung damage.",
"   </p>",
"   <p>",
"    Volume-limited mechanical ventilation is the mode of choice in most circumstances. Pressure ventilation is used if the peak and plateau airway pressures are very high, due to poor compliance or elevated airway resistance [",
"    <a class=\"abstract\" href=\"UTD.htm?24/18/24874/abstract/48,49\">",
"     48,49",
"    </a>",
"    ]. Decelerating flows should be set on the ventilator as the flow is more laminar at the end of inspiration and decreases the airway resistance [",
"    <a class=\"abstract\" href=\"UTD.htm?24/18/24874/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The initial setting of positive end-expiratory pressure (PEEP) should be a minimum of 5 cm H2O [",
"    <a class=\"abstract\" href=\"UTD.htm?24/18/24874/abstract/51\">",
"     51",
"    </a>",
"    ], to maintain a reasonable functional residual capacity (FRC) and prevent atelectasis. The fraction of inspired oxygen (FiO2) should be kept &lt;0.5 as long as oxygen saturations are above 95 percent. A PaO2 near or above 100 mmHg (9.3 and 13.3 kPa) is desirable [",
"    <a class=\"abstract\" href=\"UTD.htm?24/18/24874/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    To determine whether the patient's lungs are suitable for organ donation, an oxygen challenge is performed. The potential donor is preoxygenated by providing an FiO2 of 1.0, and the PaO2 is measured. If the PaO2 is &gt;300 mmHg, the lungs are considered suitable for donation in many centers.",
"   </p>",
"   <p>",
"    An increase in ventilatory requirements suggests pulmonary edema, atelectasis, mucous plugging, aspiration, or infection. Pulmonary edema can be cardiogenic, pulmonary or neurogenic in origin. PEEP can be increased to improve oxygenation but kept to a minimum as it may impair venous return and cardiac output. If increased PEEP is required and hemodynamic compromise is noted, volume loading with crystalloid or colloids or adjustment in inotropic medication may be required to improve cardiac output. Pulmonary edema of cardiac origin should be treated with appropriate inotropic agents, alterations in fluid management,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    diuretics.",
"   </p>",
"   <p>",
"    If hypoxemia is an issue, the following strategies may be helpful to maximize functioning lung zones and recruit alveoli [",
"    <a class=\"abstract\" href=\"UTD.htm?24/18/24874/abstract/50\">",
"     50",
"    </a>",
"    ]: (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/48/43784?source=see_link\">",
"     \"Modes of mechanical ventilation\"",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Convert to pressure-cycled strategies for ventilation [",
"      <a class=\"abstract\" href=\"UTD.htm?24/18/24874/abstract/53\">",
"       53",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Increase PEEP.",
"     </li>",
"     <li>",
"      Increase the inspiratory time.",
"     </li>",
"     <li>",
"      Place the patient in a prone position (may be difficult to perform in a patient who is large",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      hemodynamically unstable).",
"     </li>",
"     <li>",
"      Use advanced ventilation strategies, such as airway pressure release ventilation, or in rare circumstances, high frequency oscillation ventilation, which may improve FRC.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Additional measures to improve oxygenation include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Maintain adequate hemoglobin concentration to improve oxygen carrying capacity",
"     </li>",
"     <li>",
"      Maximize cardiac output",
"     </li>",
"     <li>",
"      Correct acidosis",
"     </li>",
"     <li>",
"      Treat with inhaled nitric oxide",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The PaCO2 should be kept within the normal range (35 to 45 mmHg), aiming for a pH 7.38 to 7.44. Tidal volumes of 8 to 10",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    should be set, with low respiratory rates [",
"    <a class=\"abstract\" href=\"UTD.htm?24/18/24874/abstract/54\">",
"     54",
"    </a>",
"    ]. Setting higher tidal volumes can minimize atelectasis but may predispose to barotrauma. If lung injury is present or the peak pressure generated is too high, the tidal volumes can be dropped to 6 to 8",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    to prevent barotrauma [",
"    <a class=\"abstract\" href=\"UTD.htm?24/18/24874/abstract/49\">",
"     49",
"    </a>",
"    ]. High peak inspiratory pressures may decrease venous return and may exacerbate hypotension, thereby requiring volume loading.",
"   </p>",
"   <p>",
"    Regular chest physical therapy with tracheal suctioning should be performed to keep secretions to a minimum. The use of high frequency oscillation applied to the chest wall has also been proposed [",
"    <a class=\"abstract\" href=\"UTD.htm?24/18/24874/abstract/55\">",
"     55",
"    </a>",
"    ]. Periodic reassessment of the lungs with chest radiograph is recommended and should be performed earlier if oxygenation is worsening. Brain death extinguishes all laryngeal protective reflexes and the patient is at risk for aspiration of material from the hypopharynx. As a result, many centers routinely use cuffed endotracheal tubes, inflated to high pressures (inflated until no air leak is observed, often &gt;25 cm H2O), to maximally protect the lungs. Because swallowing no longer occurs after brain death, regular suctioning of the hypopharynx for accumulation of debris is also recommended.",
"   </p>",
"   <p>",
"    In most centers, bronchoscopy is performed to evaluate the lungs. The goal of bronchoscopy is to assess the airways, identify anatomic variations, evaluate for airway trauma, and to locate, characterize, and remove secretions. Lower respiratory tract samples are collected in small aliquots (&lt;20 cc) via limited bronchoalveolar lavage, for immediate microbiological examination and culture. The amount of fluid used for lavage should be kept to a minimum because extensive lavage will lead to new infiltrates and transient worsening of oxygenation, which can confuse the clinical picture for the evaluating transplant team.",
"   </p>",
"   <p>",
"    Early bronchoscopy is a valuable addition to the initial assessment of the potential organ donor, may identify potential pathogens to guide antibiotic therapy, and provides therapeutic bronchial toilet [",
"    <a class=\"abstract\" href=\"UTD.htm?24/18/24874/abstract/34,56\">",
"     34,56",
"    </a>",
"    ]. Repeated bronchoscopies may be indicated in some individuals.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     FLUIDS AND ELECTROLYTES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adequate organ perfusion and oxygenation are essential to preserve organ function for transplantation. Fluid resuscitation may be necessary to restore intravascular volume and maintain atrial filling pressures, but should be balanced against the potential risks of pulmonary edema [",
"    <a class=\"abstract\" href=\"UTD.htm?24/18/24874/abstract/57\">",
"     57",
"    </a>",
"    ]. Excessive fluid resuscitation can lead to volume overload and pulmonary edema, with impaired gas exchange, hypoxemia and end organ ischemia.",
"   </p>",
"   <p>",
"    Judicious use of colloid boluses to sustain blood pressure and maintain keep the CVP around 8 to 10 mmHg is one of the first steps to maintain adequate urine output. Glucose containing fluids should never be used for resuscitation because these fluids may induce an osmotic diuresis, further complicating the fluid balance. After the potential donor has been resuscitated the serum sodium and glucose levels guide the choice of maintenance fluid. The \"hemodynamic profiling\" of a potential donor, with meticulous measurement of fluid input, output and vital signs, and invasive monitoring techniques including measurement of CVP and cardiac function will help in directing the therapy required to maintain a normal blood pressure [",
"    <a class=\"abstract\" href=\"UTD.htm?24/18/24874/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Diabetes insipidus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diabetes insipidus occurs in approximately 40 percent of pediatric organ donors following brain death (",
"    <a class=\"graphic graphic_table graphicRef82673 \" href=\"UTD.htm?0/14/235\">",
"     table 5",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Endocrine abnormalities'",
"    </a>",
"    above.) Lack of ADH results in massive amounts of dilute urine, which leads to intravascular fluid depletion in the donor if not corrected. The high urine output also produces biochemical and electrolyte abnormalities, including hypokalemia, hypomagnesemia, hypocalcemia and hypophosphatemia; these abnormalities should be treated aggressively to prevent arrhythmias.",
"   </p>",
"   <p>",
"    The management goal for DI is to achieve a euvolemic and normonatremic state. The first step of management is fluid replacement to restore a normal circulating volume to support blood pressure and tissue perfusion. In a hypotensive patient fluid resuscitation should be performed with isotonic or colloid solutions. Once euvolemia has been established, the fluid requirement consists of the usual maintenance needs plus replacement of urine output. The required solute content of the fluid depends on serum sodium and glucose levels. Hypernatremia is common in the setting of DI; therefore fluids for maintenance and replacement should be low in sodium. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/31/505?source=see_link\">",
"     \"Treatment of central diabetes insipidus\"",
"    </a>",
"    .) Excessive urine output associated with DI should be replaced with quarter-normal saline or half-normal saline, and pharmacologic therapy initiated to decrease urine output. Additionally, free water can be administered through an NG tube to provide more free water for the potential donor in an effort to correct the hypernatremia. Rapid changes in serum osmolarity are of no concern since neurologic death has occurred.",
"   </p>",
"   <p>",
"    Most donors have high glucose levels and little or no exogenous glucose is required. If glucose levels fall, replacement fluids should also contain dextrose to maintain hepatic glucose stores. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Hyperglycemia'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Replacement ADH analogues should be contemplated early if polyuria persists despite fluid therapy (eg, urine output greater than 5 to 7",
"    <span class=\"nowrap\">",
"     mL/kg/hour).",
"    </span>",
"    The two available analogues are the synthetic",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?14/45/15062?source=see_link\">",
"     desmopressin",
"    </a>",
"    (1-desamino-8-D-arginine",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/9/22678?source=see_link\">",
"     vasopressin",
"    </a>",
"    , DDAVP) or the naturally occurring arginine vasopressin (AVP). Both analogues have anti-diuretic activity, but only vasopressin has vasopressor action. Early reports of ADH analogue usage suggested poor renal graft outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?24/18/24874/abstract/59\">",
"     59",
"    </a>",
"    ]. However, a large randomized controlled trial showed no detrimental effect on early or late kidney graft function [",
"    <a class=\"abstract\" href=\"UTD.htm?24/18/24874/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Arginine",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/9/22678?source=see_link\">",
"     vasopressin",
"    </a>",
"    has the benefit of increasing blood pressure and decreasing the amount of additional vasopressor required [",
"    <a class=\"abstract\" href=\"UTD.htm?24/18/24874/abstract/17,57,61\">",
"     17,57,61",
"    </a>",
"    ]. In one study, arginine vasopressin helped to maintain cardiac output and improved serum osmolality. A separate small retrospective study showed that vasopressin exerted a pressor effect at time of organ recovery; children treated with vasopressin were more likely to tolerate weaning off of alpha-agonists than a control group [",
"    <a class=\"abstract\" href=\"UTD.htm?24/18/24874/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?14/45/15062?source=see_link\">",
"     Desmopressin",
"    </a>",
"    has a theoretical advantage over",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/9/22678?source=see_link\">",
"     vasopressin",
"    </a>",
"    because it is not a splanchnic vasoconstrictor and does not negatively affect hepatic, renal, and pancreatic blood flow. Nonetheless, clinical outcomes are similar for the two drugs [",
"    <a class=\"abstract\" href=\"UTD.htm?24/18/24874/abstract/62\">",
"     62",
"    </a>",
"    ]. A small number of children may be resistant to vasopressin; desmopressin should be used in these patients [",
"    <a class=\"abstract\" href=\"UTD.htm?24/18/24874/abstract/63\">",
"     63",
"    </a>",
"    ]. Desmopressin also may be useful in the donor with an ongoing coagulopathy because of platelet effects from this agent.",
"   </p>",
"   <p>",
"    Drug dosing for patients with diabetes insipidus is adjusted according to the clinical response. The dosing and duration of action of these two agents differ slightly:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?14/45/15062?source=see_link\">",
"       Desmopressin",
"      </a>",
"      (DDAVP) &ndash; DDAVP is preferably administered by continuous IV infusion starting at doses of 0.5",
"      <span class=\"nowrap\">",
"       mcg/hour.",
"      </span>",
"      This agent has a half-life of 75-120 minutes. Subcutaneous and intramuscular injections are avoided because of the possibility of diminished absorption from the tissues in this patient population.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/9/22678?source=see_link\">",
"       Vasopressin",
"      </a>",
"      &ndash; Vasopressin is administered by continuous IV infusion, in doses of 0.5 to 1",
"      <span class=\"nowrap\">",
"       milliunit/kg/hour",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?24/18/24874/abstract/35,64\">",
"       35,64",
"      </a>",
"      ]. This agent has a half-life of 10 to 35 minutes.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Hypernatremia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sodium levels may be elevated due to antemortem practices to reduce intracranial pressure: fluid restriction,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?42/60/43975?source=see_link\">",
"     mannitol",
"    </a>",
"    , hypertonic saline and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?5/26/5544?source=see_link\">",
"     furosemide",
"    </a>",
"    . The finding of hypernatremia also should prompt consideration of DI (see",
"    <a class=\"local\" href=\"#H18\">",
"     'Diabetes insipidus'",
"    </a>",
"    above). Sodium levels in excess of 160",
"    <span class=\"nowrap\">",
"     mmol/L",
"    </span>",
"    may contribute to cellular edema, dysfunction, apoptosis and necrosis. These factors are thought to contribute to primary graft failure and decreased graft function after orthotopic liver transplant [",
"    <a class=\"abstract\" href=\"UTD.htm?24/18/24874/abstract/65\">",
"     65",
"    </a>",
"    ]. Therefore, every effort should be made to restore serum sodium levels to a normal range. However, there are no controlled studies to prove whether hypernatremia should be a contraindication to donation. In practice, many liver transplant programs will not accept organs from donors with hypernatremia. Attention to serum sodium early in the course of donor management is therefore strongly recommended.",
"   </p>",
"   <p>",
"    To avoid hypernatremia, the fluid status should be evaluated and DI corrected if present. Isotonic solutions should be used until the patient has achieved a euvolemic state. DI is managed by replacing urine output with hypotonic fluids and by titrating pharmacologic agents to reduce but not stop urine output. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Diabetes insipidus'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Hyperglycemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Brain death frequently leads to hyperglycemia, most likely caused by catecholamine release during the \"autonomic storm\" decreased metabolic rate of the brain as death approaches or completion of neurologic death occurs, and the use of exogenous inotropes and steroids. Catecholamines cause glucose release and decreased tissue sensitivity to insulin, while pancreatic endocrine function is generally preserved after brain death [",
"    <a class=\"abstract\" href=\"UTD.htm?24/18/24874/abstract/66\">",
"     66",
"    </a>",
"    ]. The hyperglycemia may be exacerbated by dextrose administration in intravenous fluids.",
"   </p>",
"   <p>",
"    In some cases, hyperglycemia is associated with central diabetes insipidus, and low CO2 production. This association has been described as a pathognomonic sign for the onset of brain death, and is known as \"Turner's triad\". Hyperglycemia occurs most frequently and the full triad is not always present [",
"    <a class=\"abstract\" href=\"UTD.htm?24/18/24874/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hyperglycemia raises the serum osmolality and can cause osmotic diuresis. For most children the goal is to maintain blood glucose levels between 60 and 150",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (3.3 to 8.3",
"    <span class=\"nowrap\">",
"     mmol/L).",
"    </span>",
"    Higher glucose levels may be acceptable if the transplant surgeon intends to keep the islet cells active for pancreas transplantation. Excessive glucose levels can exacerbate fluid loss through an osmotic diuresis. If the levels remain persistently above 180",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (10",
"    <span class=\"nowrap\">",
"     mmol/L),",
"    </span>",
"    intravenous insulin should be commenced as a continuous infusion, at doses of 0.05 to 0.1",
"    <span class=\"nowrap\">",
"     units/kg,",
"    </span>",
"    and titrated to the desired glucose levels. Insulin also can be dosed on a sliding scale; however, it may be more difficult to achieve tight glucose control with a sliding scale. Glucose levels should be checked frequently to avoid hypoglycemia. It is important to monitor potassium levels, as insulin infusions can promote hypokalemia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     HORMONE MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aggressive management to improve cardiac function and improve oxygen delivery to the tissues of a previously unacceptable donor can result in increased recovery of organs [",
"    <a class=\"abstract\" href=\"UTD.htm?24/18/24874/abstract/39,67\">",
"     39,67",
"    </a>",
"    ]. Aggressive management of the donor is important because an estimated 25 percent of potential brain dead donors are lost due to cardiovascular collapse [",
"    <a class=\"abstract\" href=\"UTD.htm?24/18/24874/abstract/68\">",
"     68",
"    </a>",
"    ]. Hormonal resuscitation is provided to normalize circulating volume, electrolyte status and hematological parameters, and is recommended for donors who are failing to respond to conventional medical management. Because of preliminary data suggesting that aggressive medical treatment incorporating hormonal replacement therapy improves recovery of organs and leads to a higher incidence of organs transplanted in adults and children, many centers now use hormonal replacement therapy for all potential donors [",
"    <a class=\"abstract\" href=\"UTD.htm?24/18/24874/abstract/35\">",
"     35",
"    </a>",
"    ]. Until more definitive information is available, we suggest that hormonal replacement therapy be considered early in the course of donor management. There is increasing evidence that hormonal therapy with optimization of central venous pressure significantly increases heart and lungs for transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?24/18/24874/abstract/69,70\">",
"     69,70",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several hormonal changes commonly are seen after brain death, and provide the rationale for hormonal resuscitation. Studies of humans and animals show that ADH, triiodothyronine (T3), thyroxine (T4), cortisol and insulin are depleted after brain death [",
"    <a class=\"abstract\" href=\"UTD.htm?24/18/24874/abstract/21\">",
"     21",
"    </a>",
"    ]. Progressive lactic acidosis is often seen after brain death, and this likely contributes to cardiac instability. Intravenous",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?16/63/17401?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    improves oxygenation leading to a progressive increase in PaO2 and decrease in FiO2 requirements [",
"    <a class=\"abstract\" href=\"UTD.htm?24/18/24874/abstract/71\">",
"     71",
"    </a>",
"    ]. Steroids are believed to attenuate proinflammatory cytokines, decrease the upregulation of cytokines and prevent leukocyte migration into the new allograft.",
"   </p>",
"   <p>",
"    Infusions of a three-hormone regimen consisting of thyroxine, cortisol and insulin have been shown to restore aerobic metabolism, normothermia, organ stability, and cardiac function, replenish ATP, and diminish requirements for inotropes and bicarbonate [",
"    <a class=\"abstract\" href=\"UTD.htm?24/18/24874/abstract/21,72-74\">",
"     21,72-74",
"    </a>",
"    ]. In a large study in the United States, donor resuscitation with a combination of corticosteroids, thyroid hormones, and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/9/22678?source=see_link\">",
"     vasopressin",
"    </a>",
"    reduced the odds of early recipient death by 46 percent, and of graft dysfunction by 48 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?24/18/24874/abstract/75\">",
"     75",
"    </a>",
"    ]. There was an increase in 22.5 percent of total organs transplanted per donor when systematic combination hormonal replacement program used [",
"    <a class=\"abstract\" href=\"UTD.htm?24/18/24874/abstract/20,76,77\">",
"     20,76,77",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Based on these and other data, the United Network for Organ Sharing (UNOS) recommends hormonal replacement therapy for organ donors unresponsive to conventional resuscitation measures as manifested by poor cardiac output, inadequate organ perfusion pressures, and increasing lactic acidosis (",
"    <a class=\"graphic graphic_table graphicRef56534 \" href=\"UTD.htm?35/7/35964\">",
"     table 6",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/18/24874/abstract/43,78,79\">",
"     43,78,79",
"    </a>",
"    ]. This practice is also applicable to pediatric organ donors, and is supported by unpublished data from UNOS. A typical regimen for hormonal replacement therapy consists of:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?16/63/17401?source=see_link\">",
"       Methylprednisolone",
"      </a>",
"      &ndash; 20 to 30",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      bolus, repeated 8 to 12 hours later and repeatedly thereafter depending on the duration of donor management.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?30/47/31480?source=see_link\">",
"       Levothyroxine",
"      </a>",
"      (T4) &ndash; 0.8 to 1.4",
"      <span class=\"nowrap\">",
"       micrograms/kg/hour",
"      </span>",
"      IV. In the hemodynamically unstable child, treatment may be initiated with a bolus dose of 1 to 5",
"      <span class=\"nowrap\">",
"       micrograms/kg.",
"      </span>",
"      Infants and small children may require larger bolus and infusion doses [",
"      <a class=\"abstract\" href=\"UTD.htm?24/18/24874/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/9/22678?source=see_link\">",
"       Vasopressin",
"      </a>",
"      &ndash; 0.5 to 1",
"      <span class=\"nowrap\">",
"       milliunits/kg/hour,",
"      </span>",
"      titrated to decrease urine output to 3 to 4",
"      <span class=\"nowrap\">",
"       cc/kg/hour",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?24/18/24874/abstract/35,64,80\">",
"       35,64,80",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Hemodynamic monitoring'",
"      </a>",
"      above.)&nbsp;",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?14/45/15062?source=see_link\">",
"       Desmopressin",
"      </a>",
"      may be used as an alternative.",
"     </li>",
"     <li>",
"      Insulin &ndash; Infusion to maintain blood glucose 60 to 150",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (3.3 to 8.3",
"      <span class=\"nowrap\">",
"       mmol/L).",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Hyperglycemia'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Some centers prefer to use T3 instead of thyroxine (T4) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/18/24874/abstract/34\">",
"     34",
"    </a>",
"    ]. The dose of T3 for pediatric patients is 0.05 to 0.2",
"    <span class=\"nowrap\">",
"     mcg/kg/hour",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?24/18/24874/abstract/34\">",
"     34",
"    </a>",
"    ]. T4 is a prohormone and is converted to active T3, but this process may be inhibited by conversion of T4 to inactive rT3 during the catecholamine storm [",
"    <a class=\"abstract\" href=\"UTD.htm?24/18/24874/abstract/20\">",
"     20",
"    </a>",
"    ]. T3 is more potent and has a shorter half-life and onset of action, and therefore a more predictable action. However, T3 is seldom used in the US because of its expense.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     HYPOTHERMIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Brain death causes failure of thermoregulatory mechanisms. The patient often becomes poikilothermic and active measures to maintain normal body temperature are frequently required. Heat loss occurs via convection and radiation. The vasodilation that occurs after brain death results in further heat loss, exacerbating thermoregulatory instability. The administration of resuscitation fluids maintained at room temperature can easily lead to inadvertent hypothermia as well.",
"   </p>",
"   <p>",
"    Hypothermia causes a variety of problems that affect management and organ viability. Hypothermia is a direct myocardial depressant and will lead to bradycardia and hypotension. As body temperature drops, the kidney's ability to maintain tubular concentration gradients is lost, resulting in cold diuresis. Temperatures below 32&ordm;C adversely affect coagulation. The oxyhemoglobin curve is shifted to the left decreasing oxygen delivery to the tissues further exacerbating tissue acidosis and contributing to organ deterioration.",
"   </p>",
"   <p>",
"    All efforts should be made to keep the patient's temperature above 35&ordm;C [",
"    <a class=\"abstract\" href=\"UTD.htm?24/18/24874/abstract/54,81\">",
"     54,81",
"    </a>",
"    ]. If possible, all potential donors should be managed in private rooms within the intensive care unit, not only for privacy but also for more effective environmental temperature manipulation. The ambient temperature in the room should be increased. Passive heating methods such as the use of warmed blankets and space blankets (such as the Bear Hugger&reg;) are easy to use and valuable in reducing radiant heat loss. If these measures are inadequate, active rewarming may be needed. Warmed intravenous fluids and warmed gastric and bladder lavage may be effective. All ventilator gases should be humidified and heated to 38.5&ordm;C.",
"   </p>",
"   <p>",
"    In the unlikely event that the donor is febrile, all blankets should be removed, intravenous fluids should not be warmed and a cooling blanket should be used if needed. Antipyretics can be administered via nasogastric tube or by suppository every four to six hours.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     INFECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although severe overwhelming infection such as meningococcemia may rule out donation, the majority of patients with bacteremia are suitable candidates after adequate treatment with antibiotics. Organs transplanted from bacteremic donors do not transmit bacterial infection nor result in poorer outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?24/18/24874/abstract/82,83\">",
"     82,83",
"    </a>",
"    ]. There are reports of successful transplantation from donors with bacterial meningitis [",
"    <a class=\"abstract\" href=\"UTD.htm?24/18/24874/abstract/84,85\">",
"     84,85",
"    </a>",
"    ]. Transmissions of unusual infection of modest virulence to immunosuppressed recipients may lead to severe life-threatening or even fatal illness. The risk of transmission can be reduced by a careful medical and travel history from the donor's family. Transplant centers must have sophisticated molecular and antigen detection facilities to obtain early diagnosis in case of an unusual infection [",
"    <a class=\"abstract\" href=\"UTD.htm?24/18/24874/abstract/86-88\">",
"     86-88",
"    </a>",
"    ]. Exclusion criteria for a donor are determined by the transplant coordinator and the medical director of the organ procurement organization.",
"   </p>",
"   <p>",
"    Once the donor status is confirmed blood cultures should be carried out and repeated after 24 hours. A tracheal aspirate, urine sample, and blood should be cultured and any infection appropriately treated. Broad spectrum antibiotics should be commenced where infection is suspected or proven. The duration of treatment is typically determined by the transplant and infectious disease teams. Routine use of broad-spectrum antibiotics for prophylactic purposes in the potential donor is not universally accepted [",
"    <a class=\"abstract\" href=\"UTD.htm?24/18/24874/abstract/43\">",
"     43",
"    </a>",
"    ]. However, because of evidence that the lungs of organ donors are particularly susceptible to infection, pre-emptive antibiotic therapy is utilized by many centers in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?24/18/24874/abstract/89,90\">",
"     89,90",
"    </a>",
"    ]. The choice of antibiotic varies between centers. Consultation with the transplant coordinator, infectious disease specialists, and transplant surgeons is recommended for all potential donors.",
"   </p>",
"   <p>",
"    The use of prophylactic antibiotics",
"    <strong>",
"     after",
"    </strong>",
"    the transplantation procedure is recommended. This practice leads to significant reduction in the transmission of bacterial infections from bacteraemic patients [",
"    <a class=\"abstract\" href=\"UTD.htm?24/18/24874/abstract/91\">",
"     91",
"    </a>",
"    ]. Some studies suggest that broad-spectrum antibiotics may be beneficial as compared to narrower spectrum antibiotics such as first-generation cephalosporins [",
"    <a class=\"abstract\" href=\"UTD.htm?24/18/24874/abstract/60,90\">",
"     60,90",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     HEMATOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The catecholamine and cortisol surge that occurs immediately after brain death produces release of tissue thromboplastin and cerebral gangliosides, typically leading to a hypercoagulable state. In trauma patients with large transfusion requirements, the procoagulant factors may become diluted and contribute to the coagulopathy. DIC can be seen in the pediatric patient and requires aggressive treatment to preserve organ function. Hematological parameters should be monitored and maintained near the normal range. If a coagulopathy develops, clotting factors should be transfused as needed, platelet levels should be kept above 50,000",
"    <span class=\"nowrap\">",
"     /microliter",
"    </span>",
"    (50 x",
"    <span class=\"nowrap\">",
"     10(9)/L),",
"    </span>",
"    and anti-coagulant medications (if being administered) should be discontinued.",
"   </p>",
"   <p>",
"    Sites for potential ongoing loss of blood should be assessed regularly. The hemoglobin should be kept close to the normal range (eg, hemoglobin &gt;10",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    or hematocrit &gt;30 percent), to optimize oxygen carrying capacity and oxygen delivery to the tissues.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     SUPPORTIVE CARE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Coordination of care",
"    </span>",
"    &nbsp;&mdash;&nbsp;In many centers in the United States with a high volume of potential donors, coordinators from the organ procurement organization (OPO) are placed in the hospital. These coordinators are available to staff and families in all stages of end-of-life care and organ donation, even before the formal declaration of brain death [",
"    <a class=\"abstract\" href=\"UTD.htm?24/18/24874/abstract/92,93\">",
"     92,93",
"    </a>",
"    ]. Staff from the OPO are trained for the consent procedure, and are often matched to the donor family culture, language and religion to provide the most sensitive and effective interface for the grieving family. The bedside nurse and intensivist should be aware of and work in concert with these OPO personnel.",
"   </p>",
"   <p>",
"    Supportive care of the potential organ donor is a multidisciplinary endeavor, and requires inter-agency co-operation and management strategies. The pediatric intensive care specialist and critical care team is instrumental in the success and quality of organs recovered from donors. Care of the organ donor should be viewed as a continuum of care with ongoing support for the family during the most difficult time in their lives as they endure the loss of their child. Social workers, chaplains, child life specialists, and family support personnel from the OPO are important components of an effective support team.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Nursing",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of the intensive care nurse is vital in the successful management of a potential organ donor. Due to the intensive contact with the patient, the nurse in the Pediatric Intensive Care Unit (ICU) may be the first healthcare practitioner to identify a potential donor. Nurses in the ICU are a useful resource to access in discussions with the donor's family.",
"   </p>",
"   <p>",
"    Intensive nursing care is critical to maintain homeostasis and preserve organ viability. In addition to the management issues discussed above, routine care of the potential donor includes:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Repeated turning to prevent pressure sores",
"     </li>",
"     <li>",
"      Lubrication and protection of eyes",
"     </li>",
"     <li>",
"      Nasogastric tube insertion to provide drainage of secretions and to reduce or prevent aspiration",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Respiratory care is vital to maintain the integrity of the potential lung donor. Repeated percussion and pulmonary toilet to maintain lung volume is required. In some centers in the United States, high-frequency chest wall oscillation devices are used for continuous mucus clearance therapy.",
"   </p>",
"   <p>",
"    There is an element of urgency to procure organs as soon as brain death has occurred. However there may be delay due to logistic problems. A current review [",
"    <a class=\"abstract\" href=\"UTD.htm?24/18/24874/abstract/94\">",
"     94",
"    </a>",
"    ] observed that an increase in time interval between brain death and organ procurement was not associated with reduced organ procurement rates nor salvageable organ. There are family and cultural reasons for successful organ donation to be declined. Certain groups should be targeted to improve organ donation rates [",
"    <a class=\"abstract\" href=\"UTD.htm?24/18/24874/abstract/95\">",
"     95",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a patient in whom brain death is established and is a potential organ donor, the primary management goal is to maintain perfusion of potential donor organs (",
"    <a class=\"graphic graphic_table graphicRef64564 \" href=\"UTD.htm?1/36/1611\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Cardiovascular",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cardiovascular events following brain death frequently include a hyperdynamic phase followed by severe hypotension. Maintaining organ perfusion after brain death is critical to organ preservation.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We suggest continuous use of invasive central venous and arterial pressure monitors in all potential organ donors (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Fluid intake and output should be monitored and recorded. Children under the age 10 years are commonly managed without PA catheters. In older children, PA catheters may be used at the discretion of the clinicians. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Hemodynamic monitoring'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hypotension is almost universal after brain death, and is typically managed with a combination of judicious fluid administration to restore circulating volume, and inotropic drugs. Appropriate management goals are to maintain the central venous pressure (CVP) at 8 to 10 mmHg, and to maintain urine output of &gt;1",
"      <span class=\"nowrap\">",
"       mL/kg/hour",
"      </span>",
"      for the older child, and 2",
"      <span class=\"nowrap\">",
"       cc/kg/hour",
"      </span>",
"      for the younger child. Diabetes insipidus commonly contributes to hypovolemia and should be treated. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Fluids and electrolytes'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H18\">",
"       'Diabetes insipidus'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Management of hypotension includes judicious use of colloid boluses to restore normal circulating volume, if hypovolemia is clinically suspected. Glucose-containing fluids should not be used for volume expansion because these may promote osmotic diuresis. Excessive fluid administration can increase the risk of pulmonary edema. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Fluids and electrolytes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If judicious fluid boluses do not achieve these goals,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?12/54/13157?source=see_link\">",
"       dopamine",
"      </a>",
"      should be administered for inotropic support (",
"      <a class=\"graphic graphic_table graphicRef76583 \" href=\"UTD.htm?26/22/26988\">",
"       table 4",
"      </a>",
"      ). We suggest NOT administering dopamine at rates greater than 10",
"      <span class=\"nowrap\">",
"       micrograms/kg/minute",
"      </span>",
"      (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Dopamine'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Vasopressors with primarily alpha agonist effects (epinephrine,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?1/25/1429?source=see_link\">",
"       norepinephrine",
"      </a>",
"      or",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/46/41696?source=see_link\">",
"       phenylephrine",
"      </a>",
"      ) may be added for vasoconstriction and additional pressure support (",
"      <a class=\"graphic graphic_table graphicRef76583 \" href=\"UTD.htm?26/22/26988\">",
"       table 4",
"      </a>",
"      ).",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/9/22678?source=see_link\">",
"       Vasopressin",
"      </a>",
"      is often used to treat concomitant diabetes insipidus, and has the added benefit of increasing systemic vascular resistance. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Vasopressors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Arrhythmias are common and may be caused by electrolyte disturbances, inotropes, hypovolemia, hypothermia, hypoxia, acid base disturbances, and myocardial ischemia or damage. Bradyarrhythmias should be treated only if they are associated with hypotension. Bradyarrhythmias will not respond to",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?25/13/25816?source=see_link\">",
"       atropine",
"      </a>",
"      in patients who have progressed to brain death. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Arrhythmias'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Electrolytes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients frequently develop hypernatremia following brain death. This may be caused by diabetes insipidus",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    sodium administration during resuscitation, and from therapies rendered prior to brain death.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Diabetes insipidus is characterized by dilute urine production and intravascular volume depletion (",
"      <a class=\"graphic graphic_table graphicRef82673 \" href=\"UTD.htm?0/14/235\">",
"       table 5",
"      </a>",
"      ). Treatment includes administration of hypotonic fluid for urine output replacement and maintenance fluid administration to prevent intravascular volume depletion, in conjunction with pharmacologic agents to decrease, but not completely stop urine output. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Diabetes insipidus'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/31/505?source=see_link\">",
"       \"Treatment of central diabetes insipidus\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hyperglycemia may be caused by catecholamine release",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      exogenous inotropes, steroids, or decreased or absent cerebral metabolic rate, and can contribute to osmotic diuresis. Blood glucose concentrations should be monitored and maintained between 60 and 150",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      by minimizing the use of exogenous glucose. If blood glucose levels are consistently greater than 180",
"      <span class=\"nowrap\">",
"       mg/dL,",
"      </span>",
"      we suggest treatment with insulin. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Hyperglycemia'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Ventilation",
"    </span>",
"    &nbsp;&mdash;&nbsp;All potential organ donors will require mechanical ventilation to maintain appropriate ventilation and oxygenation. We prefer to use a cuffed endotracheal tube to minimize the risk of aspiration in children regardless of age. Ventilator settings should be tailored to maintain adequate oxygenation, normalize ventilation, and prevent atelectasis. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Respiratory'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Hormonal replacement therapy",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hormonal replacement therapy with a combination of corticosteroids, thyroid hormones, and",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/9/22678?source=see_link\">",
"       vasopressin",
"      </a>",
"      appears to increase rates of successful organ recovery from adult organ donors that are unresponsive to or failing conventional resuscitation measures, as manifested by poor cardiac output, inadequate organ perfusion pressures, and increasing lactic acidosis. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Hormone management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hormonal resuscitation therapy should be considered early in the course of managing the potential pediatric organ donor. When such patients are unresponsive to or failing conventional resuscitation measures, we suggest treatment with a combination of",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?16/63/17401?source=see_link\">",
"       methylprednisolone",
"      </a>",
"      ,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?30/47/31480?source=see_link\">",
"       levothyroxine",
"      </a>",
"      or T3, and",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/9/22678?source=see_link\">",
"       vasopressin",
"      </a>",
"      &nbsp;(",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      )&nbsp;(",
"      <a class=\"graphic graphic_table graphicRef56534 \" href=\"UTD.htm?35/7/35964\">",
"       table 6",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Hormone management'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Antibiotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evidence of infection should be rigorously sought and treated in the potential organ donor.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Routine use of broad-spectrum antibiotics for prophylactic purposes in the organ donor is not universally accepted. Antibiotics are commonly used in many centers in the United States for this select population following declaration of neurologic death because of the increased incidence of lower respiratory tract infection or colonization. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Infection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend using prophylactic antibiotics after the transplant procedure (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). Consultation with the transplant surgeons and infectious disease specialists will assist in determining the specific needs for antibiotics. This practice reduces the transmission of bacterial infections from bacteremic patients. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Infection'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Hypothermia prevention",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thermoregulatory mechanisms fail during the progression and upon completion of brain death. Hypothermia can promote arrhythmias, cold diuresis, decreased organ perfusion, and exacerbate an ongoing coagulopathy.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The temperature of the potential organ donor should be monitored and maintained in a normal range through passive measures (blankets, ambient heat, and warmed ventilator gasses) and active measures (warmed intravenous fluids, gastric",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      bladder lavage). (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Hypothermia'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/18/24874/abstract/1\">",
"      Shivalkar B, Van Loon J, Wieland W, et al. Variable effects of explosive or gradual increase of intracranial pressure on myocardial structure and function. Circulation 1993; 87:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/18/24874/abstract/2\">",
"      Novitzky D, Wicomb WN, Cooper DKC, et al. Electrocardiographic, hemodynamic and endocrine changes occurring during experimental brain death in the Chacma baboon. J Heart Transplant 1984; 4:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/18/24874/abstract/3\">",
"      Novitzky D. Haemodynamic change, myocardial injury and pulmonary oedema induced by sympathetic activity during the development of brain death in the baboon. Transplant Proc 1986; 18:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/18/24874/abstract/4\">",
"      Cooper DK, Novitzky D, Wicomb WN. The pathophysiological effects of brain death on potential donor organs, with particular reference to the heart. Ann R Coll Surg Engl 1989; 71:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/18/24874/abstract/5\">",
"      Chen EP, Bittner HB, Kendall SW, Van Trigt P. Hormonal and hemodynamic changes in a validated animal model of brain death. Crit Care Med 1996; 24:1352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/18/24874/abstract/6\">",
"      Pilati CF, Bosso FJ, Maron MB. Factors involved in left ventricular dysfunction after massive sympathetic activation. Am J Physiol 1992; 263:H784.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/18/24874/abstract/7\">",
"      White M, Wiechmann RJ, Roden RL, et al. Cardiac beta-adrenergic neuroeffector systems in acute myocardial dysfunction related to brain injury. Evidence for catecholamine-mediated myocardial damage. Circulation 1995; 92:2183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/18/24874/abstract/8\">",
"      Owen VJ, Burton PB, Michel MC, et al. Myocardial dysfunction in donor hearts. A possible etiology. Circulation 1999; 99:2565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/18/24874/abstract/9\">",
"      Novitzky D, Wicomb WN, Rose AG, et al. Pathophysiology of pulmonary edema following experimental brain death in the chacma baboon. Ann Thorac Surg 1987; 43:288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/18/24874/abstract/10\">",
"      Chen HI, Su CF, Chai CY. [Neural and hemodynamic mechanisms of neurogenic pulmonary edema]. Sheng Li Ke Xue Jin Zhan 1999; 30:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/18/24874/abstract/11\">",
"      Finfer S, Bohn D, Colpitts D, et al. Intensive care management of paediatric organ donors and its effect on post-transplant organ function. Intensive Care Med 1996; 22:1424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/18/24874/abstract/12\">",
"      Soifer B, Gelb AW. The multiple organ donor: identification and management. Ann Intern Med 1989; 110:814.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/18/24874/abstract/13\">",
"      Staworn D, Lewison L, Marks J, et al. Brain death in pediatric intensive care unit patients: incidence, primary diagnosis, and the clinical occurrence of Turner's triad. Crit Care Med 1994; 22:1301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/18/24874/abstract/14\">",
"      Fiser DH, Jimenez JF, Wrape V, Woody R. Diabetes insipidus in children with brain death. Crit Care Med 1987; 15:551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/18/24874/abstract/15\">",
"      Yoshioka T, Sugimoto H, Uenishi M, et al. Prolonged hemodynamic maintenance by the combined administration of vasopressin and epinephrine in brain death: a clinical study. Neurosurgery 1986; 18:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/18/24874/abstract/16\">",
"      Kinoshita Y, Yahata K, Yoshioka T, et al. Long-term renal preservation after brain death maintained with vasopressin and epinephrine. Transpl Int 1990; 3:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/18/24874/abstract/17\">",
"      Zuppa AF, Nadkarni V, Davis L, et al. The effect of a thyroid hormone infusion on vasopressor support in critically ill children with cessation of neurologic function. Crit Care Med 2004; 32:2318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/18/24874/abstract/18\">",
"      Cooper DK, Basker M. Physiologic changes following brain death. Transplant Proc 1999; 31:1001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/18/24874/abstract/19\">",
"      Masson F, Thico&iuml;pe M, Latapie MJ, Maurette P. Thyroid function in brain-dead donors. Transpl Int 1990; 3:226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/18/24874/abstract/20\">",
"      Rosendale JD, Kauffman HM, McBride MA, et al. Aggressive pharmacologic donor management results in more transplanted organs. Transplantation 2003; 75:482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/18/24874/abstract/21\">",
"      Novitzky D, Cooper DK, Morrell D, Isaacs S. Change from aerobic to anaerobic metabolism after brain death, and reversal following triiodothyronine therapy. Transplantation 1988; 45:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/18/24874/abstract/22\">",
"      Birks EJ, Burton PB, Owen VJ, et al. Molecular and cellular mechanisms of donor heart dysfunction. Transplant Proc 2001; 33:2749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/18/24874/abstract/23\">",
"      Takada M, Nadeau KC, Hancock WW, et al. Effects of explosive brain death on cytokine activation of peripheral organs in the rat. Transplantation 1998; 65:1533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/18/24874/abstract/24\">",
"      Ropper AH. Unusual spontaneous movements in brain-dead patients. Neurology 1984; 34:1089.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/18/24874/abstract/25\">",
"      Saposnik G, Bueri JA, Mauri&ntilde;o J, et al. Spontaneous and reflex movements in brain death. Neurology 2000; 54:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/18/24874/abstract/26\">",
"      Novitzky D, Wicomb WN, Cooper DK, et al. Prevention of myocardial injury during brain death by total cardiac sympathectomy in the Chacma baboon. Ann Thorac Surg 1986; 41:520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/18/24874/abstract/27\">",
"      Goldberg LI. Dopamine--clinical uses of an endogenous catecholamine. N Engl J Med 1974; 291:707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/18/24874/abstract/28\">",
"      Schaub M, Ploetz CJ, Gerbaulet D, et al. Effect of dopamine on inflammatory status in kidneys of brain-dead rats. Transplantation 2004; 77:1333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/18/24874/abstract/29\">",
"      Liu Z, Hoeger S, Schnuelle P, et al. Donor dopamine pretreatment inhibits tubulitis in renal allografts subjected to prolonged cold preservation. Transplantation 2007; 83:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/18/24874/abstract/30\">",
"      Marshall R, Ahsan N, Dhillon S, et al. Adverse effect of donor vasopressor support on immediate and one-year kidney allograft function. Surgery 1996; 120:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/18/24874/abstract/31\">",
"      Schnuelle P, Lorenz D, Mueller A, et al. Donor catecholamine use reduces acute allograft rejection and improves graft survival after cadaveric renal transplantation. Kidney Int 1999; 56:738.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/18/24874/abstract/32\">",
"      Schnuelle P, Berger S, de Boer J, et al. Effects of catecholamine application to brain-dead donors on graft survival in solid organ transplantation. Transplantation 2001; 72:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/18/24874/abstract/33\">",
"      Wahlers T, Cremer J, Fieguth HG, et al. Donor heart-related variables and early mortality after heart transplantation. J Heart Lung Transplant 1991; 10:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/18/24874/abstract/34\">",
"      Zaroff JG, Rosengard BR, Armstrong WF, et al. Consensus conference report: maximizing use of organs recovered from the cadaver donor: cardiac recommendations, March 28-29, 2001, Crystal City, Va. Circulation 2002; 106:836.",
"     </a>",
"    </li>",
"    <li>",
"     Nakagawa TA. Updated pediatric donor management and dosing guidelines. NATCO, The Organization for Transplant Professionals, 2008. Available at: www.natco1.org/prof_development/index.htm#guidelines (Accessed on September 16, 2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/18/24874/abstract/36\">",
"      Ware LB, Fang X, Wang Y, et al. Selected contribution: mechanisms that may stimulate the resolution of alveolar edema in the transplanted human lung. J Appl Physiol 2002; 93:1869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/18/24874/abstract/37\">",
"      Chamorro C, Silva JA, Romera MA. Cardiac donor management: another point of view. Transplant Proc 2003; 35:1935.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/18/24874/abstract/38\">",
"      Silva JA, Chamorro C, Romera MA. High doses of catecholamines in heart donor is not associated with early graft failure in recipient. Intensive Care Med 2002; 28:S66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/18/24874/abstract/39\">",
"      Wheeldon DR, Potter CD, Oduro A, et al. Transforming the \"unacceptable\" donor: outcomes from the adoption of a standardized donor management technique. J Heart Lung Transplant 1995; 14:734.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/18/24874/abstract/40\">",
"      Hunt SA, Baldwin J, Baumgartner W, et al. Cardiovascular management of a potential heart donor: a statement from the Transplantation Committee of the American College of Cardiology. Crit Care Med 1996; 24:1599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/18/24874/abstract/41\">",
"      Lutz-Dettinger N, de Jaeger A, Kerremans I. Care of the potential pediatric organ donor. Pediatr Clin North Am 2001; 48:715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/18/24874/abstract/42\">",
"      Powner DJ, Darby JM. Management of variations in blood pressure during care of organ donors. Prog Transplant 2000; 10:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/18/24874/abstract/43\">",
"      Shemie SD, Ross H, Pagliarello J, et al. Organ donor management in Canada: recommendations of the forum on Medical Management to Optimize Donor Organ Potential. CMAJ 2006; 174:S13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/18/24874/abstract/44\">",
"      Gramm HJ, Zimmermann J, Meinhold H, et al. Hemodynamic responses to noxious stimuli in brain-dead organ donors. Intensive Care Med 1992; 18:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/18/24874/abstract/45\">",
"      Spittler JF, Wortmann D, von D&uuml;ring M, Gehlen W. Phenomenological diversity of spinal reflexes in brain death. Eur J Neurol 2000; 7:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/18/24874/abstract/46\">",
"      Powner DJ, Allison TA. Cardiac dysrhythmias during donor care. Prog Transplant 2006; 16:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/18/24874/abstract/47\">",
"      Brembilla-Perrot B, Muhanna I, Nippert M, et al. Paradoxical effect of isoprenaline infusion. Europace 2005; 7:621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/18/24874/abstract/48\">",
"      Powner DJ, Delgado E. Using pressure-limited mechanical ventilation in caring for organ donors. Prog Transplant 2001; 11:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/18/24874/abstract/49\">",
"      Powner DJ, Darby JM, Kellum JA. Proposed treatment guidelines for donor care. Prog Transplant 2004; 14:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/18/24874/abstract/50\">",
"      Recicar J, Niles P. Improving oxygenation when conventional ventilation fails: a case study. Prog Transplant 2002; 12:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/18/24874/abstract/51\">",
"      Barber K, Falvey S, Hamilton C, et al. Potential for organ donation in the United Kingdom: audit of intensive care records. BMJ 2006; 332:1124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/18/24874/abstract/52\">",
"      Venkateswaran RV, Patchell VB, Wilson IC, et al. Early donor management increases the retrieval rate of lungs for transplantation. Ann Thorac Surg 2008; 85:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/18/24874/abstract/53\">",
"      Angel LF, Levine DJ, Restrepo MI, et al. Impact of a lung transplantation donor-management protocol on lung donation and recipient outcomes. Am J Respir Crit Care Med 2006; 174:710.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/18/24874/abstract/54\">",
"      Scheinkestel CD, Tuxen DV, Cooper DJ, Butt W. Medical management of the (potential) organ donor. Anaesth Intensive Care 1995; 23:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/18/24874/abstract/55\">",
"      Babcock WD, Menza RL, Riznyk S, et al. Results of a prospective study using high-frequency chest wall oscillation for organ donors. J Heart Lung Transplant 2002; 21:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/18/24874/abstract/56\">",
"      Kutsogiannis DJ, Pagliarello G, Doig C, et al. Medical management to optimize donor organ potential: review of the literature. Can J Anaesth 2006; 53:820.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/18/24874/abstract/57\">",
"      Pennefather SH, Bullock RE, Dark JH. The effect of fluid therapy on alveolar arterial oxygen gradient in brain-dead organ donors. Transplantation 1993; 56:1418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/18/24874/abstract/58\">",
"      Powner DJ, Crommett JW. Advanced assessment of hemodynamic parameters during donor care. Prog Transplant 2003; 13:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/18/24874/abstract/59\">",
"      Schneider A, Toledo-Pereyra LH, Zeichner WD, et al. Effect of dopamine and pitressin on kidneys procured and harvested for transplantation. Transplantation 1983; 36:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/18/24874/abstract/60\">",
"      Guesde R, Barrou B, Leblanc I, et al. Administration of desmopressin in brain-dead donors and renal function in kidney recipients. Lancet 1998; 352:1178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/18/24874/abstract/61\">",
"      Katz K, Lawler J, Wax J, et al. Vasopressin pressor effects in critically ill children during evaluation for brain death and organ recovery. Resuscitation 2000; 47:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/18/24874/abstract/62\">",
"      Debelak L, Pollak R, Reckard C. Arginine vasopressin versus desmopressin for the treatment of diabetes insipidus in the brain dead organ donor. Transplant Proc 1990; 22:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/18/24874/abstract/63\">",
"      Holmquist M, Chabalewski F, Blount T, et al. A critical pathway: guiding care for organ donors. Crit Care Nurse 1999; 19:84.",
"     </a>",
"    </li>",
"    <li>",
"     Nakagawa TA, Mou SS, American Transplant Coordinators Organization (NATCO). Management of the pediatric organ donor. In: The Clinician's Guide to Donation and Transplantation, Applied Measurement Professionals Inc, Lenexa, KS 2006.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/18/24874/abstract/65\">",
"      Totsuka E, Dodson F, Urakami A, et al. Influence of high donor serum sodium levels on early postoperative graft function in human liver transplantation: effect of correction of donor hypernatremia. Liver Transpl Surg 1999; 5:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/18/24874/abstract/66\">",
"      Masson F, Thicoipe M, Gin H, et al. The endocrine pancreas in brain-dead donors. A prospective study in 25 patients. Transplantation 1993; 56:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/18/24874/abstract/67\">",
"      Van Bakel AB. The cardiac transplant donor: identification, assessment, and management. Am J Med Sci 1997; 314:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/18/24874/abstract/68\">",
"      Phongsamran PV. Critical care pharmacy in donor management. Prog Transplant 2004; 14:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/18/24874/abstract/69\">",
"      Abdelnour T, Rieke S. Relationship of hormonal resuscitation therapy and central venous pressure on increasing organs for transplant. J Heart Lung Transplant 2009; 28:480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/18/24874/abstract/70\">",
"      Nath DS, Ilias Basha H, Liu MH, et al. Increased recovery of thoracic organs after hormonal resuscitation therapy. J Heart Lung Transplant 2010; 29:594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/18/24874/abstract/71\">",
"      Follette DM, Rudich SM, Babcock WD. Improved oxygenation and increased lung donor recovery with high-dose steroid administration after brain death. J Heart Lung Transplant 1998; 17:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/18/24874/abstract/72\">",
"      Novitzky D, Cooper DK, Reichart B. Hemodynamic and metabolic responses to hormonal therapy in brain-dead potential organ donors. Transplantation 1987; 43:852.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/18/24874/abstract/73\">",
"      Jeevanandam V, Todd B, Regillo T, et al. Reversal of donor myocardial dysfunction by triiodothyronine replacement therapy. J Heart Lung Transplant 1994; 13:681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/18/24874/abstract/74\">",
"      Salim A, Vassiliu P, Velmahos GC, et al. The role of thyroid hormone administration in potential organ donors. Arch Surg 2001; 136:1377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/18/24874/abstract/75\">",
"      Rosendale JD, Kauffman HM, McBride MA, et al. Hormonal resuscitation yields more transplanted hearts, with improved early function. Transplantation 2003; 75:1336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/18/24874/abstract/76\">",
"      Rosendale JD, Chabalewski FL, McBride MA, et al. Increased transplanted organs from the use of a standardized donor management protocol. Am J Transplant 2002; 2:761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/18/24874/abstract/77\">",
"      Ranasinghe AM, Bonser RS. Endocrine changes in brain death and transplantation. Best Pract Res Clin Endocrinol Metab 2011; 25:799.",
"     </a>",
"    </li>",
"    <li>",
"     United Network for Organ Sharing. Available at: www.unos.org (Accessed on September 14, 2007).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/18/24874/abstract/79\">",
"      Wood KE, Becker BN, McCartney JG, et al. Care of the potential organ donor. N Engl J Med 2004; 351:2730.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/18/24874/abstract/80\">",
"      Lugo N, Silver P, Nimkoff L, et al. Diagnosis and management algorithm of acute onset of central diabetes insipidus in critically ill children. J Pediatr Endocrinol Metab 1997; 10:633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/18/24874/abstract/81\">",
"      Robertson KM, Cook DR. Perioperative management of the multiorgan donor. Anesth Analg 1990; 70:546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/18/24874/abstract/82\">",
"      Freeman RB, Giatras I, Falagas ME, et al. Outcome of transplantation of organs procured from bacteremic donors. Transplantation 1999; 68:1107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/18/24874/abstract/83\">",
"      Gonz&aacute;lez-Segura C, Pascual M, Garc&iacute;a Huete L, et al. Donors with positive blood culture: could they transmit infections to the recipients? Transplant Proc 2005; 37:3664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/18/24874/abstract/84\">",
"      Mirza D, Hastings M, Reyes J, et al. Organ donation from children with meningitis. Pediatr Infect Dis J 2003; 22:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/18/24874/abstract/85\">",
"      Satoi S, Bramhall SR, Solomon M, et al. The use of liver grafts from donors with bacterial meningitis. Transplantation 2001; 72:1108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/18/24874/abstract/86\">",
"      Sweet SC. Update on pediatric lung allocation in the United States. Pediatr Transplant 2009; 13:808.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/18/24874/abstract/87\">",
"      Humar A, Fishman JA. Donor-derived infection: old problem, new solutions? Am J Transplant 2008; 8:1087.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/18/24874/abstract/88\">",
"      Kotton CN. Update on infectious diseases in pediatric solid organ transplantation. Curr Opin Organ Transplant 2008; 13:500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/18/24874/abstract/89\">",
"      Bonde PN, Patel ND, Borja MC, et al. Impact of donor lung organisms on post-lung transplant pneumonia. J Heart Lung Transplant 2006; 25:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/18/24874/abstract/90\">",
"      Avlonitis VS, Krause A, Luzzi L, et al. Bacterial colonization of the donor lower airways is a predictor of poor outcome in lung transplantation. Eur J Cardiothorac Surg 2003; 24:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/18/24874/abstract/91\">",
"      Lumbreras C, Sanz F, Gonz&aacute;lez A, et al. Clinical significance of donor-unrecognized bacteremia in the outcome of solid-organ transplant recipients. Clin Infect Dis 2001; 33:722.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/18/24874/abstract/92\">",
"      Shafer TJ, Davis KD, Holtzman SM, et al. Location of in-house organ procurement organization staff in level I trauma centers increases conversion of potential donors to actual donors. Transplantation 2003; 75:1330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/18/24874/abstract/93\">",
"      Salim A, Brown C, Inaba K, et al. Improving consent rates for organ donation: the effect of an inhouse coordinator program. J Trauma 2007; 62:1411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/18/24874/abstract/94\">",
"      Inaba K, Branco BC, Lam L, et al. Organ donation and time to procurement: late is not too late. J Trauma 2010; 68:1362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/18/24874/abstract/95\">",
"      Brown CV, Foulkrod KH, Dworaczyk S, et al. Barriers to obtaining family consent for potential organ donors. J Trauma 2010; 68:447.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1664 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-14.112.150.18-37D25D05A2-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_18_24874=[""].join("\n");
var outline_f24_18_24874=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H28\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOPHYSIOLOGIC CONSEQUENCES OF BRAIN DEATH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Autonomic storm",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Cardiovascular",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Pulmonary",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Endocrine abnormalities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Hematological",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Inflammatory changes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Mobility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      HEMODYNAMIC MONITORING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      INOTROPES AND VASOPRESSORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Dopamine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Vasopressors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Beta-agonists",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      ARRHYTHMIAS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      RESPIRATORY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      FLUIDS AND ELECTROLYTES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Diabetes insipidus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Hypernatremia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Hyperglycemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      HORMONE MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      HYPOTHERMIA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      INFECTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      HEMATOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      SUPPORTIVE CARE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Coordination of care",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Nursing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Cardiovascular",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Electrolytes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Ventilation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Hormonal replacement therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Antibiotics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Hypothermia prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/1664\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/1664|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?2/26/2479\" title=\"figure 1\">",
"      Hemoglobin oxygen dissociation curve",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/1664|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?1/36/1611\" title=\"table 1\">",
"      Management organ donor",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?18/1/18459\" title=\"table 2\">",
"      Possible causes of hypotension in a potential organ donor",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/41/17051\" title=\"table 3\">",
"      Abnormal vital signs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?26/22/26988\" title=\"table 4\">",
"      Inotropic drugs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?0/14/235\" title=\"table 5\">",
"      Criteria DI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?35/7/35964\" title=\"table 6\">",
"      Hormonal resuscitation",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/1/7193?source=related_link\">",
"      Assessment of the pediatric patient for potential organ donation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/2/30761?source=related_link\">",
"      Diagnosis of brain death",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/37/44633?source=related_link\">",
"      Elevated intracranial pressure in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/56/19337?source=related_link\">",
"      Hypoxic-ischemic brain injury: Evaluation and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/48/43784?source=related_link\">",
"      Modes of mechanical ventilation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/31/505?source=related_link\">",
"      Treatment of central diabetes insipidus",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_18_24875="Host factors Salmonella";
var content_f24_18_24875=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F51300&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F51300&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Host factors that predispose to severe Salmonella infection",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Impaired cell-mediated immunity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        AIDS",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Use of corticosteroids or other immunomodulatory agents",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Malignancy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Impaired phagocytic function",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hemoglobinopathies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chronic granulomatous disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Malaria",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Histoplasmosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Schistosomiasis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Extremes of age",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Neonates",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Elderly",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Decreased gastric acidity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Antacids or suppression of acid secretion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Achlorhydria",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Altered intestinal function",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Inflammatory bowel disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Prior antibiotic therapy",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_18_24875=[""].join("\n");
var outline_f24_18_24875=null;
var title_f24_18_24876="Testing in rapidly progressive dementia";
var content_f24_18_24876=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F55420&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F55420&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Rapidly progressive dementia: Potential diagnostic testing",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        In all patients:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Brain MRI, including FLAIR and DWI, with and without gadolinium enhancement",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Serum electrolytes, liver, renal, and thyroid function tests",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vitamin B12, homocysteine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Urinalysis, culture",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        In most patients:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lumbar puncture, cell count and differential, protein, glucose, syphilis serology",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        EEG",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        In selected patients (based on abnormalities in above tests or suggestive clinical features):",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        CSF",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Cryptococcal antigen",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Bacterial fungal AFB stains and cultures",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Cytology",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Viral PCRs and cultures",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Lyme serology",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        14-3-3 protein",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Blood",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Rheumatological screen (ESR, ANA, CRP)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Antithyroglobulin, anti-thyroperoxidase antibodies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        HIV",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Lyme",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Paraneoplastic antibodies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Copper, ceruloplasmin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Whipples PCR",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Urine copper, heavy metal screen",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Further imaging (angiography, PET, SPECT)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Brain biopsy",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     MRI: magnetic resonance imaging; FLAIR: fluid-attenuated inversion recovery; DWI: diffusion weighted imaging; PET: positron emission tomography; SPECT: single photon emission computed tomography; ESR: erythrocyte sedimentation rate; ANA: antinuclear antibodies; CRP: C-reactive protein.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_18_24876=[""].join("\n");
var outline_f24_18_24876=null;
var title_f24_18_24877="Isolation precautions system";
var content_f24_18_24877=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F50001&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F50001&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    System of isolation precautions for infection control",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Type of precaution",
"       </td>",
"       <td class=\"subtitle1\">",
"        Selected patients",
"       </td>",
"       <td class=\"subtitle1\">",
"        Major specifications",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Standard",
"       </td>",
"       <td>",
"        All patients",
"       </td>",
"       <td>",
"        <p>",
"         Handwashing before and after every patient contact*",
"        </p>",
"        <p>",
"         Gloves, gowns, eye protection as required",
"        </p>",
"        <p>",
"         Safe disposal or cleaning of instruments and linen",
"        </p>",
"        <p>",
"         Cough etiquette: Patients and visitors should cover their nose or mouth when coughing, promptly dispose used tissues and practice hand hygiene after contact with respiratory secretions",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Contact",
"       </td>",
"       <td>",
"        <p>",
"         Colonization of any bodily site with multidrug-resistant bacteria (MRSA, VRE)",
"        </p>",
"        <p>",
"         Enteric infections (",
"         <em>",
"          C. difficile",
"         </em>",
"         ,",
"         <em>",
"          E. coli",
"         </em>",
"         O157:H7, viral infections (RSV, HSV, enterovirus, parainfluenza))",
"        </p>",
"        <p>",
"         Scabies",
"        </p>",
"        <p>",
"         Impetigo",
"        </p>",
"        <p>",
"         Noncontained abcesses or decubitus ulcers (especially for",
"         <em>",
"          Staphylococcus aureus",
"         </em>",
"         and group A streptococcus)",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         <strong>",
"          In addition to standard precautions:",
"         </strong>",
"        </p>",
"        <p>",
"         Wash hands with soap and water before and after leaving the patient's room",
"        </p>",
"        <p>",
"         Private room preferred; cohorting allowed if necessary",
"        </p>",
"        <p>",
"         Gloves required upon entering room. Change gloves after contact with contaminated secretions.",
"        </p>",
"        <p>",
"         Gown required if clothing may come into contact with the patient or environmental surfaces, or if the patient has diarrhea",
"        </p>",
"        <p>",
"         Minimize risk of environmental contamination during patient transport (eg, patient can be placed in a gown)",
"        </p>",
"        <p>",
"         Noncritical items should be dedicated to use for a single patient if possible",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Droplet",
"       </td>",
"       <td>",
"        <p>",
"         <strong>",
"          Known or suspected:",
"         </strong>",
"        </p>",
"        <p>",
"         <em>",
"          Neisseria meningitidis",
"         </em>",
"        </p>",
"        <p>",
"         <em>",
"          Haemophilus influenzae",
"         </em>",
"         type B",
"        </p>",
"        <p>",
"         <em>",
"          Mycoplasma pneumoniae",
"         </em>",
"        </p>",
"        <p>",
"         <em>",
"          Bordetella pertussis",
"         </em>",
"        </p>",
"        <p>",
"         Diphtheria",
"        </p>",
"        <p>",
"         Pneumonic plague",
"        </p>",
"        <p>",
"         Influenza",
"        </p>",
"        <p>",
"         Rubella",
"        </p>",
"        <p>",
"         Mumps",
"        </p>",
"        <p>",
"         Adenovirus",
"        </p>",
"        <p>",
"         Parvovirus B19",
"        </p>",
"        <p>",
"         RSV",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         <strong>",
"          In addition to standard precautions:",
"         </strong>",
"        </p>",
"        <p>",
"         Private room preferred; cohorting allowed if necessary",
"        </p>",
"        <p>",
"         Wear a mask when within 3 feet of the patient",
"        </p>",
"        <p>",
"         Mask the patient during transport",
"        </p>",
"        <p>",
"         Cough etiquette: Patients and visitors should cover their nose or mouth when coughing, promptly dispose used tissues and practice hand hygiene after contact with respiratory secretions",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Airborne",
"       </td>",
"       <td>",
"        <p>",
"         <strong>",
"          Known or suspected:",
"         </strong>",
"        </p>",
"        <p>",
"         Tuberculosis",
"        </p>",
"        <p>",
"         Varicella",
"        </p>",
"        <p>",
"         Measles",
"        </p>",
"        <p>",
"         Smallpox",
"        </p>",
"        <p>",
"         SARS",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         <strong>",
"          In addition to standard precautions:",
"         </strong>",
"        </p>",
"        <p>",
"         Place the patient in an AIIR (airborne infection isolation room), [a monitored negative pressure room with at least 6-12 air exchanges per hour]",
"        </p>",
"        <p>",
"         Room exhaust must be appropriately discharged outdoors or passed through a HEPA (high-efficiency particulate aerator) filter before recirculation within the hospital",
"        </p>",
"        <p>",
"         A certified respirator must be worn when entering the room of a patient with diagnosed or suspected tuberculosis. Susceptible individuals should not enter the room of patients with confirmed or suspected measles or chickenpox.",
"        </p>",
"        <p>",
"         Transport of the patient should be minimized; the patient should be masked if transport within the hospital is unavoidable",
"        </p>",
"        <p>",
"         Cough etiquette: Patients and visitors should cover their nose or mouth when coughing, promptly dispose used tissues and practice hand hygiene after contact with respiratory secretions",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    This system of isolation precautions is recommended by the United States Healthcare Infection Control Practices Advisory Committee.",
"    <div class=\"footnotes\">",
"     * Alcohol-based hand disinfectant is an acceptable alternative to soap and water in all situations EXCEPT in the setting of",
"     <em>",
"      Clostridium difficile",
"     </em>",
"     , for which soap and water should be used.",
"    </div>",
"    <div class=\"reference\">",
"     Modified from Garner JS. Infect Control Hosp Epidemiol 1996; 17:53.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_18_24877=[""].join("\n");
var outline_f24_18_24877=null;
var title_f24_18_24878="Empiric abx purulent mening";
var content_f24_18_24878=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F71968%7EID%2F60707&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F71968%7EID%2F60707&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Recommendations for empiric antimicrobial therapy for purulent meningitis based on patient age and specific predisposing condition*",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Predisposing factor",
"      </td>",
"      <td class=\"subtitle1\">",
"       Common bacterial pathogens",
"      </td>",
"      <td class=\"subtitle1\">",
"       Antimicrobial therapy",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\" colspan=\"3\">",
"       Age",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       &lt;1 month",
"      </td>",
"      <td class=\"sublist_other\">",
"       <em>",
"        Streptococcus agalactiae",
"       </em>",
"       ,",
"       <em>",
"        Escherichia coli",
"       </em>",
"       ,",
"       <em>",
"        Listeria monocytogenes",
"       </em>",
"       ,",
"       <em>",
"        Klebsiella",
"       </em>",
"       species",
"      </td>",
"      <td class=\"sublist_other\">",
"       Ampicillin plus cefotaxime; OR ampicillin plus an aminoglycoside",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       1-23 months",
"      </td>",
"      <td class=\"sublist_other\">",
"       <em>",
"        Streptococcus pneumoniae",
"       </em>",
"       ,",
"       <em>",
"        Neisseria meningitidis",
"       </em>",
"       ,",
"       <em>",
"        S. agalactiae",
"       </em>",
"       ,",
"       <em>",
"        Haemophilus influenzae",
"       </em>",
"       ,",
"       <em>",
"        E. coli",
"       </em>",
"      </td>",
"      <td class=\"sublist_other\">",
"       Vancomycin plus a third-generation cephalosporin&bull;&Delta;&loz;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       2-50 years",
"      </td>",
"      <td class=\"sublist_other\">",
"       <em>",
"        N. meningitidis",
"       </em>",
"       ,",
"       <em>",
"        S. pneumoniae",
"       </em>",
"      </td>",
"      <td class=\"sublist_other\">",
"       Vancomycin plus a third-generation cephalosporin&bull;&Delta;&loz;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       &gt;50 years",
"      </td>",
"      <td class=\"sublist_other\">",
"       <em>",
"        S. pneumoniae",
"       </em>",
"       ,",
"       <em>",
"        N. meningitidis",
"       </em>",
"       ,",
"       <em>",
"        L. monocytogenes",
"       </em>",
"       , aerobic gram-negative bacilli",
"      </td>",
"      <td class=\"sublist_other\">",
"       Vancomycin plus ampicillin plus a third-generation cephalosporin&bull;&Delta;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\" colspan=\"3\">",
"       Head trauma",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Basilar skull fracture",
"      </td>",
"      <td class=\"sublist_other\">",
"       <em>",
"        S. pneumoniae",
"       </em>",
"       ,",
"       <em>",
"        H. influenzae",
"       </em>",
"       , group A beta-hemolytic streptococci",
"      </td>",
"      <td class=\"sublist_other\">",
"       Vancomycin plus a third-generation cephalosporin&bull;&Delta;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Penetrating trauma",
"      </td>",
"      <td class=\"sublist_other\">",
"       <em>",
"        Staphylococcus aureus",
"       </em>",
"       , coagulase-negative staphylococci (especially",
"       <em>",
"        Staphylococcus epidermidis",
"       </em>",
"       ), aerobic gram-negative bacilli (including",
"       <em>",
"        Pseudomonas aeruginosa",
"       </em>",
"       )",
"      </td>",
"      <td class=\"sublist_other\">",
"       Vancomycin plus cefepime; OR vancomycin plus ceftazidime; OR vancomycin plus meropenem",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Postneurosurgery",
"      </td>",
"      <td>",
"       Aerobic gram-negative bacilli (including",
"       <em>",
"        P. aeruginosa",
"       </em>",
"       ),",
"       <em>",
"        S. aureus",
"       </em>",
"       , coagulase-negative staphylococci (especially",
"       <em>",
"        S. epidermidis",
"       </em>",
"       )",
"      </td>",
"      <td>",
"       Vancomycin plus cefepime; OR vancomycin plus ceftazidime; OR vancomycin plus meropenem",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Immunocompromised state",
"      </td>",
"      <td>",
"       <em>",
"        S. pneumoniae",
"       </em>",
"       ,",
"       <em>",
"        N. meningitidis",
"       </em>",
"       ,",
"       <em>",
"        L. monocytogenes",
"       </em>",
"       , aerobic gram-negative bacilli (including",
"       <em>",
"        P. aeruginosa",
"       </em>",
"       )",
"      </td>",
"      <td>",
"       Vancomycin plus ampicillin plus cefepime; OR vancomycin plus ampicillin plus meropenem",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * For recommended dosages for adults, see the table \"Recommended intravenous dosages of antimicrobial therapy for adults with bacterial meningitis\".",
"     <br>",
"      &bull; Ceftriaxone or cefotaxime.",
"      <br>",
"       &Delta; Some experts would add rifampin if dexamethasone is also given.",
"       <br>",
"        &loz; Add ampicillin if meningitis caused by Listeria monocytogenes is suspected.",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Modified with permission from: Tunkel, AR, Hartman, BJ, Kaplan, SL, et al. Practice guidelines for the management of bacterial meningitis. Clin Infect Dis 2004; 39:1267. Copyright &copy;2004 University of Chicago Press.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Recommended intravenous dosages of antimicrobial therapy for adults with bacterial meningitis who have normal renal and hepatic function",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Antimicrobial agent",
"       </td>",
"       <td class=\"subtitle1\">",
"        Dose (adult)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Amikacin",
"       </td>",
"       <td>",
"        5 mg/kg every 8 hours*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ampicillin",
"       </td>",
"       <td>",
"        2 g every 4 hours",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Aztreonam",
"       </td>",
"       <td>",
"        2&nbsp;g every 6 to 8 hours",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cefepime",
"       </td>",
"       <td>",
"        2 g every 8 hours",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cefotaxime",
"       </td>",
"       <td>",
"        2&nbsp;g every 4 to 6 hours",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ceftazidime",
"       </td>",
"       <td>",
"        2 g every 8 hours",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ceftriaxone",
"       </td>",
"       <td>",
"        2 g every 12 hours",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chloramphenicol",
"       </td>",
"       <td>",
"        1 to 1.5 g every 6 hours",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ciprofloxacin",
"       </td>",
"       <td>",
"        400 mg every 8 to 12 hours",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gentamicin",
"       </td>",
"       <td>",
"        1.7&nbsp;mg/kg every 8 hours*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Meropenem",
"       </td>",
"       <td>",
"        2&nbsp;g every 8 hours",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Moxifloxacin",
"       </td>",
"       <td>",
"        400 mg every 24&nbsp;hours",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nafcillin",
"       </td>",
"       <td>",
"        1.5 to 2&nbsp;g every 4 hours",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Oxacillin",
"       </td>",
"       <td>",
"        1.5 to 2 g every 4 hours",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Penicillin G potassium",
"       </td>",
"       <td>",
"        4 million units every 4 hours",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rifampin",
"       </td>",
"       <td>",
"        600 mg every 24 hours",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tobramycin",
"       </td>",
"       <td>",
"        1.7&nbsp;mg/kg every 8 hours*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Trimethoprim-sulfamethoxazole (cotrimoxazole)",
"       </td>",
"       <td>",
"        5 mg/kg every 6 to 12 hours",
"        <sup>",
"         &sect;&yen;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vancomycin",
"       </td>",
"       <td>",
"        15 to 20 mg/kg every 8&nbsp;to 12 hours",
"        <sup>",
"         ",
"        </sup>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    MRSA: methicillin-resistant",
"    <em>",
"     Staphylococcus aureus",
"    </em>",
"    <div class=\"footnotes\">",
"     * Dose based on ideal body weight or dosing weight, except in underweight patients. A calculator for ideal body weight and dosing weight is available in UpToDate.&nbsp;Dosage and interval must be individualized to produce a peak serum concentration of 7-9 mg/L and trough &lt;1-2 mg/L for gentamicin or tobramycin and a peak of 25-40 mg/L and trough &lt;4-8 mg/L for amikacin. For additional information, see the topic review on aminoglycosides.",
"     <br>",
"      &bull;&nbsp;The higher dose is recommended for patients with pneumococcal meningitis.",
"      <br>",
"       &Delta;&nbsp;No data on optimal dosage needed in patients with bacterial meningitis.",
"       <br>",
"        &loz;&nbsp;For the treatment of MRSA meningitis, the Infectious Diseases Society of America (IDSA)&nbsp;suggests a rifampin dose of 600 mg orally once daily or 300 to 450 mg twice daily.",
"        <sup>",
"         [1]",
"        </sup>",
"        <br>",
"         &sect;&nbsp;Dosage is based on the trimethoprim component.",
"         <br>",
"          &yen;&nbsp;For the treatment of MRSA meningitis, the IDSA suggests a trimethoprim-sulfamethoxazole dose of 5 mg/kg (based on the trimethoprim component) IV twice or three times daily.",
"          <sup>",
"           [1]",
"           <br/>",
"          </sup>",
"          &Dagger;&nbsp;The vancomycin dose should not exceed 2 g per dose or a total daily dose of 60 mg/kg.&nbsp;Adjust dose to achieve vancomycin serum trough concentrations of 15 to 20 mcg/mL.",
"          <sup>",
"           [1]",
"          </sup>",
"         </br>",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Modified with permission from: Tunkel AR, Hartman BJ, Kaplan SL, et al. Practice guidelines for the management of bacterial meningitis. Clin Infect Dis 2004; 39:1267. Copyright &copy; 2004 University of Chicago Press.",
"     <br>",
"      <em>",
"       Additional data from:",
"       <br/>",
"      </em>",
"      [1] Liu C, Bayer A, Cosgrove SE, et al. Clinical Practice Guidelines by the Infectious Diseases Society of America for the Treatment of Methicillin-Resistant Staphylococcus Aureus Infections in Adults and Children: Executive Summary. Clin Infect Dis 2011; 52:285.",
"     </br>",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.journals.uchicago.edu/\">",
"      file://www.journals.uchicago.edu/",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_18_24878=[""].join("\n");
var outline_f24_18_24878=null;
var title_f24_18_24879="Treatment algorithm malignant pheochromocytoma and paraganglioma";
var content_f24_18_24879=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F87044&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F87044&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Treatment algorithm for malignant pheochromocytoma and paraganglioma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 595px; background-image: url(data:image/gif;base64,R0lGODlh+AFTAsQAAP///wAAAIiIiERERLu7uyIiIpmZmd3d3WZmZjMzMxEREczMzO7u7lVVVXd3d6qqqt/f35+fnz8/P+/v78/Pz19fXw8PD7+/v39/fy8vL6+vrx8fH29vbwAAAAAAAAAAACH5BAAAAAAALAAAAAD4AVMCAAX/ICCOZGmeaKqubOu+cCzPdG3feK7vfO//wKBwSCwaj8ikcslsOp/QqHRKrVqv2Kx2y+16v+CweEwum8/otHrNbrvf8Lh8Tq/b7/i8fs/v+/+AgYKDhIVFAYiJiouMjY6PkJGSk5SVlpeYmZqbnJ2ejoZ+AaGkg6Oleqeoq3uqrHWur7JzsbNwtba5a7i6u72/vsBuvFcHBQECMwEESgPJNATEXQMGT9E+0sJksQaJBc/OPtcvDgM1y+M4AuYr4dDZP+43BwoM1qPrO/DaYdwFIgIUPIvSYKCMZTzytTMYI90ReTYEIIDiUMc+fl/8jRCQAEC4YwEKLAAgIJG5AQkQ/008kDKAAwAGFCAScC3mTBIEZCow0A3RgREDQAYNoOAnSJEA0I1imYhAtJQKRiJIVA2lygOJJo4I0LJqy5VfATB1KbZlg6dERwYwUABBTqLVBIBM0PIBSUQJRhIAKTcZA4FU3+70KPRYUQBHRyJmJldmAgZY8TKIFo0tIqQlEZmbisiryrJNr+UTXLUwUaOXFW/FGGwE2xHXIBZwsCCA3XwDzEU70KABgAUKCAx4KSI28RICYdaD6NFcN2bfSMxO6nRUg47UKXvUKgJBx9wAdiskgYykgubhA/BeGbX37+AN2KVnNmBiAN8AksdkIPcA1mQIDFCbVOYkJ8Jrr7mj3/9yziEU3QjTPYCdXAww8KBYtkXD0Gy13SYfAN6ht9t1IihFUoHJ7Afec4gZNB15rKmhEUDfCcAAZwEg8NqJHiWDlTHVeGQAASkJeA2RAQg4wo8lHsBcOOM4c2NW2Y1SQJAmgjhRQJf1iOEB423FzG7h/AhSZ1eKQE2axZ2CgH3MMJkUmOwgtM6Oe8kJwF9EVuWjek1CeYqUOE5UEEDs1LfAAIGdMqVKO+bDZUhemolldSfKqZ6gatpYaAkXxbjFjAH52Y09CSAwIADxVaqee7UxI0IDbrlCKwnJBcTAk8lEKcCpAKRaJau+xTrOm1jZ5cA/ZarHkQkILevqeiTAukz/q212B6cIudajkJ0CBjBSqwbSeJ5HxHW7a6+D/hoAqggw8C6iYu0UorxDngJsqqvGlywA0jbLW7Em5qMupz3uy12JoqLBjTdBOjNWWyBedtKf/rX0EqMhLRBbajjp5GcJCEvcEsUmLnDMMZhq6dFlzGIMXI7kXUYfxmOpN9ZLY53l5rbhicwjdTxmllfQN8n7TE9DCl2yABMjIAB+dyHi21vH5CtC1BWHdBLM06ocUsG6Oc1up1zD2LAZoapwqxi1/WSRrGDkZI8OCdhF7w1vuxA3EG2vbUXgJOMltxfR3KQP3V8kcJwPYcbAcQKHq5B4eYALXgbhmnf+A+eePwF6/+ik3zB66UqcjvrqL6jO+iGvx/657Fm4TvvtSeE++Ce89+7778AHL/zwxEui+/Fe2I788swjoXzz0EePjfTUVy+69dhnb8Tz2nfvPcPfhy++MuOXb/4K3J+vPu7pr+++DcXHL//89NfPyPuhtI8/D/rvz7b/WOgfAMcgwAGew4CBKCACD7LAPyiwga2DYB8eKEEWULCCUoAABcBHAQhg0Aga5KAHPwiHCQRAAhEIQAQkEIAJkJAIJkShClnowhe+oQKLqIANiYBDRehwh26gwCI2CMQgCFERRCwiG1iICAkoUQhMPOET25BCRERgikCoogqxyAYLBMACXASCF8EYRv81YCAAGCijD86YRjWiAQIBGKEbdQBHOc6xDBe4Iw/yqMc++vGPgKSd/QZJyEIaUhOpO6QiFWmHC3LRkauJHSSdMMknVrKSCWxkIC2SOtlhcgmfBOIlPanJTeJglJIsJRcQIjmGQIE5STAG5nDyQFRGIRysjEMok1CLMzWgcrA5XeQsyDgX4LKYJ0BIRXgASxUMEwXLNEE5oImPD/XAlmrSClaQGYRj1kAhzUzBM2vQk7WASpUQqoaTCnA3WvKSmwtpHTyZ6UpnWjMF0SzBoU6QT/51kgT12VouieBNGoyTBQeNyLkiSYdeBik/dmmAZI7CKsmsoyTdMIxEyYKbsFT/lCvtJBrHBmCPzIgLRyNbBo7+kRiULkVj6YGKamBCJbkc4zEfnSVoaIYSADwgKlkZy0SsQjOKwkZk5TzcXhLBIwckYgFCpelnbIKMqKrNeSTTJkJGao+1tGUoSTLMT4ymlq50zZzHDJCaHofS8PAlK86ICY2qhhSBqiQ6P4qGRhHBM5heFFAw+cdVaWECNvWII6iiySkQGywByGVMDmoQj8AjHpwmwCDLoBADLhsrE4SooECSzkuUaZ1iBUc7ATXBqfrzFwP0x0sjuBU9RpKABgRnaLKNCmXVs8wFrQs5Z8uHbWLLHtWcajjErddMsfkyRRBAs5dNCn5W5CABrEqt/+WRCwk+m4xl/EhP2+1IucBpo8HsBDgjcQDVhoZX3kaWpsR6z3MLIKsb1ZWhhC2BYRXwABzl6FiKkBo7fJWeyWLMvwtTqVYksiOAyIRS3gRONR5FM9IiJmJac5lrWuIsdlzpTZ2SjiLUSRb2jlhgFdGUkwzCJNGYQy45stCIDcDhAyBJQGcyJ363l1WBEgDEJAHa0/D0D4S8ZlIxE6kAHLAw81xGT+Q90QP+UU5KbcTDGCPwNdhEjfGAF3wNLaw6g0ISnLappGYemparOS3GQmu+FfpGZzGkrCQvAziyUlhS7HINa7UMyCKIUIcD7Vp2WsggfRNBbe2EnUSjeF64Sv+GrpiTKzaPYCeJFvThaJXowfIYoFqF86GJ5iVf9cscRi7AvwLW3TEVICokWPU/xoudZkUHvSd41nbuYuN2FdjPCQVzfkVstbttdC2bpdSxXTtgX7t4Wjl9qEg1U9KncqwAdhaOIrjGmW7s9CXHWlhmjkEnQidbARfa6aZ8E5AFzAwBOVvxl5It2OKYrQQ9ScmJ/iKZeI97U6mJt6dhB2ofN5ekpH5a1Y6W6uZi20usTMA9r/2PtyDj3e5AQD0AQqURvDtxKel1iK+xs6F9CVroNCUNmEsFPr1hl1hVOfz+eQUHYGcYKZd5DFheOpgfweck5DnpgE5wnZOPl6SEhdH/V05z1hGdCE+voNBDF3UhLPLqWM+6/BKp9a4TD5BVN2DYl35Osrdg7GYXdtpRgPa0t31/byd73N83d6PXfX13D2QIcwcACNgx7Xs/RQfX/oQJWECGK4wj4UUQwxQmvoaLZ0IPE/HDyE8eEZWP/BLgqAg+Rv6IiUii5pcQxQyMXgRRdOLpmaCBRFzx9Fp8/eqXsIEvQn70Y5x9E87IAd2zUfdMMOHfNV9H4DPB87NHvvGXz/zmOx9+Xo++9IUXwOlbf36AyHvPA0g97WfukdyXnvdnB/4rjD/nqQgj2s+vdAeqP/zRY78/pfDMcGYr2FnITA8gYn+1T0H+Q9BPJoB//zuXfSVgUutVYEFQf/UUTCb3gOZHAPIyTzKAGwbRf3w3OD0AaKdEgULwbCtAgDAAgJxEAtplDA0IBAxoOZYWBrURDxeYgv4nBenDgabjgUEggAd4T6ZjgCYoWLTyV94GY1xRF2flJ0ERHX+hNxynGW7VGR4RFmp1Yc/GFs91EmGRM4zjVIiwAFN4JZSxFialGyCBhNjmF/xFHktFM22SEpiBFwuwK4hwHlwoLh31GeEwbjOVgVVQg+IGh0lhVmsYCzgCJiDjVQFiGoexEXNhhGtYDYPII2voLp8hghHkfj/4HoUGWSShav8BIh/yWZQTWKToceCSH9XwUx5BMF7oYf9acyejiBu68SrYMVDD1R2uqCG/MVwGk4rngRI/gSD1ViItE0zj0gDXNQDR0E63OFms6Ay4pl5lp4E8AGjJmBSSNmvgNgqcsS3R6Bv3oSYNAh0G0R+fqFaDoYrJ8Wzl4hrvYokuQII5EAsmtSXNNjSniGSwxScJIG2RMgCRkQjylhQG8IWvKBN6Y4FfwiYDBWPxYpDj8I8B6RPuwI/SNizu1IlEBjBEkY0xppAEGVeKMIx8SAV+6BqCtRdEwxYtVgtGNpIJdzawtTfgMpHqASgupic0JpDweHY+yIgmeI/fwhgAOVysthEJsFAicGqoCFDJ8ADOUnE7IRr9eIoC42f/J7AT2pUTGcaUgwEUA8ERSkmMFTEO/CIurCIff8MtzOYlULliuJZM8KcD1oiWrdJwlQYtdhGXxDhyvnZlfdmLkXYXPFIumtaTFvSTADGMCgGCVgk28qA0noUXZNglHFMespSUr9ggbSkwYsMyI8BvIJWZU6kKnFEAlQlhAyGZoFKMbWI4C+cxWSGaj4EbiZAMedhxO/Z/G+hcZLWSVHYZtcAZhvgZrKRwgEk0o0FR+cZmFudYwllu8ycKR2A3U7CWNdBp/LRxLqCD30eNUKBdpqCYQ+A4UXA5MtgOsLkC5vkC3kl+4MkEmXFb44mJWLR+3UeeSoSf4qefRcSfaaB//2kgj6f0fuYnTzKAgS2AgRMIODh4Tf4pSnOJPg9KMum5oOn5gg6KdA50fR76oZcwoSlQiIj4iEdYTgYAVkNxGHoYiJ2BogBFbSDBHQtgFvtRZkkxo3gRUx1TiFyVoyqxozVqNYR5ifdZPaHCSuHYlKo4AtwljjRFjt+IjZ04k4tZIZdVEbpGaBdGpQjgiUpxjMppaNFVHl/qH5l1c0Uajwban/EoKwhhk2DyYElWau1SZUXGDAnCEEAmESkmUf0oZYJ1ihipXQjRp9sylLzBFRfJpuXnpmenN6z0lXQGMMxCHE/Dl8CJLgdoaN+QT9r1F9GlnHXSMsLCi57aavhIN//aVRIj2Kbx9wLEyUpryCxgwzQKV4+byjQxmiSTQY9UIQIOwJ2EqhSwSZw/WqzPFayuaqRTRKC3gAcK+p5DAK2sYa04ZwdQGVLUBAXY+guBJwJ+Bz3f2hpAZHiIx0LDpzvlKiNTdHkBkHnLMzrUqgPRVK/2FJQsgK/OCkSclwjKhzzEQFVKUgLeOQ6ImZEGGzjTtIP6ugL86qhPVHqQWgLyYhcM0ACNerDKc69t44QOm5wsCJ9K1HpWVLEkwJqxJRkkl4VmcRTrgBV68S4muiSJ8Bii8WoghRawlhi5dk+NAVKjITQ9cw0qAzVh8VdDuqQq0K6/UHsWcHvMM7AcEy//jJWl1lFc2KKAuGEoE5GOYylQD5CzcaZY9LEwsxGQcjNMmvUNBpMi9bC10aAyzJBbC/BYOCqxT8R7+bkCm8VkAbZlI2ZYCFs237UIh7MojTI09RFuFNZke/Ow9RGzgKUehEsUxJFjbSkWgNqoKIdFwte3JiAcI7FZjpVmfbYwcjsvCoFt7ECp4bUna/Fs9JBhb6JnAwi05lC7b2seGSsflJEciRY5rcqdn4tFATu1KLCoRBptLSuQPUNvCsEiT2hl9jY2r5gIV/MzaVMzPmGC2iuJRGsWRqsA8FZjCmFS1bBPcvl8vTB+CVsFf8GtA+e+rwC/PNgGTtsPIIp9+SO6/+xTn4awv2dAwBkhwIWgQAr6v8djwK/KwN10oUpaoYMDpy3Drw7cBRmst4SgwBJMwbXDOBG7m0mXSRCsJh7FVTwbhxxzHiaamx1TNUkikCo1XS+xUWnmouZUcjYFUh91Hr85Njmyo2jxhj1Kw7W6ZWg4tmU4jQEsCBvMQAA1i2BCpma7Hct4ab7YI984Z6SmFAcQN1eLWdkYX3jGWlqpakuJltgFIGBaHcc4pRM8DjlbpWDrxLcTC4YVvzBAgCNcAgHZZFFcgE75JYgabhwpEHIqkhAzjBPcI0x2VmzYl6/BZZv7YdyxkcqKsFcCk3N8CtdgkXJav6kkHZ4rBH78PP+rQsImDJZf0raKpS2mWLtOyZdefItGpgC35WatSYrA5oqvtYvjgmpESZanwC+wthWSWh32cCyvZg+wS8qvo8cPRbkzOxlN7AxkthU6yhWzAodZUU4TQVVEqGo3ywBLy26pkc42WzmD/MCuzCQq/DOXMxG16iW6alJe6BOshJorC4ViQoo87IrNBcSAuMk3O1ZUMqsS6Ibj8InVS5LvPKF7fBJey6S/OIrk4cZo+lyW5VjWdFzHkWK2saXfuKUOdpETzcGl8MdM18D6Vc2GqzOIC0vKimDTW2M3JptLeZkGsKj9iKdAHSSGxcoRaggufXTsGtPJ6bpsWci9PJS8rGv/mkZcWXwvOtaJmrqYTUsKK63BAqtfijC9tEpRNl3MRLNs7/ZvTpIa9IY1YsisWaG+XIrHCNw8X92Hd73X8MNNA9W0jKOgC5wD6aCSJJvHfN3K8+jXFTpQgn2h9mqakK3UT6zYHcw/jP2mUK0Cg40D4/AXwKQPYQ3FXm0DPqsUblhWUCjOoGJWMHw0+hwO3lGcSIGIdThTpy2IZ3Ig7PCb2kyS8FzZR22fpj1acBxf2TWMwLIVkvaL1sXG4UI3zqBWcowfzXgC05Hc+SGTeSPMoBiFoR3ciE3aJxwDj1uoeUqKO/m9AU0mv5KSVzKMA6DLwejJsuKQ7XTeqdaS73Eg//BtpZQ93pad2C2gZ1lyqnrKUi/xlmpoqVxsl9ENFEymapr615Rq4Am+3YTpAMTBlJ3NdgLbv1tX3jDANcbKFT/RcGztvfSFz4AY2258t1SCELTZTiae4c2ZH6rh25OdAnlN4srbA0ndBRJSrbBKruLw4yV4pACM10fu5Ci7n0i6BB/OT7Hw18kEwk2g5Ak85c0ggxhYEVj+ZmCtROHad+sq3A8B5ukp5jg45vG5Q+jqeOqK5M3gspBCFW0VTKk9bb76w9SxWercMWG4DnMISu+aQ7HaDKxot8wRIsaI3KJ2WcG8Z9H1jbqYxUzA5YHwr4iQvEv95SViGVThDvrogP9VqmAA8SYJpgDYgafp4FTt+HNYRLGLngTh8JaOxjNGOYxmCSewXOlrIXHvoRoVgZ20PkUmu0W3jgSX6SM1hqtgE0ywuVXUVtCBThf8kRV0rJsxN0VQK7Xz2uRFxLdRPu6gq3jnPtrI6+XNbr+ywOkHCu+2IO9xvjsinu/6vu+QQMjvfu/0Pp3xyO8EbwmjEvBBYO9Uh/DfqXsKD3fL9/D4I/Ga8+N87Ng93gRVvg0RDwZLm24uECYXH9j19MhOsPEE1PFeQA8LloAzMPKb3eBSgPJiQPGCk3corSbUtsIc2YWSYhLVa4bEVtuunQwthcQIYMNWtRVFHxQlB+g4bA//xwY1DffbUUXOB2x8ON9k0HXFAdWM69BZgqmKwIgC2d3cVprdFrwbcWO3G20e4G3GwRHMY/xaElP1o+joj5M8Kt8F4umkC1YrsozfdyJYlLttzKHfkLViit+XzhDJmtvg7l3X1ABoCAZkd5/h7qC5O531wJd39IAfUwPLiKzFYQ/hTenKJIDhDi6S8LJnlKzLdQu5fXmUZpxZalxm7QTLBEkYsKWdrEL7Inp62ockXIGbO/8zNZ4PnEHs98wcJm4zPcJt/Cwr/qxu7iz97vD0LRxt5xYdRlOn8XZte6gFNr825x8FcM4K6S8q7S86Wk7gkff+5UP/GGH/4oP/2lAL/7QMAoA4kqV5loOAsmNAtMLQ0rUt27mutkSgA4MknzD4KyKTyiWz6XwqjySEo8aj4UxX4Ss269Ku4GUWal2xiGVWdgsl0uBwndRsv+Pz+r2rdAgwnCW5AY2drIWhPSHyARCWzNUwmkWiVBY2Zmpucu7VARgkjBQEBBQsAAQYkJaqErAapK4i4CC0xrodJJQiOLIOkCocpO6qAhAoBCjE4rzYlhYAsJ4a3HYNlA4EBhTHnryWCggUkCYECkAv+AQ3lFbpuou0czOMlyYUPzgW98IHVKkZ8OdWNV4DAyDggY4bqgH8UBhIFmDFPHNE/PUr1mAakQIrGCh4AM4YiU+dTv+iTKmyxCcBvUoUqBKggYgrywA8UJCKJoA1CES5adBPwYIBM6rB8JhqhQCdClZErPcFBoADBbyJiOkIzYtxDBgkWDGxZ7QTT0eMOwDSwAKiABw08JH06I8GNNsSEGAOQNi0f1YkdHQ3wAK7APAGRLtXRDWpNQUsIAwgsNFjAYZpqSJCb6CwRIRWJdpghgg5P8aRBXAzJ8uVrl/D5tPyJYNnCFNR5XGw1B+qOJpC20qCVSkDPODw6OLjD+bLzWC0jVW7VS8xBBC8dIkbVFk/l9GSvloQGvIVHb0NMGAbYZYuOMSsQm8g8eS9oVodaCNgVelour+bQMAuAyywHgIdtaL/ylUjmAYASAIasBuAIpgUm4UXYpjDJ6EwBghfvYAxgGY3ueCbQAHo44B/igAA2gjHHZEcDCqqxpQCjr2AV4edVadZVwV8pVQX/EVGlQhnbRYeW26VFqN5dQ2W12I9kebeDDw8cJlhRSYWWFZVZJmfKFtFhspowjFX4wlCccZgXS/JQ5plgcCBQAE3qoZVaxny2aeffZDwRyD+FAAiVQXNN812VDoCzYqBFnMZjI+lQt4xydz0HDb4FVMoKMVdk802MPCHCDLhZLHgQgiVZ1lVxWg2jyrtwfBeKyv4A9BpA/hw60KkHNAWQgrd0xCul7UVyIvptHjLRZEe4E8DYJkC/8df/QVX0p/bcgubSVR0e1ICRobLhwMsvlZhueuyC4VJB5DYrrzz9qkuvffiy4K9+fLbLyf7+htwuwALXLDBTBB8sMIZJtyJIRqSy4acr10SKCnowrZGxUUggxkXC4McbsMlTDIJFxHb8ELFWZiMEn0lODDxhRpXyLLMEiMxcsg7o6SzJDcX8XDKKIOXpIUby4NxbDQfAjQNDEyICc9TY+iz0Q4ZRB1GVKJTzS5uTYOKISoAM15GrRDwrDsH0UIOPc3SI5cqrVjEjSkLRNXTmCzNYlssI+16qTIGjIfUrMyuOoNSzG09TjmBzLMMnnqRYDZZydT9ada84HDqTVjfJv9CWEFTXXpsVjNa2XJZgAbvAuPAIJcjcEojE7kOefwpA2fi9tldCuRFWlprtenZWCP8IZJkhi24oAkzlfCTmomdFRWMK7SFClxFMrq4lkO9XoBay6Q1SizOl9CYVwx4FIn6ws9Q/Y2qA0gL6abjrxLq7x2bX3gJGiALdULAdHixKEqBAlrOU9kPnJcem2VFPQk60BGK4qwjoEYGD+gOS3wjEfF9JyBpSsUBJqU5aPCne/0jzqyUhB0SaJCDCcRPGyg4Q97YbISS6p8I7Pex/AHRYUXgX1WcMyYXGc1Vk0FAYz50QOHUDidaipLvDtOVMaUqgFOqkyigNp8jJKAXIBn/XVOURSEYJO8t0TgLOhjFxvk9SQTZG0GZWnSlXqDjAEhklDQCKL4RjBFdWgkTDuD1xSgSEovxsxED/oOZ0f0wiJJsxP6u1D9hIcAfziHNAAllKBJc4VfIKgcDXxUPTGYRbq44wqlI8cV7YMYBeGoAukLkKM3tglGew0UcN0OdyUBjBr3aRbSglcpN6eQteIIhNJzTCpqooZnBSgYthIkpXhZxGFDLHR0m6U1PfNMGl+ABSMyIkpYF4RGcQGcLUBfOd7YTnj34RJbMuRJ25qCeKulYzuTpzyW4858C/ddAC9pNgyLUQgFNqDcXytCHNsGhEM2fRCdqUSNc9KEVzShH/+PZUYMmKKQiHSlJS2rSk6I0pSpdKUtb6tKXwjSmMp1pgj5q05umAqc63SlPc9rTnwJ1ohsNKlGLerChGjWpSr0XUpfq1Kdyq6lQnSpVT1fVq2KVqVndKle7JdWugvWpNB3rTMNq1p9+VRNpPStbKUqvtbY1rlODq2zkateL0hWcd90rQ/OqB7/yNbD4WujYAuC0OwBWsIodGMmeWYNS5sSej6WK0GiQ2MVi1qski4ZVlFYSI+HzeUTTUGZLO8mWlIVNKpCUqHp3mVv8Sh0vUFA6bNObRhmWAT74Giq0Zdrf4g+1hyFfAWoFJLCIJW2BmyNcfCBI251xfcaDwQBo5/9T4GKXZy35ZRZe2BNDJWY81TpCAW8DBmdkx4ZL3FN227sw4RaNLEFKbmLm2KQdORFF0T1u+47gXUC5N8AFg28ScasN1/JxVer1JDBfS11RDZC9Ap4wvy5rBwtTOMN4wLC7NOzheXH4CSH+MImTMOKIljjFUX2riltcLxa7OMYKhbGMa7wSsuL4pTbescFOzOMfs8vHQB7yiolsZHkK+chKnvGSmxzEJDs5yieBspSrnAkqWznLecCylj+a4y+DOcxiHjOZadplq+K1o1zO8prL1eZ1vVnKcS5yRufsZDv/Cc/b0rOS+cwnP7/4zOmqs5oFnRIIUIBCIoAABBCKaEX/A4DRDH20TyVtaE1MwAISiEAAIiCBADTaoJnedKc/HWqEjprTngb1pTdRgZBWgKGvTlCsHzrrVtS61ZmAQEgvMOleQ5TXCfK1rjXx6VJkAKLHDkCyJ7rsZhc7ExpoRQQgOu1SVHui1+50tDexgQBYYAIT/Xa4L0pucXc7ExgIAAcsuu52X/Td6cY0qyc6gXpb9N6nnjcfiG1Rf18U4PweOMELbnCbhrlfZS5rhcd8cEiLWOF/ljhiH35dJwDashOv8IYt3tSMe7RqFL+wx80Acn1tPF9pPbliPz7yC7H8BCsveYc5roTQRnKwSUBazAO7IRli1OZoIUnXvJBOz/pW/+WbHUVyA2SvnvP151F4eU+4kRWSoADnL0I6gHUOw+4oxRJPp/kIUuhLhrCGjh7qula/XtwHYIMZxap6No4Bi60Aw2+FG4meLt52tIC96bISwG6V0Vu2E1zqcpRMQqCGN/EJgCeIB/FmXdKAarCF8QSyUp5wohPcTQEoaFhNMicvr+0mKLlNGYYKZFddCRdc8dzpD1/0oh5awp7GmwGhTlSRwlekUAYSKiEagGMKNIU0d1BP+u6Zjhvvtt6/1l3+XWVfxzM1pRcKYJLpGfv1Fokl82ba/Pg7v/Uipsg/I+p794O89Kyonr+El37uB76h1C8kAajgHo3qf/r3U4jcMf9EgyWAMCnKFWwKOWhOomRL+8EZAAoJAVCLKcxfD00f2WEc1aGZ0gUB+7Cf/82bywkdzGlgO9Wdxj2cCHKgyI1gzR2cCnodC66gyWEgirXgBsYgDaagDs4gk/VgxO2gC+agDw4hEL4gmCncwsVUEoqZxR2URVGfa0Rhi03hlHmZE5JcmhUaFgohRFVhSnxhiYXhJoyhEHGhEQrVFZ6hElDaEVhaQbXhou2bRq2hEqRaqeHbQN3hqs1hX9WhEtxaKeSaQQViAAyiF/5hEghbKwjcQC1iKTSiHyYiEjybsrUCtEHhJCLBtmUbQ3EiR5Whhp3buIEbummhJgqBvE2UKhL/GioKgb7lWx5moisKQSQmlC3SIS3qYsrsYi+G3KUpYTCmVEQJYzGamfvpWiiCoNSE08kp41I9owOS1js5Y7FFI8RNHTV6X6tdo9/1kzYiIzfuTEV1IzO6mTWqhNYNDQqQ4ziO1vNsIzCSgONJESqkHQxZUhKoY4nI3Gi1IzN5Q9f0SjQkCE+UVwMcXg1UTIMA1DsuY6CJIwmMjiytAFywgDrlwD6eUT+yow0O3Zi4khIZgw80RAIMgx59YBAgTdA4JPOJDDqSgEWGBU2EheXIQOEgD93olt24ReLEpOTpjTTUFg21QmR0w0NOI+C9XdyJZCxsEANEBjfBTFFKixq4/405cMQPaJJy+cB41M0unAIxFMdt+YA5VWMylkCy3MiNSMaOENEJJI/rIQD3rAFrBAbujQJ0cQ+FMIUM/SPgWR7mieQz4U2MFEdBEKQ+xImbkMX4HJKrNMCYMBCLxOXy0MRYoMYL/Rc2viRalsBT0CTl3AcO5SMJWFBxDFDwTQzUwJ0DRMQClNcnmd12zKY33g/g/UHv/c0RkERkRqX5bBZCeCBjZlGDLJByydGmrFLzDUk0dEzU2OaewSQJNMBZyFIVDNImOYJmjID0eNEAXZ/MVOeS6EQThVEq6MNe0qZfemTz4d5I8qY3nAk+9Fa8fKYB8I6rFKeHVBGX+FcXLf9nfpFKWTgEUHKmZnkmM9mjfomS/ywggySDK0XYMxQgyeDJeTLYM+RHUTYnUvLi97nAKxEk3aDCQSYkSNwDA1Rl4PQRtRTXDywAKZACcgqOhNLNMHSoFKHMWUYkyPxluPxmGhDMJPCoPIbMj/5JrxyPkNIAvCimh8qgkfpoe5aAGUHlPCpMkRpaNyJpaSAAT0SEAohPfgCdv2ipoHEplW5GAvCEWmwFAVRnuajjmZ5ZmiJM1kkeAVTGcNVEcaQAgGBDCaFm6iUndUiW0TWNOXZmj76Xmm6G5JEpdJTeI2DDO/CGcCxHT+gESPCEgEgloprAnMbjlhpjqdbUnR4CT8D/pnC0xfmlwADcSMx8B4wMg0WiBgrcFn+ATiZRh00eRXHxncyNqi8O2AnIkgKIwrEexfYJg3Ag5uykxzLM6pMYqpfgR04OqGBY0evIzPuEwjCQnrCGI7H22AlA5QJgRrDQ0QL0FqUy0UxkKq06SEzcajZh6+zBRxaMpnMkgz4MHzyOK7kKjEO5q2ooF+s9iTZ5BLwcWJAGoC8IRyJ9iRSJCVKYX0cGrMCaqRJsSt+9XpMI6io9UyCcpnAyEzf4x60MF3tIEw5g3kiUKZ1q7A92C0ai6gPO7MDKi80C1LDmbBFKksz+LOWBI84O7Q0Grc8e7f8V7TkuLc0+mdI+LZyZ/2rVspTUTq0kgmLWbuHWcm0reu3XzmLYii0idm3Z5iLZom1CleNfra3Zqu3bFlTbbpncDqzVMtyR2m3ACK3O7m0JSuc4/i3g5pl2DS7SBq7eHi7QJu6ULu7fOa3iPu66xGGk9eGFVO4b+kvmXu7kZsgemtqfgK4s8svodq7nYkghHiKfqO7BtC7qcssjBgAuWojs0u692C7sdksl7u4lLgzv6u62fGK3DO/BFG/w/skohovyKgzzIq+fsGK3RO/BTO/z8gkslgv2Loz2Wq+f3C6ffG+/hG/3km/5mm9p4W0rFEL6jhQXsO/C6a6P6QyXWc0z0m2Nya+iSmHOFSvs5v/vE3oL//ot6v5vUgZw0B1V/N6Y/i4wAper/zawAQ+aA2fdYemjBaPh5H6CcnIdpZxXS0IpZ2LDsYAwR66kuJIABJgiCpcdK4yLRlZwgbktBINSL5AkxHyjBAPDZdzWyeTwCPBaBSQaC0uRN9ACDCcqH+kVAafAS5BPsTRSKXyeS+CHM/CEiGyNS6LgiyTEicBARUCOyoaN3zTQR4REFk/esWVAJ7JdA3Dn7j0O3NQNO8RDrrCN47wNGMvNKjCL3agCWa7dgS7uBvdCNdRRQpTl+X3wckRl63BfdGIsFzvXFXWGODSrG2iFcpxGNKCGIydkhWwbuGHAqW1w3w0P+ez/xXRJA120yO8Ez+45ZvHM33Mthaau12ZC8t9uMEGUxSu8hTKsgIxspAo4QC+wkJ7MbxPDzXVMEPQJQGxuBxE8SAKcDwCVxEpl2yfsER9dhYG0ynnURADBTwR5M3nZxictx3Ny0/3KGCGrXfktHvGh50aG6RdblzS65OsNhJSY0fp4hHmCiD7UyZ1Azj0LcihbwCizXZagwRErSZvcF6ZCiRVJSRJdBUQrEUBvR/8VKMAycQ2frP4paXUABm+AQQGQhiYpn6J+rC188S1M4MJ2Si88QzWIwLWY0qWmMbKx8YEaH6+kkqw85qTkyspWUwSp0mMyWCsUlwhkyY4qsP4w/3AODGcXRpohDrFHu1nEEGlUg+FUW9YJWrUK/6LIkIuTEvHjFvCH4qAED7DnrvVjkSAFv7UGRzBbHzBYI+7gxvUW5zUA9+9HfzVg7y9d8238su/6vu+pKvZiN+H5unVXsfPQTvaiQvZcn1Vl56xm09llE2FYcbbGhnbhevZrcC5ol/ZrmC5qp7ZrvC5YjXYv5i5rt/ZKAC9s17ZrHK9k57ZrOC9v97ZKVC9XxbYvci9uB7dKjO9UFXdyI5lzH1lz25hjU3cp/JN04+9z+xN2t7N2e/f5cjd3C3L3hvd1e3Z5b/d5m6tpHmqWmvdlm8Q4oAK8bJ8+GEcHQ+1pqfc8Vv9nb6FC5KkRfusBz2ZgesO3WfTW7vwR+FnG8QGkL4kobnGDNtkGQpIMaRC4ozbUfn/m4ckAGuDlJaADSMJnTYjRWYAeSl44As3wd5tvhbhFtPQET4R4fJMDAcBdic9OaLArdAYKdeyqPKToh79WihYeNUzO3uRy1B54oDAr4WzfHyXA9ulKEeGQR3ypYCIH3RCOYfpecLSBMBlRJcPOjyuPmdBE8yDze0O2SbBrgh9esKyqiPOeLCjRx6KDw6JPEjmSgWRByT5mBg3ABoVw6Yi3iwUUnTO4juP5jdDnkZjymDgSRncXgD7meQZSoVPNoVMhEgwkAMrCpyvngphoWlL/kyMltQBFqMhOuAjIkj0dOqerWDmOE8bEOoeDTCXok6bPFa5/0603edMKe/mit4sTe3U7NptDN5DJ+rIHl7N3wnJDVbP/Ia+dLlZRex2uGwawVbavoQWAW7dDuyZwGrZl9rhnwrJJwLmj+x5QQEhlNXC3ex68trzPux3cG6mt2gpvlbc7YeVSwLUz973XlbgTfIublb+focKb4cF3nME7fMVBfMTzYMJT/BMAvMBP+8U7Qb6r2qfxe1Yx/MPVO3FzvBO8e4LEu8mffBOoO7u3/BKUO7dZfMwzAbhbwMTbPBJsu87vvBBYu8//fBBIu1gN/YSN/NEjKNcie9Mj+8Z+/23SD/Ze/6zU9wzUM33UYX3WWr0VEm7Va/3Xb7aFYAMGX0h6WFYJRzbRZj0o+SknRJYUqj28tDc/FjgKTIDGf/bTmkSG3wESp4R2pH0GjwAFvNrKk3bbg9KT8BaklEIDHIQ5LIBG0F1YIg+sHARWjAPm7GRX5t9/t4IlAcPWREQ4TP7jb8emaEPhMUlT73Fs4YblHDm7Uj7sI96qBcC6Ry7Xa8GTUBft5GdOPgDlyJFbWOQIbAnwIII/z/K2Tsbm6cN7mGSLgI+IKMZnSdf8/T5OjIlzDZf2XKaRNMYN2wXxf/9bAKUUQAAGgDu1GS3vp0AvbSb6ALoecUOXM/VwyP/H8mM4CCBEAABGURLFWQoDMAhlEdSBQSTBsBxNkDAAAgQEoiUiAYyAhgwwKhlsARTRoKsdogBBwQc0TG2o0rB0oarX7Lb7DY/XzPS6/Y7P6/f8vv8PGCg4SFho6KdEFwOlxGTW8FKCkADAcGPmtaCwcNfQALBA5FI3eqCAoxTKCana9LLYdGTXINtlReDFwFAgwGVkyZCSuklHVOAA8BCwpZRQm0lslwiBYUEVcZitvc3d7f0NHi5umFgyUIMqWQtwkNVAoFB1I2AjRF+z3l6DPEp3H/CJS5caCTghqFHg1RN9Ws5VWfBPCBEYNQYw8IVAwCdhmGwcEYVw2QiCByL/DsRXzE4ECTUkjHsJM6bMmTRrfitnk08/QLRgJnhgSCAgnGYoVAhAIafSpUybOn16hyjUFpH6OExwYGoeoX+kmpkAQavYsWTLmi3h9axamGnXun0LNy45uXRv1r2LN2/dtnr74uHrN7DgweEAE+5r+LDixYz1JG4s9zHkyZQDy7mMObPmzZw7e35TObTo0ZZJmz6NOnVOyapbu34NG23s2bRru2ZtO7fu3XFx8/4NPHhT38KLGz++DULSMwAohEUOPbr0bBMCSIgQYGWACdO7e/+u5yiVCuDLm/dOQc3y8+zbC2fZ0r38+bqx18BGP79+19Ys7P8PIGkYBIBBgAYe/8gYBAE8h2CDDup1wYMSTkhhhRZeiGGG3XzGYYcefghiiCKOSKJmGt5F3Im5pajiUiy2ONuLMNYk44y32fhWjTimpuOO4/ToI2lABmmXNxPdAQuReg2pJDfljFBAMAhUNRQBijyRJFtWDrFlYV1qyGST2jxZxRFTDnKkOVg+EVOaL7mZYZhiHkLmFEW8AE8ApxwQACcjMHBPAZykOcYNA2RxBENHuEBPoYsWEE8CwfwABANTqHOQFhNRqgAdjrKTxaYEXQSEngtk2qdDnVoo55yFkHnAAAWcqYAMBijAwABH0KIJJw584iYsA+C5TE+mQFTAl1MAGuUuAgggKQAJCP9w6RIfbSnKF3ks2wAlXEIbzLQjWKkrl4wEg2GrrqJJxwgHhLIDn1kNsYUC8hZahblmCCuDvDTU0w8WNpQUia6oBoBAtUwcSYQjdQisxQpoFUFFEuro64CebFKo7rqBwLrEDgDU2gWuABSQECjRTKwIMjD0W+w6/RyTzDKlnAKuGe628xFQ32pbB83K+PBJKLhEy5G1Q/hcQijzcuwxVCDziWc8p0hx5D/XeorOIvIyZHMkgdpsw0aUXnKOAs6EvMxEqvoT0rs00GDl2ekonemnrEb9VMfc7CST0x77zTcfhGsD+DgjBbDxnIcXnsfjkEc2uYuV0yb55WZkrrlanGv//nnnZYVeOemii2U65KmfLjXrMq2eR+I6w65UloPY/uqXduD+Mp26G+56m3/wqcbvf/DuD5VccGWI7IU43w3ykX8pfTFPF4Ot8fvKEGzje3AFJ/DBvykI9IBU34XySjAPlfnboM8H/PRGlb0evMvvmPaRj09+IKXYIKlxzcMGePqXGOqhAnScRGRm+FeySkWMQA3qBEaoBwwQlT4oGDBXNVgV4/ZAPIQlEG3/kpWesnKPguCrXnoSwiJSyAkT7oAG9jLX2WRAKaTVYRl2QBWfsiAEVLmQe3WzgQxgOIR/ZYoSUQBbESu1B9oNrnxU4tMDRiCDUABlFFd7QKdg0cVN/0wEcMtzGwJ6BYBfDWEjZpgEDIrWJy4KwYt/Kob37NCPMMLgBXY6mQBacSZzHIFkt8rVH/u0hFfwcSK8+FlWYpCzadHhYAzcHLaOWAZJUGIR2XrkIQ3ygg8i4At8IkAUIDGxSN4xJfwTB25GsQCH3IALLEhfCBsCMyrUkozra0TCqHCLFsQjX7CYxwBuuYyMkewP/6NCrGTAhRjUUgWVWJu80PLMaaJgEdEkoiNicLB1bO56lmQZCwQwzG16UxbSLAM1xxgJIkRBYlwKZxRb6UoqLoESlrhbK1B5tX25LKCgQCQqZxcMjKCxnFZMozprRrCRCaEOgvvgHqBVAoL2rv+b/7SIJDN6RFzFoKMbVQIncdEsXuQscuREi88mcoKGOuCh2dIFL0gKz4mdEo5HQ5f48FkkQIwiTzS4G9tSNkIUjAEHDmRbAqjEAB088GJa05dDUEaRGhyxgAhZnCwsqgdNiLCp3DTpEQkCESqY0mpDPElBSqomLkVVT420W1RayrZSmmCbCKEpAeaqgEYiMadcisICaKCDJ17CMUAFR8d6ohX88U2K65LTVfDKFMlGjbKu4mxj+/dZJ4W2Mp4VU2l5o1nYnFZJqw1NFPrBu1Gk9jWtDVJtReO+Kx3ntjvirVwW4A69suBQKHGXRzgJxAwSF2HC8a2NnAsXjJZAuNv/JBYzMti7D3pBuXDkBHCgCyPwugUMQaBu7+T12oIRca/KfcJifyNeFcX3Ldsl4XlFQgLpnpS9spXB0IIzXzCZxyQpfCh6SSDWKa33nK8wYnNHK1oIQybAcZLwhC2cDQpj+J4bflWHFaPhC4X4w9IgMbtMLJgRV0jFKGZOixHxYr+weEKtCh8mqLQ9PbiPfZSx8TZy+6PfgU9/Lo4xh/2wuGRF0ZRScV71diwnH9cBeQwjMpqs3Dwcx2S/dRgyY4380z64K43eml7stNy7M+uBxxnGcpql4WZCSDkbQHalkHEy5xlLSDJj9oQJPAIqGzA50AHgxwuEeEGUKCqDIxTC/wjLwUE9QYGtMCghDbPiwFMNDIaRPkU9Mu1DeULQu9MFIKl0QIxMm8shFmmCETuNh4+WoAEO8AJigyFBATJVgWb4VCMZoIAHIPqkIQxgqQRlw1GxEsxfRjIBr8eteA7az5rABZXcOIDuGmsTckxGp0gmlDqC1AQiXaSVGtlAZEwEkAMQ95tnoO7sjQsG4iz1Fc1IB5rVNKrPqmEM3H0HNZaL218AtgHQ+CssZnSOq3pYAJhli0lucr32HsEqgNVTaW1Mzw/i8zJulRWILYOeoj7ZRAdggFGgEyFpvsG/0OECZF6TK8oUwDXpVVY1MQBVW9NmGjXWu50DusoYoUMsEf/oS6GjpGGyEIAR2CmDmuPBiyn/SadmdkAycEHmvQ7VAYCdA3ukM7sEODo6uFBfigF6c8w+sph56ABJCa1YPN1pQa0t04cODbJUkSgdSEaPOzgN8CKFplmXJa2eFXQVVXHaAJCB+LUF4KWDVlob+TlLX0b+WrlwVufRXdB3wUkB9kLnJ7C+UEaYQaPphugSIMWAvJPdjf3kguQzXuK27+8PY97j2ORWqkEzxNBZxaos++X1oTZ1DDpoF6DzdLWcv4whs8orDL365xtkofqZKmXRdRaPomKE+ltjtS623wtAyw6V/cSuxLQmkKTCTR5Z4ROW+kp2omaeJMnmtWx0/xdlorMLE0UHCRBnMgaAAXg5BNQaHOcgDthhEIggEohhFGggFihhGAggGjhaHLgfHvhZIJgfJUKCJWiCJ4iCKYiCCciCLeiCLwiDMSiDM0iDNWiDN4iDOaiDO8iDPeiDPwiEQTgWIQAAOw==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Modified with permission from: Adjalle R, Plouin PF, Pacak K, Lehnert H. Treatment of malignant pheochromocytoma. Horm Metab Res 2009; 41:687. Copyright &copy; 2009 Thieme Publishers.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_18_24879=[""].join("\n");
var outline_f24_18_24879=null;
